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  Foreword 
 
 
For many generations, attempts have been made to combat the adverse effects of 
illicit drug trafficking and abuse, and institutions have been set up at the national 
and international levels to address those issues. Significant progress has been made 
in reducing illicit drug trafficking and abuse, though a lot more remains to be done. 
Many countries are being targeted by drug traffickers, as evidenced by the shipment 
of large consignments of illicit narcotic drugs, psychotropic substances and 
precursor chemicals to those countries. Larger seizures of cocaine and heroin 
suggest the existence of well-organized criminal syndicates that are moving drugs 
around the globe with impunity; those syndicates must be dismantled. The seizures 
also suggest that there is a need to improve the effectiveness of interdiction efforts 
and intelligence-sharing. 
Although the phenomenon of the unregulated market is not new, it is of particular 
concern to the Board that, in recent years, the variety of internationally controlled 
substances available on the unregulated market have been increasing. In addition, 
drug traffickers are turning to innovative ways of diverting and smuggling such 
substances, such as the transnational distribution of counterfeit drugs and the use of 
the Internet and postal and courier services. 
By making available medicines that are often poorly documented, unsafe, 
ineffective or of low quality, the unregulated market exposes patients to serious 
health risks. Moreover, this serious development, if it remains unchecked, may 
undermine progress made over the years in international drug control. The root 
causes of the problem need to be identified and remedial measures taken as a matter 
of urgency. The measures require a concerted response from relevant parties, 
including Governments, professional organizations and regional and international 
organizations. 
The national and international organizations established for the purpose of curtailing 
illicit drug trafficking and abuse need to cooperate more closely with one another in 
order to effectively address this important issue. All Governments need to show 
greater commitment to the ideals of the Single Convention on Narcotic Drugs of 
1961 and the Convention on Psychotropic Substances of 1971, in particular to limit 
the possession, use, distribution, import, export, manufacture and production of, and 
trade in, drugs exclusively to medical and scientific purposes and to address drug 
trafficking through international cooperation aimed at deterring such activity. 
In an age where technological developments are being used for sinister purposes, 
persons engaged in drug law enforcement and drug regulation need to be better 
trained and equipped to seize illicit drugs that are being trafficked and counterfeit or 
substandard drugs that appear in national and international distribution channels. 
Law enforcement authorities should use their expertise for the good of all by 
improving cooperation while fulfilling their mandates. States should share 
intelligence to facilitate the interception of illicit drug consignments. 
Governments should recognize the importance of drug demand reduction activities 
in alleviating the drug problem. Governments should also introduce drug demand 
reduction programmes, including programmes for the treatment, rehabilitation and 
social reintegration of drug abusers, that are effective, accessible, affordable and 
sustainable. 
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The success of efforts aimed at tackling the world drug problem depends not only 
on effective implementation of the appropriate legislation, but also on well-designed 
demand reduction programmes that are conducted by well-motivated personnel, as 
the personnel of such programmes play a significant role in successful drug control 
efforts. There is a need for more circumspection in designating men and women to 
lead drug control agencies. 
At the international level, organizations involved in international drug control 
should work more closely together. Let us put an end to unilateral efforts in the field 
of drug control. Ultimately, resolving the world drug problem depends on 
responsible action by all of us – parents, children, civil society and Governments. 
Let us join hands to rid the world of its drug problem. This is a wonderful 
opportunity to make a difference in the lives of the peoples of the world. Let us 
make that difference. 
 
   Philip O. Emafo 
    President of the International Narcotics Control Board 
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 I. Internationally controlled drugs and the unregulated market 
 
 
 A. Background 
 
 
1. The international drug control treaties, 
particularly the Single Convention on Narcotic Drugs 
of 1961 as amended by the 1972 Protocol1 and the 
Convention on Psychotropic Substances of 1971,2 seek 
to ensure a delicate balance between making narcotic 
drugs and psychotropic substances available for 
medical and scientific purposes and preventing their 
abuse or non-medical use. That delicate balance can be 
achieved through a carefully worked out international 
and national system of controls with regard to the 
manufacture, importation, exportation, distribution, 
prescribing, dispensing and use of narcotic drugs and 
psychotropic substances. 
2. Obligations imposed by the international drug 
control treaties must be translated into national 
legislation, and most States have enacted domestic 
legislation for that purpose. Some States have also 
introduced control systems that are in line with what is 
prescribed by the treaties, but with modifications to 
suit local conditions.  
3. The international drug control treaties were 
conceived as a response to widespread drug abuse and 
as an attempt to reduce to a minimum the medical, 
public health and other problems emerging in the wake 
of the misuse of drugs while, at the same time, not 
reducing the availability of drugs for medical and 
scientific purposes. The drafters of the treaties were 
conscious that there would be attempts to defeat 
whatever control systems that would be in place. 
Accordingly, the drafters introduced several measures 
to minimize the possibility of the treaty objectives 
being undermined. 
4. Notwithstanding the drug control regime 
prescribed by the international drug control treaties and 
related national laws and regulations, there have been 
reports of the diversion, misuse or abuse of drugs. The 
problem has assumed more significant dimensions with 
regard to psychotropic substances under international 
control. In more recent times, however, there have 
been growing concerns that the unregulated market – 
in general, for medicinal products, and in particular, 
__________________ 
 1  United Nations, Treaty Series, vol. 976, No. 14152. 
 2  Ibid., vol. 1019, No. 14956. 
for some narcotic drugs and psychotropic substances – 
may be becoming too ubiquitous in certain parts of the 
world and that the underlying contributory factors need 
to be identified and remedial measures taken. 
5. The concerns of the International Narcotics 
Control Board stem from reported incidences of the 
availability of internationally controlled drugs in the 
unregulated market. For example, benzodiazepines, 
amphetamines and other internationally controlled 
drugs can be easily obtained in street markets in 
several developing countries. Even in developed 
countries, there are reports of the abuse or misuse of 
controlled drugs originating in the unregulated market. 
Through Internet pharmacies, internationally controlled 
drugs such as benzodiazepines, opioids, stimulants and 
barbiturates can be obtained without a prescription. 
According to estimates of the World Health 
Organization (WHO),3 at least 10 per cent of the 
world’s drugs are counterfeit. 
6. The Board therefore decided that it would be 
timely to have the unregulated market as the special 
theme of its report for 2006. The unregulated market is 
examined in the present chapter primarily in relation to 
narcotic drugs and psychotropic substances under 
international control. 
 
 
 B. Selected features of the unregulated 
market for drugs 
 
 
7. The unregulated market for drugs has evolved 
and exists in different forms in different parts of the 
world. Given the wide variation in the forms of 
unregulated markets and in the ways they operate, the 
phrase “unregulated market for drugs” is commonly 
used in a generic sense. From a more technical 
perspective, an unregulated market for drugs can be 
considered to exist where: 
 (a) Unlicensed individuals and/or entities4 trade 
in drugs that they are not authorized or entitled to deal 
__________________ 
 3  World Health Organization, “Counterfeit medicines”, 
Fact Sheet No. 275, February 2006. 
 4  The term “entities” covers manufacturing 
establishments, pharmacies, clinics etc. 
E/INCB/2006/1  
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with or in contravention of the applicable laws, 
regulations and norms; or  
 (b) Licensed individuals and/or entities trade in 
drugs that they are not authorized or entitled to deal 
with or in contravention of the applicable laws, 
regulations and norms. 
8. The situation described in subparagraph 7 (a) 
above would include, for instance, the case of a person 
who is not a registered pharmacist selling a controlled 
drug at a village fair. The situation described in 
subparagraph 7 (b) above would include, for example, 
the case of a registered pharmacist selling a controlled 
drug in a pharmacy but without a prescription as 
required by law. Both situations cover legally 
manufactured or imported drugs, as well as 
counterfeit5 or substandard drugs, which cannot be the 
subject of legitimate commerce. They also cover 
unauthorized Internet sales. The phrase “trade in” is 
intended to apply to all commercial transactions in 
relation to such drugs.  
9. The unregulated market ranges from ad hoc or 
makeshift outlets in village fairs or markets where 
drugs are sold along with other commodities, such as 
balms, tonics and creams, to more organized systems 
operated by unscrupulous manufacturers, importers, 
retailers, wholesalers and health-care professionals.  
10. Any activity on the unregulated market is 
unlawful; in some countries such activity may be part 
of a much larger criminal operation transcending 
national frontiers, particularly where counterfeit or 
banned or substandard drugs are manufactured or 
imported or exported. The possibility of making a 
substantial profit drives such markets. Such profits are 
particularly enhanced where the quality of drugs is 
compromised; where customs or import duties are 
avoided; where taxes are not paid on the turnover; or 
where price control systems are undermined.  
__________________ 
 5  “A counterfeit medicine is one which is deliberately and 
fraudulently mislabelled with respect to identity and/or 
source. Counterfeiting can apply to both branded and 
generic products and counterfeit products may include 
products with the correct ingredients, wrong ingredients, 
without active ingredients, with insufficient quantity of 
active ingredient or with fake packaging” (“Counterfeit 
drugs: report of a WHO/IFPMA workshop, 1-3 April 
1992” (WHO/DMP/CFD/92), p. 1). 
11. Drugs enter the unregulated market through a 
number of channels. These vary from one country to 
another and sometimes even from one geographical 
area within a country to another. For its supplies the 
unregulated market depends on two principal sources: 
official sources (regulated channels) and “other 
sources”: 
 (a) Official sources (regulated channels): 
 (i) Drugs may be stolen from licensed 
manufacturers, wholesalers or retail distributors. 
Unscrupulous manufacturers may manufacture 
and sell products for which they have no licence 
or may sell products in contravention of the 
conditions of their licence. Drugs that are 
substandard or recalled by the manufacturer 
because they have expired or have quality defects 
may be sold and find their way into the 
unregulated market; 
 (ii) Imported drugs or drugs for export may find 
a way into the unregulated market through theft 
or unauthorized sales; 
 (iii) Drugs may be diverted from health-care 
institutions and/or health service providers, again 
through theft or unauthorized sales; 
 (iv) Controlled drugs obtained legitimately by 
retailers or by health-care institutions, for 
example, may be stolen and diverted to the 
unregulated market; in some cases, individuals 
who have obtained such drugs using prescriptions 
may sell them for profit; 
 (b) Other sources: 
 (i) Counterfeit drugs may be manufactured or 
imported or distributed and supplied to the 
unregulated market, as well as to the regulated 
market. Unscrupulous manufacturers, importers, 
exporters, pharmacists, distributors and brokers 
have been implicated in such operations; 
 (ii) Drugs that are stolen from prescription 
holders may find their way into the unregulated 
market; 
 (iii) Through the Internet, even drugs for which 
prescriptions are required can be obtained 
relatively easily. 
  3 
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 C. The demand for the unregulated 
market 
 
 
12. The unregulated market is driven by several 
factors; the underlying dynamics vary from situation to 
situation. Some of the more common factors that have 
created demand for an unregulated market or 
responded to demand from an unregulated market are 
described below. 
 
  Limited access to health-care facilities 
 
13. In countries with limited access to health-care 
professionals, hospitals, clinics or pharmacies, 
unauthorized or unregulated outlets are more likely to 
exist. Such a situation is particularly common where a 
person may have to travel a long distance to consult a 
health-care professional or where drugs are in short 
supply in established or formal health-care outlets, 
such as hospital or community pharmacies, or where 
there is a long waiting period to consult a service 
provider. 
 
  Cost of drugs 
 
14. The price of most medicinal products found on 
the unregulated market is likely to be lower than the 
price of those products in regulated pharmacies. In the 
case of counterfeit drugs, there are significant profits 
for the illicit manufacturer, as counterfeit drugs cost 
much less to manufacture and distribute than genuine 
drugs. Drugs smuggled into a country or diverted from 
licit channels may be cheaper, as customs or import 
duties and other applicable taxes are usually evaded.  
15. On the other hand, the price of certain 
internationally controlled drugs available through the 
Internet may in fact be higher than the price of those 
products in regulated pharmacies, and the consumer 
might not be aware of this. However, the price may not 
necessarily deter some individuals from obtaining such 
drugs. 
 
  Privacy 
 
16. The ability to obtain controlled drugs through the 
Internet offers a degree of privacy, as there are no 
medical records indicating that the person has been 
taking a course of treatment for an ailment or illness, 
which might pose problems regarding that person’s 
current or prospective employment or health insurance. 
 
  Lack of public awareness  
 
17. Unscrupulous individuals or entities may exploit 
individuals who are not aware of the dangers of buying 
drugs on the unregulated market or who are not able to 
distinguish between registered and unregistered sales 
outlets or practitioners. Where law enforcement is 
weak because of poor planning, a shortage of 
inspectors or corrupt practices, such individuals or 
entities will be able to carry out their illegal activities 
with impunity. 
18. Aggressive promotion and advertising to the 
general public, in contravention of the treaty 
obligations, may influence public perception about the 
availability of drugs on the unregulated market. 
 
  Drug control regulations and enforcement 
 
19. Some countries have drug control laws and 
regulations with provisions that go beyond treaty 
requirements without necessarily preventing abuse or 
misuse. Overly stringent prescription requirements is 
one such example. This may lead to a situation where 
certain controlled drugs are more readily available on 
the unregulated market. In the absence of effective law 
enforcement, particularly through inspections and 
reporting systems, outlets selling such drugs will be 
able to operate outside the regime of legal controls. 
 
  Consumer demand for illicit drugs 
 
20. The unregulated market caters to individuals, 
including persons who are dependent on drugs of abuse 
and who are unable to obtain them without a 
prescription. In addition to recreational use, some 
individuals may seek access to performance-enhancing 
drugs that are available only with a prescription. 
 
 
 D. Some emerging issues  
 
 
  Counterfeit drugs 
 
21. Though the existence of counterfeit drugs is not 
new, their availability was first formally acknowledged 
as a problem only in the mid-1980s and has since 
assumed alarming proportions, not only in developing 
but also in developed countries. According to WHO, an 
estimated 25-50 per cent of the medicines consumed in 
developing countries are believed to be counterfeit. 
The use of certain counterfeit medicines can be fatal: a 
E/INCB/2006/1  
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counterfeit vaccine used in the Niger in 1995 resulted 
in 2,500 deaths.6 
22. Some counterfeit drugs are easy to manufacture. 
Such drugs may closely resemble genuine products in 
terms of their packaging and labelling. Controlled 
narcotic drugs and psychotropic substances may be 
present in products without any mention of such drugs 
or substances on the labels or package inserts. This has 
been a problem in some countries with herbal or 
traditional medicines. 
23. The manufacture and distribution of counterfeit 
drugs on a larger scale often involve unscrupulous 
manufacturers, pharmacists, wholesalers, retailers and 
brokers. In many countries, brokers facilitate 
international trade in drugs and remain largely 
invisible to the authorities. Contrary to treaty 
requirements, brokers in some countries are not 
regulated by national drug control legislation. 
 
  Internet orders 
 
24. Internet pharmacies that are properly regulated 
serve a useful purpose, especially in underserved areas, 
making drugs available to the population. However, in 
many countries, Internet pharmacies have not been 
regulated yet. 
25. A recent survey of 185 Internet pharmacies in one 
Member State revealed that 84 per cent of them sold 
benzodiazepines, 68 per cent sold opioids, 8 per cent 
sold stimulants and 1 per cent sold barbiturates. 
Eighty-nine per cent of the Internet pharmacies did not 
require a prescription, and 8 per cent of them accepted 
a prescription sent by telefax (allowing customers to 
easily use forged prescriptions or to obtain medicine 
from several Internet pharmacies with a single 
prescription). Only 3 per cent of the Internet 
pharmacies indicated that, before dispensing medicine 
requiring a prescription, they would request for the 
original prescription to be mailed or would contact the 
prescribing doctor.7 
26. The risks involved in buying a medicinal product 
through an illegal Internet pharmacy are high: (a) the 
__________________ 
 6  World Health Organization, “Counterfeit medicines”, 
Fact Sheet No. 275, February 2006. 
 7  National Center on Addiction and Substance Abuse at 
Columbia University, “‘You’ve got drugs!’ Prescription 
drug pushers on the Internet: 2006 update”, CASA White 
Paper, June 2006. 
medicinal product may be marketed on a website using 
incorrect or fraudulent health claims; (b) the medicinal 
product may be issued without a valid prescription or 
the proper supervision of a pharmacist or medical 
professional; (c) the product may be counterfeit or of 
substandard quality or the expiration date of the 
product may have elapsed; (d) the price of the 
medicinal product may be higher than in legal 
pharmacies; and (e) the buyer’s privacy or the security 
of the buyer’s credit card or medical data may be 
compromised.  
27. Internet pharmacies are dependent on postal 
services to deliver drugs, some of which are of an 
illicit nature, to end-users. The huge numbers of 
parcels pose challenges in scanning, identifying and 
intercepting parcels with illicit drugs. In one country, 
the law enforcement authority examined 
1,153 imported parcels containing medicinal products 
during a three-day operation in 2003. The 
overwhelming majority of the products (88 per cent) 
were illegal imports – drugs not registered or supplied 
without the required prescription. The products 
included over 25 different internationally controlled 
substances, including narcotic drugs such as codeine 
and psychotropic substances such as diazepam.8 
28. Websites that provide advice and consultations 
with so-called “cyberdoctors”, recommending 
medicinal products for use and facilitating access to 
the “prescribed drugs”, are a matter of increasing 
concern, particularly in cases where there are no proper 
clinical consultations. The costs of using such websites 
vary; in fact, there are hidden costs, such as fees for 
consultations with “cyberdoctors”, and handling and 
packaging fees. 
 
 
 E. Requirements of a regulatory system 
 
 
29. Drugs must be effective, safe and of good quality. 
Every country should therefore have a drug regulatory 
authority to assess the efficacy, safety and quality of 
drugs before allowing them to be imported, 
manufactured or marketed. Countries that do not have 
the resources to assess all products on their markets 
__________________ 
 8  United States of America, Food and Drug 
Administration, “FDA/U.S. Customs import blitz exams 
reveal hundreds of potentially dangerous imported drug 
shipments”, FDA News, 29 September 2003. 
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can rely on the decisions of drug regulatory authorities 
in other countries with advanced regulatory systems in 
place. However, there should at least be a provisional 
authorization process, in order to identify the drugs 
that can be marketed. 
30. To effectively regulate the drug market, national 
drug regulatory authorities require political will, 
relevant legislation, appropriate organizational 
capacity and skilled professionals. They also need to 
have adequate financial resources, as well as well-
structured and motivated drug inspectorate services 
and international cooperation. 
31. The training of health-care professionals should 
include guidance on how to promote the rational use of 
drugs in the context of the applicable regulatory 
requirements. Codes of conduct for associations of 
health-care professionals, industry and trade chambers 
should address the issue of the incorrect or improper 
handling of drugs.  
32. The premises on which medicines are stored also 
need to be controlled. The procurement, storage, 
distribution and dispensing of medicines must be done 
according to specific technical standards and 
guidelines. Most States require such premises to be 
inspected and licensed by the national drug regulatory 
authority. Internationally controlled drugs need even 
more care and require special storage conditions and 
administrative procedures, in order to reduce the risk 
of such drugs being diverted into illicit channels. 
33. Professional organizations have a responsibility 
to promote, monitor and ensure ethical behaviour of 
health-care professionals. In countries with weak 
regulatory control of medicines, that responsibility is 
even more important. Ethical conduct is expected of all 
health-care professionals.  
34. In some countries, inadequate legal frameworks 
and lax law enforcement are areas of concern. In 
countries where drug control legislation is lacking or 
obsolete, the regulation of trade in medicinal products, 
including internationally controlled drugs, is 
hampered. According to a 2003 study conducted by 
WHO,9 in 30 per cent of countries, drug regulation is 
either non-existent or very limited. In such countries, 
__________________ 
 9  “Effective medicines regulation: ensuring safety, 
efficacy and quality”, WHO Policy Perspectives on 
Medicines (Geneva), No. 7, November 2003, p. 1. 
Governments are unable to ensure the safety, efficacy 
and quality of medicines on their markets. That makes 
it very difficult to implement the controls required 
under the international drug control treaties. As a 
result, patients may be at serious risk. In half of the 
countries in the world, drug regulation exists but is less 
than optimal. In such countries, the implementation, 
supervision and/or enforcement of drug legislation is 
compromised. This may lead to any of the following 
undesirable situations: (a) uncontrolled imports, 
leading to medicines with doubtful efficacy, safety or 
quality being available on the market; (b) smuggling of 
medicines; (c) illicit manufacture of internationally 
controlled drugs; (d) counterfeit medicines infiltrating 
the licit market; (e) poor storage conditions and 
administrative controls in the wholesale or retail sector, 
allowing pilferage or diversion of internationally 
controlled drugs; (f) repetitive trading of medicines to 
obscure their source, storage conditions or previous 
ownership; (g) poor enforcement of the “prescription 
only” requirement in pharmacies, allowing patients to 
use potent and even internationally controlled drugs 
without professional supervision; and (h) sale of 
controlled drugs to consumers without a prescription at 
places such as street markets or bus stops. Even the 
20 per cent of countries with well-developed drug 
regulatory systems may experience occasional 
problems, especially when new technologies are not 
yet fully understood by drug regulators or adequately 
regulated in new legislation on, for example, Internet 
pharmacies.  
 
 
 F. Conclusions 
 
 
35. The unregulated market exposes patients to 
serious health risks by providing access to poorly or 
incorrectly labelled medicines that are ineffective, 
substandard and, in some cases, even lethal. The 
problem is compounded when professional supervision 
is virtually absent and consumers are not able to assess 
or avoid the risks. This is a serious situation that 
requires action from all those concerned, including 
Governments, professional organizations, the 
pharmaceutical industry and international 
organizations. 
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36. While there is no precise figure on the amount of 
internationally controlled substances reaching patients 
through the unregulated market, it is believed to be 
increasing rapidly. In some regions, people abuse 
licitly produced prescription medicines in quantities 
similar to or greater than the quantities of illicitly 
manufactured heroin, cocaine, amphetamine and 
opioids that are abused. The Internet allows easy 
access to internationally controlled substances but is 
inadequately regulated at the national and international 
levels. The widespread availability of counterfeit drugs 
has further compounded the problems associated with 
the unregulated market. The progress made over the 
last 40 years in the control of illicit drugs is now being 
undermined. The Board is greatly concerned about 
these developments. 
 
 
 G. Recommendations 
 
 
37. The Board recognizes that the elimination of the 
unregulated market must be done through a concerted 
effort involving Governments and relevant parties such 
as the pharmaceutical industry, wholesalers, retailers, 
professional associations, consumer and patient groups 
and international organizations. 
 
  Recommendations to Member States in the 
context of treaty obligations 
 
38. The Board is of the view that much can be 
achieved to prevent internationally controlled drugs 
from being diverted to the unregulated market if all the 
parties concerned strictly enforce the applicable 
control requirements. In that connection, the Board 
recommends the effective implementation of the 
following control requirements and related measures:  
 (a) Member States need to enforce existing 
legislation to ensure that narcotic drugs and 
psychotropic substances are not illegally manufactured, 
imported or exported and are not diverted to the 
unregulated market; 
 (b) In compliance with article 15 of the 1971 
Convention, Member States need to conduct 
inspections of manufacturers, exporters, importers and 
wholesale and retail distributors, as well as of stocks 
and records, and to take appropriate action against 
those who fail to comply with applicable legal 
requirements and professional codes of conduct. 
Activities of market intermediaries such as brokers 
must be regulated as appropriate; 
 (c) Member States need to assess their 
requirements of narcotic drugs and psychotropic 
substances on a systematic basis to ensure that supplies 
are sufficient to meet legitimate demand. Records of 
operations involving manufacture, import, export and 
distribution must be verified and any discrepancies 
resolved; 
 (d) Member States need to take appropriate 
measures to increase the availability of drugs through 
legitimate channels, particularly in areas where there is 
little or no access; 
 (e) Member States need to take prompt and 
effective action to implement previous 
recommendations of the Board10 on Internet trading 
and inform it of the actions taken; 
 (f) Member States need to address the issue of 
the unregulated market for drugs in national drug 
control policies and legislation; strengthen the drug 
regulatory authority and its inspectorate; enlist the 
assistance of customs, law enforcement and postal 
services to intercept illegal or unauthorized 
consignments; and prevent the illegal sale of drugs 
through effective law enforcement; 
 (g) Member States need to build the capacity of 
staff attached to the drug regulatory authority and other 
agencies concerned; 
 (h) Member States need to implement effective 
policies to combat counterfeit drugs and provide a 
comprehensive legal framework to make trading in 
counterfeit products a serious criminal offence. 
Exporting countries must regulate the export of drugs 
with a view to preventing the export of drugs that are 
counterfeit or of poor quality. The Declaration of Rome 
adopted at the WHO International Conference 
“Combating Counterfeit Drugs: Building Effective 
International Collaboration”, held in Rome in 
February 2006, should be supported by Member States, 
and they should actively participate in the work of the 
new International Medical Products Anti-
Counterfeiting Taskforce (IMPACT), as well as other 
regional initiatives. 
__________________ 
 10  Report of the International Narcotics Control Board for 
2005 (United Nations publication, Sales No. E.06.XI.2), 
paras. 219-236. 
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  Recommendations to international and 
intergovernmental organizations 
 
39. The Board recommends the following to 
intergovernmental organizations: 
 (a) WHO should consider studies to be 
undertaken at the national, regional and international 
levels to develop a better understanding of the 
dynamics underlying the operations of the unregulated 
market and formulate relevant guidelines; 
 (b) WHO should consider the development of a 
guide on best practices in dealing with the unregulated 
market, to be compiled and widely distributed; 
 (c) The United Nations Office on Drugs and 
Crime (UNODC) and WHO should consider providing 
technical assistance to Member States that require such 
assistance for building capacity and for updating drug 
control laws in order to be able to deal more effectively 
with problems emerging in the wake of the unregulated 
market; 
 (d) The pharmaceutical industry and relevant 
associations need to notify the relevant national and 
international authorities of any consignments that are 
being diverted to the unregulated market or of any 
attempts to manufacture and distribute counterfeit 
drugs. 
E/INCB/2006/1  
 
8  
 
 
 II. Operation of the international drug control system 
 
 
 A. Narcotic drugs 
 
 
  Status of adherence to the Single Convention on 
Narcotic Drugs of 1961 
 
40. As at 1 November 2006, the number of States 
parties to the Single Convention on Narcotic Drugs of 
196111 stood at 184. Of those States, 181 were parties 
to that Convention as amended by the 1972 Protocol. 
Since the publication of the report of the Board for 
2005, Montenegro12 has become a party to the 1961 
Convention as amended by the 1972 Protocol. 
Afghanistan, Chad and the Lao People’s Democratic 
Republic continue to be parties to the 1961 Convention 
in its unamended form only. A total of nine States have 
not yet become parties to the 1961 Convention: one 
State in Africa (Equatorial Guinea), two in Asia (the 
Democratic People’s Republic of Korea and Timor-
Leste), one in Europe (Andorra) and five in Oceania 
(Kiribati, Nauru, Samoa, Tuvalu and Vanuatu). 
 
  Cooperation with Governments 
 
  Submission of annual and quarterly statistical 
reports on narcotic drugs 
 
41. The majority of States regularly submit the 
mandatory annual and quarterly statistical reports. As 
at 1 November 2006, a total of 171 States and 
territories had submitted annual statistics on narcotic 
drugs for 2005, in conformity with the provisions of 
article 20 of the 1961 Convention. That accounts for 
81 per cent of the 210 States and territories required to 
furnish such statistics. A total of 187 States and 
territories provided quarterly statistics of imports and 
exports of narcotic drugs for 2005; that figure 
represents 89 per cent of the 210 States and territories 
requested to furnish those data. The rates of submission 
are similar to those of previous years. 
42. In 2006, an improvement was noted in the 
furnishing of statistical data by Cuba, the Democratic 
People’s Republic of Korea, Djibouti, the Gambia, 
Kiribati and Luxembourg. The Board encourages the 
__________________ 
 11  United Nations, Treaty Series, vol. 520, No. 7515. 
 12  By its resolution 60/264 of 28 June 2006, the General 
Assembly decided to admit Montenegro to membership 
in the United Nations. 
Governments of those countries to continue to submit 
the required reports on a regular basis and is ready to 
assist all Governments with a view to facilitating their 
compliance with their reporting obligations under the 
1961 Convention. 
43. Parties to the 1961 Convention have an obligation 
to furnish annual statistical reports on narcotic drugs 
not later than on 30 June following the year to which 
they relate. The Board notes with concern that several 
States, including some that are major manufacturers, 
importers, exporters or users of narcotic drugs, did not 
comply with that requirement in 2006. The delays in 
submission of reports make it more difficult to monitor 
the manufacture of, trade in and consumption of 
narcotic drugs and hinder the analysis of statistical 
data. The Board reiterates its request to all States that 
experience difficulties in complying in a timely manner 
with their reporting obligations to take all measures 
necessary to ensure the observance of the deadline set 
in the 1961 Convention for the submission of annual 
reports. 
 
  Estimates of requirements for narcotic drugs 
 
44. The universal application of the system of 
estimates is indispensable for the functioning of the 
control system for narcotic drugs. Lack of adequate 
national estimates is often an indication of deficiencies 
in the national control mechanism and/or health system 
of a country. Without proper monitoring and 
knowledge of the actual requirements for narcotic 
drugs, there is a risk, if estimates are too low, that there 
will not be sufficient narcotic drugs available for 
medical treatment. In case estimates are too high, drugs 
traded in a country may be in excess of medical needs 
and may be diverted into illicit channels or used 
inappropriately. A well-functioning health system is 
necessary to assess the actual requirements of narcotic 
drugs in every country. 
45. As at 1 November 2006, annual estimates of 
narcotic drug requirements for 2007 had been 
furnished by 164 States and territories, or 78 per cent 
of the States and territories required to furnish such 
estimates. Several States and territories failed to 
provide their estimates in time for examination and 
confirmation. The Board had to establish estimates for 
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them in accordance with article 12, paragraph 3, of the 
1961 Convention. 
46. The estimates established by the Board are based 
on the estimates and statistics reported in the past by 
the respective Governments. Estimates for countries 
that had not submitted statistics and estimates for 
several years were in some cases lowered considerably, 
as a precaution in view of the risk of diversion. 
Consequently, the States and territories concerned may 
experience difficulties in importing in a timely manner 
the quantities of narcotic drugs required to meet their 
medical needs. The States and territories concerned 
should take all necessary measures to establish their 
own estimates of narcotic drug requirements and 
furnish those estimates for confirmation as soon as 
possible. The Board is ready to assist those States and 
territories by providing clarifications on the provisions 
of the 1961 Convention relating to the system of 
estimates. 
47. The Board reviews the estimates received, 
including supplementary estimates, with a view to 
limiting the use of narcotic drugs to the amount 
required for medical and scientific purposes and to 
ensuring adequate availability of those drugs for such 
purposes. Several Governments were contacted prior to 
confirming estimates for 2007, as those estimates, 
according to information available, appeared to be 
inadequate. Most Governments have provided the 
clarifications or corrected their estimates. 
48. As a result of inaccurate estimates, some 
Governments had to submit supplementary estimates 
for narcotic drugs. The Board encourages those 
Governments to calculate their annual estimates for 
narcotic drugs as accurately as possible and to make 
every effort to submit supplementary estimates only in 
cases of unforeseen circumstances. However, when 
developments in medical treatment, including use of 
new medications, result in additional needs for narcotic 
drugs, Governments should not hesitate to submit 
supplementary estimates. The Board also wishes to 
remind all Governments to always provide an 
explanation of the circumstances necessitating 
supplementary estimates, as required under article 19, 
paragraph 3, of the 1961 Convention. 
49. The number of supplementary estimates 
furnished by Governments in accordance with 
article 19, paragraph 3, of the 1961 Convention 
decreased in 2006 compared with recent years. A total 
of 325 supplementary estimates had been received as at 
1 November 2006, which is less than the number of 
supplementary estimates received during the previous 
years. The Board appreciates that the Governments of 
several countries, such as Germany, the Netherlands, 
South Africa and Turkey, have submitted more accurate 
estimates for 2006. 
 
  Prevention of diversion into the illicit traffic 
 
  Diversion from international trade 
 
50. The system of control measures laid down in the 
1961 Convention provides effective protection of 
international trade in narcotic drugs against their 
diversion into illicit channels. In 2006, as in recent 
years, no cases of diversion of narcotic drugs from licit 
international trade into the illicit traffic were detected, 
in spite of the large number of transactions involved. 
Attempts at diversion were thwarted. 
51. Effective prevention of the diversion of narcotic 
drugs from international trade requires the 
implementation by Governments of all control 
measures for those drugs, as provided for in the 1961 
Convention. The Board welcomes the vigilance of the 
Government of China, which, in cooperation with the 
Board, identified and prevented in March 2006 an 
attempt by traffickers to use falsified import 
certificates of a country in Central America to divert 
150 kg of hydrocodone bitartrate and 50 kg of 
oxycodone hydrochloride from licit international trade. 
Also appreciated is the vigilance of the authorities of 
Hungary, which prevented in 2005 and 2006 repeated 
attempts to use falsified import permits of a country in 
West Asia to import methadone tablets from Hungary 
into that country. 
52. The authorities of a country in Western Africa 
submitted to the Board for confirmation the estimates 
for 100 kg of hydrocodone and 100 kg of oxycodone 
for 2006. Those narcotic drugs had not been used for 
medical purposes in that country before. The estimates 
were based on a request from a company claiming that 
it would import hydrocodone and oxycodone for the 
manufacture of preparations destined for domestic 
consumption. Following a request by the Board to 
examine the actual medical needs for those opioids, the 
authorities found that the estimates were not realistic 
and decided to withdraw those estimates. 
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53. While most Governments are fully implementing 
the system of estimates and the import and export 
authorization system, in 2005 and 2006 a few 
Governments authorized exports of narcotic drugs from 
their countries in excess of the corresponding total of 
the estimates of the respective importing countries. 
Such exports were contrary to the provisions of 
article 31 of the 1961 Convention and could have 
resulted in the diversion of narcotic drugs into illicit 
channels. The Board has urged the Governments in 
question to ensure compliance with the provisions of 
article 31 of the 1961 Convention when authorizing 
exports of narcotic drugs in the future and has advised 
them to consult the annual estimates of requirements 
for narcotic drugs for each importing country and 
territory, which are published by the Board. 
 
  Diversion from domestic distribution channels 
 
54. Diversion of pharmaceutical preparations 
containing narcotic drugs from domestic distribution 
channels for subsequent abuse continues to be reported 
by some Governments. The narcotic drugs in question 
include codeine, dextropropoxyphene, fentanyl (see 
paras. 180-186 below), hydrocodone, ketobemidone, 
levomethorphan, methadone (see paras. 187-195 
below), oxycodone and pethidine. Among the reasons 
for such abuse are an erroneous belief that those 
products are less harmful than drugs manufactured 
illicitly and the fact that in many countries it is easier 
for drug abusers to obtain such preparations than 
illicitly manufactured drugs. Drug abusers are able to 
remove the active substances from high-dosage 
formulations and separate drugs from inactive 
ingredients. 
55. In Canada, the diversion and abuse of 
pharmaceutical preparations containing opioid 
analgesics, such as codeine, hydromorphone, 
morphine, oxycodone and pethidine, are on the 
increase, although the exact extent of the problem is 
not known to the authorities. In particular, abuse of the 
controlled-release product OxyContin® (containing 
oxycodone) has become a concern in Canada. The 
methods used for diversion are primarily theft from 
pharmacies and fraudulent prescriptions. The 
Government is taking steps to address the diversion 
and abuse of prescription opioids and is planning to 
undertake further studies to identify the extent of the 
problem and the underlying reasons for such abuse. 
56. The Board notes the measures taken and planned 
in the United States of America to tackle the growing 
problem of diversion and abuse of opioid analgesics, 
including fentanyl, hydrocodone and oxycodone, in 
that country (see para. 330 below). The measures 
envisaged by the Government include the 
establishment of prescription monitoring programmes 
to identify unusual consumption patterns and the 
investigation and sanctioning of negligent or criminal 
behaviour, if applicable. Actions are also being taken 
to seize assets of the individuals and criminal groups 
involved in the illicit traffic in prescription drugs. 
However, those actions appear not to sufficiently 
address the diversion and abuse of hydrocodone, the 
most prescribed and diverted narcotic drug in the 
United States. The Board requests the Government to 
take further measures to enable prevention of diversion 
and abuse of pharmaceutical preparations containing 
hydrocodone. 
57. The Governments of El Salvador, Estonia, Latvia, 
Portugal and Romania, which had identified cases of 
diversion of pharmaceutical preparations containing 
narcotic drugs, have taken actions to prevent similar 
occurrences in the future. 
58. Diversion and abuse of narcotic drugs in the form 
of pharmaceutical preparations continue to be 
underreported, in particular, if they involve 
preparations that may be exempted from certain control 
measures (preparations in Schedule III of the 1961 
Convention). Many States have not established any 
mechanism for the systematic collection of data on 
those issues and are not aware of the extent of 
diversion and abuse of pharmaceutical preparations 
containing narcotic drugs in their territories. The Board 
commends those Governments which have introduced 
systems to collect such data and invites all 
Governments to remain vigilant and take 
countermeasures, as appropriate, in cooperation with 
health-care professionals. Such countermeasures 
should include providing regular feedback on seized 
pharmaceutical products to the regulatory authorities. 
Abuse of pharmaceutical preparations should be 
included in the surveys aimed at establishing the extent 
and types of drug abuse. 
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  Ensuring the availability of drugs for medical 
purposes 
 
  Demand for and supply of opiates 
 
59. Pursuant to the 1961 Convention and relevant 
Economic and Social Council resolutions, the Board 
examines on a regular basis issues affecting the supply 
of and demand for opiates used for medical and 
scientific purposes. In cooperation with Governments, 
the Board strives to maintain a lasting balance between 
supply and demand. A detailed analysis of the current 
situation with regard to the supply of and demand for 
opiates used for medical and scientific purposes 
worldwide is contained in the 2006 technical report of 
the Board on narcotic drugs.13 
 
  Monitoring of the global situation concerning the 
supply of and demand for opiate raw materials 
 
60. For decades, Governments of producing countries 
have cooperated in maintaining the total production of 
opiate raw materials at the level of global annual 
demand. From 1999 to 2004, total production of opiate 
raw materials exceeded global demand, resulting in a 
high level of stocks being held in some producing 
countries.  
61. Global stocks of opiate raw materials should 
normally cover global demand for about one year.14 
However, at the end of 2005, total stocks of opiate raw 
materials rich in morphine were sufficient to cover 
global annual demand for two years. While total stocks 
of opiate raw materials rich in thebaine in 2005 were 
sufficient to cover global annual total demand for 
about one year, the additional stocks of thebaine and 
opiates derived from thebaine, mainly oxycodone, were 
sufficient at the end of 2005 to cover demand for more 
than two years. 
62. Global demand for opiates continues to increase 
for both types of opiates: opiates based on opiate raw 
materials rich in morphine; and opiates based on opiate 
raw materials rich in thebaine. It is anticipated that the 
increase will continue, at least partly as a result of the 
activities of the Board and WHO to ensure the 
adequate availability of opioid analgesics. 
__________________ 
 13  Narcotic Drugs: Estimated World Requirements for 
2007; Statistics for 2005 (United Nations publication, 
Sales No. E/F/S.06.XI.13). 
 14  Report of the International Narcotic Control Board for 
2005 …, para. 85. 
63. In 2005 and again in 2006 total production of 
opiate raw materials was less than global demand. For 
2007, Governments of producing countries are also 
planning to maintain the area cultivated with opium 
poppy at a level below the levels of recent years. In 
spite of the reduced production of opiate raw materials, 
the stocks and raw materials produced will continue to 
be sufficient to cover the expected demand. The Board 
urges Governments of producing countries to maintain 
future production at the levels currently planned and to 
avoid excessive stocks. 
64. Governments of producing countries should 
submit relevant estimates in a timely manner and 
maintain opium poppy cultivation within the limits of 
the estimates confirmed by the Board or to furnish 
supplementary estimates, if necessary. Those 
Governments should also report accurately and timely 
the amounts of raw materials produced to the Board, as 
well as the alkaloids contained in them.  
 
  Prevention of the proliferation of production of 
opiate raw materials 
 
65. Pursuant to the relevant Economic and Social 
Council resolutions, the Board calls upon all 
Governments to contribute to the maintenance of a 
balance between the licit supply of and demand for 
opiate raw materials and to cooperate in preventing the 
proliferation of sources of production of opiate raw 
materials. Most recently, in its resolution 2006/34 of 
27 July 2006, the Economic and Social Council urged 
the Governments of all countries where opium poppy 
had not been cultivated for the licit production of 
opiate raw materials, in the spirit of collective 
responsibility, to refrain from engaging in the 
commercial cultivation of opium poppy; and called 
upon Governments to enact enabling legislation to 
prevent and prohibit the proliferation of sites used for 
the production of opiate raw materials. The Board 
appeals to all Governments to comply with Council 
resolution 2006/34. 
 
  Informal consultation on supply of and demand 
for opiates for medical and scientific purposes 
 
66. At the request of the Governments of India and 
Turkey and pursuant to Economic and Social Council 
resolution 2005/26 of 22 July 2005, the Board 
convened an informal consultation on the supply of 
and demand for opiates for medical and scientific 
E/INCB/2006/1  
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purposes during the forty-ninth session of the 
Commission on Narcotic Drugs, to enable the 
Governments of major producers and importers of 
opiate raw materials to be informed of recent 
developments affecting global production of and 
demand for opiate raw materials and to discuss the 
various policies applied in this respect in other 
countries. 
 
  Consumption of narcotic drugs 
 
67. The low levels of consumption of opioid 
analgesics for the treatment of moderate to severe pain 
in several developing countries continue to be a matter 
of concern to the Board. Global consumption of 
morphine doubled from about 16 tons in 1996 to 
almost 32 tons in 2005. About 50 countries have 
increased the consumption of opioid analgesics by 
more than 100 per cent during the last decade. 
However, of the countries with the highest 
consumption levels, 70 per cent are either in Europe or 
North America. In countries where the availability of 
narcotic drugs for medical purposes is very high, the 
Governments should be aware that increased 
availability without adequate control may raise the risk 
of diversion and abuse of those drugs. The Board again 
requests all Governments to promote the rational use of 
narcotic drugs for medical treatment, in accordance 
with the pertinent recommendations of WHO. 
68. The education and training of health-care 
professionals and, as appropriate, professionals in the 
legal and regulatory branches can play an important 
role in the efforts to ensure the rational use of narcotic 
drugs and psychotropic substances. In April 2006, the 
Board sent a letter to all Governments encouraging 
them to ensure the inclusion in university curricula of 
health-care professionals and other professionals, as 
appropriate, of the subject of rational use of narcotic 
drugs and psychotropic substances for medical 
purposes and the risks associated with drug abuse. 
 
 
 B. Psychotropic substances 
 
 
  Status of adherence to the Convention on 
Psychotropic Substances of 1971 
 
69. As at 1 November 2006, the number of States 
parties to the 1971 Convention stood at 179. Of the 
14 States that have yet to become parties to the 1971 
Convention, there are two in Africa (Equatorial Guinea 
and Liberia), one in the Americas (Haiti), three in Asia 
(the Democratic People’s Republic of Korea, Nepal 
and Timor-Leste), one in Europe (Andorra) and seven 
in Oceania (Cook Islands, Kiribati, Nauru, Samoa, 
Solomon Islands, Tuvalu and Vanuatu). Since the 
publication of the report of the Board for 2005, 
Montenegro has become a party to the 1971 
Convention. 
 
  Cooperation with Governments 
 
  Submission of annual statistics 
 
70. As at 1 November 2006, a total of 158 States and 
territories (75 per cent) had submitted to the Board 
annual statistical reports on psychotropic substances 
for 2005 in conformity with the provisions of article 16 
of the 1971 Convention. 
71. The late submission of mandatory annual 
statistical reports creates difficulties for international 
control of psychotropic substances. The Board regrets 
that some main manufacturing and exporting countries 
do not submit annual statistical reports on a regular 
basis and in a timely manner. Statistical information on 
manufacture, imports and exports of psychotropic 
substances from those countries is needed to prepare a 
reliable analysis of global trends in manufacture and 
international trade of psychotropic substances. 
Incomplete or inaccurate details on exports and imports 
hinder identification of discrepancies in trade statistics, 
thereby impeding international drug control efforts. 
The Board urges the authorities of the countries 
concerned to examine the situation and to cooperate 
with the Board, in particular by providing annual 
statistics on psychotropic substances within the 
deadline, as required under the 1971 Convention. 
 
  Quarterly reports for substances in Schedule II of 
the 1971 Convention 
 
72. In accordance with Economic and Social Council 
resolution 1981/7 of 6 May 1981, Governments of 
countries manufacturing, exporting or importing 
substances in Schedule II of the 1971 Convention 
provide voluntarily to the Board quarterly statistics on 
their imports and exports of those substances. A total 
of 146 governments (130 countries and 16 territories) 
submitted quarterly statistical reports for the year 
2005. Methylphenidate is the most commonly traded 
substance followed by substances of the amphetamines 
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group (amphetamine, dexamphetamine and 
methamphetamine). 
 
  Assessments of requirements for psychotropic 
substances 
 
73. Governments are requested to provide to the 
Board at least every three years, assessments of annual 
domestic medical and scientific requirements for 
psychotropic substances pursuant to Economic and 
Social Council resolution 1981/7 in respect of 
substances in Schedule II of the 1971 Convention and 
pursuant to Council resolution 1991/44 of 21 June 
1991 with respect to substances in Schedules III and IV 
of that Convention. The assessments are communicated 
to the competent authorities of all States and territories 
that are required to use them as guidance when 
approving exports of psychotropic substances. The 
Government of the Sudan, for which the Board had 
established assessments since 1997, pursuant to 
Council resolution 1996/30 of 24 July 1996, furnished 
a full revision of assessments for annual medical 
requirements in August 2006. The Government of 
Montenegro has yet to indicate to the Board its own 
assessments, which until recently had been included in 
the assessments of Serbia and Montenegro.15 
74. In January 2006, all Governments were asked to 
review and update, if necessary, the assessments of 
their annual medical and scientific requirements for 
psychotropic substances. As at 1 November 2006, 
62 Governments had submitted to the Board a full 
revision of the assessments of their requirements for 
psychotropic substances and 70 had communicated 
modifications to previous assessments for one or more 
substances. 
75. The Board is concerned that, for several years, a 
number of Governments have not updated the 
assessments of their requirements for psychotropic 
substances. For those countries and territories, such 
__________________ 
 15  Following the Declaration of Independence by the 
National Assembly of Montenegro on 3 June 2006, the 
President of the Republic of Serbia notified the 
Secretary-General that the membership of the state union 
Serbia and Montenegro in the United Nations, including 
all organs and organizations of the United Nations 
system, was continued by the Republic of Serbia, which 
remained responsible in full for all the rights and 
obligations of the state union Serbia and Montenegro 
under the Charter of the United Nations. 
assessments may no longer reflect their actual medical 
and scientific requirements for psychotropic 
substances. The Board encourages all Governments to 
ensure that their assessments are regularly updated and 
that it is informed of any modifications. 
 
  Prevention of diversion of psychotropic 
substances into the illicit traffic 
 
  Diversion from international trade 
 
76. While, in the past, diversion of substances in 
Schedules II, III and IV of the 1971 Convention from 
licit international trade was one of the main sources 
used to supply illicit markets, diversions of substances 
in Schedule I had been occurring rarely. While 
diversion attempts involving substances in Schedule I 
were undertaken in recent years, no actual diversion of 
those substances was reported to the Board. Those 
successes are the result of a well-functioning 
international control regime for psychotropic 
substances in Schedule I. 
77. The use of substances in Schedule I, the group of 
substances subject to the strictest controls under the 
1971 Convention, is prohibited by that Convention, 
except if they are used for scientific and very limited 
medical purposes. Consequently, licit international 
trade in those substances is limited to a small number 
of transactions involving quantities of only a few 
grams per year. Although there have been some 
isolated attempts to divert substances in Schedule I 
over the years, those attempts have been thwarted as a 
result of having the strict international control 
mechanism in place for that group of substances. 
National authorities need to remain vigilant and ensure 
that authorized traders and industries are fully aware of 
all restrictions concerning trade in, and use of, 
psychotropic substances included in Schedule I. 
78. Among the substances in Schedule II of the 1971 
Convention, only amphetamines and methylphenidate 
are manufactured and traded in large quantities, mostly 
for the treatment of attention deficit disorder (ADD) or, 
in the case of amphetamines, for industrial processes. 
Since 1990, no more information has been reported 
involving diversion of those substances from licit 
international trade. For 2005, only one case, involving 
the importation of 4,668 grams of methylphenidate 
from the United States into Sweden without a valid 
import authorization, was reported to the Board. 
According to available information, that unauthorized 
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import was apparently not an attempt at diversion, but 
an administrative oversight. 
79. The above-mentioned development is attributable 
to the control measures set forth in the 1971 
Convention for substances in Schedule II, notably the 
import and export authorization system, which is 
supplemented by additional voluntary control measures 
recommended by the Board and endorsed by the 
Economic and Social Council, such as the assessment 
by Governments of their licit requirements for 
psychotropic substances and the quarterly reporting of 
trade statistics. The continued availability on illicit 
markets of certain countries or subregions of 
pharmaceutical preparations containing a substance in 
Schedule II, such as fenetylline or methaqualone is 
mainly attributable to the illicit manufacture of 
counterfeit products (in the case of “fenetylline 
preparations”, those products usually contain 
amphetamines). 
80. The Board is pleased that a decline in cases of 
diversion from international trade has been observed in 
2005 with regard to substances in Schedules III and IV 
of the 1971 Convention. Although licit international 
trade in those substances is widespread, involving 
thousands of individual shipments exported each year 
to many countries throughout the world, only two cases 
of unauthorized exports have been reported to the 
Board for 2005, both of them involving small 
quantities and both of them having been detected and 
seized by the competent authorities of the countries of 
destination. Such small quantities of those substances 
are in contrast with the quantities diverted during the 
1990s, which in many cases had amounted to several 
hundred kilograms. 
81. The Board notes that the above-mentioned 
development appears to have been the result of the 
continued vigilance of national competent authorities, 
the implementation by Governments of the treaty 
provisions for substances in those schedules, the 
additional controls over international trade and, in 
some cases, the voluntary cooperation of 
manufacturers of psychotropic substances with the 
authorities. The Board invites all States that have not 
yet done so to introduce mandatory import 
authorizations for all psychotropic substances in 
Schedules III and IV of the 1971 Convention, as that 
measure has proved particularly effective in the 
identification of diversion attempts. The Board also 
invites all exporting countries to use the assessments of 
requirements of psychotropic substances, which are 
published by the Board on a regular basis, to verify the 
legitimacy of orders that have been placed. Trade 
transactions identified as being suspicious because the 
import orders exceed the established assessments 
should be either verified with the Board prior to 
approving the export of those substances or brought to 
the attention of the authorities of the importing 
country. 
 
  Diversion from domestic distribution channels 
 
82. Diversion from licit domestic distribution 
channels is at present the main source used to supply 
illicit markets with psychotropic substances. It often 
involves theft from factories and wholesalers; falsified 
prescription; and the dispensing of preparations by 
pharmacies without the required prescriptions. The 
substances most often diverted are stimulants, 
benzodiazepines and the analgesic buprenorphine. 
83. Large-scale diversion of buprenorphine from 
domestic distribution channels has been observed in a 
number of countries, particularly in India, to be abused 
locally or smuggled into other countries, such as Iran 
(Islamic Republic of), Pakistan and the United Arab 
Emirates. After the authorities of the United Arab 
Emirates reported the seizure of 28,800 ampoules of 
buprenorphine smuggled out of India in 2005, the 
authorities of Pakistan, in February 2006, seized 
29,883 ampoules of buprenorphine originating in India 
and purportedly smuggled into Pakistan out of 
Afghanistan. 
84. The diversion of buprenorphine preparations is 
known to occur in some European countries, including 
France, where that substance is widely used in the 
treatment of heroin addicts. It is estimated that 
20-25 per cent of those preparations might be diverted 
to the illicit market by a small number of patients 
selling their preparations or using falsified prescrip-
tions, stolen prescriptions or preparations stolen in 
clinics or pharmacies. Preparations of buprenorphine 
(Subutex®) have also been found on the illicit market 
in the Czech Republic. The buprenorphine preparations 
available on the illicit market in Finland seem to have 
been smuggled into that country. Recently, according 
to information provided to the Board by the Belgian 
authorities, Subutex® tablets (purportedly containing 
buprenorphine) destined for Georgia were seized in 
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Belgium. Significant increases in both the quantity and 
the number of seizures of buprenorphine have also 
been reported in Mauritius; the authorities of that 
country reported that, as buprenorphine can be 
smuggled more easily than heroin or cannabis and 
there was a shortage of heroin during 2005, drug 
traffickers and abusers have been increasingly turning 
to buprenorphine. 
85. Flunitrazepam is a preferred substance of abuse 
in Scandinavian countries. As diversion of that 
substance has become more difficult as a result of the 
adoption of strict control policies for flunitrazepam by 
major manufacturing and importing countries, 
counterfeit tablets are now accounting for a sizeable 
portion of the Rohypnol tablets (presumably containing 
flunitrazepam) seized in those countries. In Egypt, 
where the substance was widely abused in the late 
1990s, the Anti-Narcotics General Administration has 
reported a significant increase in the number of 
Rohypnol tablets seized in 2005: a record of over 
325,000 tablets were seized, an amount almost 
114 times larger than the amount seized in 2004. The 
Board also wishes to encourage the Government of 
Egypt to investigate the extent of the abuse of and 
trafficking in flunitrazepam in that country and to 
report its findings to the Board. 
86. Large seizures of counterfeit Captagon, a 
pharmaceutical preparation that, in its licit form, 
contains fenetylline, continue to be made in countries 
in West Asia. Because of increased control measures, 
fenetylline can no longer be obtained from licit sources 
and as the illicit manufacture of fenetylline is difficult, 
most of the tablets seized nowadays contain 
amphetamines and other stimulants not under 
international control. The main destinations of the 
smuggled counterfeit Captagon tablets are countries on 
the Arab peninsula. According to data from the 
Customs Cooperation Council (also called the World 
Customs Organization), over 80 per cent of all seizures 
of Captagon (containing amphetamine instead of 
fenetylline) reported in the region in 2005 were 
effected in Saudi Arabia. Most of those seizures were 
made at the border with Jordan, where a significant 
increase in trafficking in psychotropic substances was 
noted in 2005. 
87. The abuse of prescription drugs, including 
pharmaceutical preparations containing controlled 
substances, continues to be a matter of concern in 
Canada, the United States and a number of European 
countries. In the United States, the level of abuse of 
prescription drugs, including stimulants such as 
methylphenidate (Ritalin) and amphetamine and 
dexamphetamine (Aderall), and over-the-counter 
medications is no less than the level of abuse of drugs 
such as methylenedioxymethamphetamine (MDMA, 
commonly known as “ecstasy”), cocaine, 
methamphetamine and heroin. In Canada, methyl-
phenidate (Ritalin and Concerta) and dexamphetamine 
(Dexedrine) are among the stimulants under 
international control that are available in pharma-
ceutical preparations. The number of prescriptions for 
methylphenidate in Canada increased by 46 per cent 
between 1999 and 2003. Methylphenidate products are 
crushed by abusers for intravenous injection, which 
entails a number of health risks. The Board urges the 
Governments concerned to develop programmes for 
drug abuse prevention that specifically target the abuse 
of such medications among youth (see para. 340 
below). 
 
  Control measures 
 
  Assistance to Governments in verifying the 
legitimacy of import transactions 
 
88. Many exporting countries continue to request the 
assistance of the Board in verifying the legitimacy of 
import authorizations for psychotropic substances. The 
Board maintains a collection of samples of official 
import certificates and authorizations in use by 
national administrations to compare them with 
questionable import documents. The Board calls on all 
States that have not yet provided such samples to it to 
do so without further delay. 
89. The Board notes that, in certain cases, responses 
to its inquiries for confirmation of the legitimacy of 
import orders are delayed considerably. Such delayed 
responses may hinder the investigation of diversion 
attempts and/or may, in turn, delay the availability of 
psychotropic substances needed for legitimate 
purposes. The Board wishes to draw the attention of 
the Governments of Iraq, Liberia, Romania, Somalia 
and Ukraine to the importance of responding in a 
timely manner to its requests. 
 
  Bilingual import authorizations 
 
90. The attention of the Board has been drawn to 
cases where import authorizations for the import of 
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psychotropic substances have been issued in the 
national language only, which has made the 
verification of the authenticity of such import 
authorizations difficult for the authorities of the 
exporting countries. 
91. While the 1971 Convention does not specify 
which language must be used by Governments issuing 
certificates for the import of controlled substances, the 
Commission on Narcotic Drugs and the Board have 
repeatedly encouraged Governments to use an official 
language of the United Nations,16 in addition to their 
languages, when issuing import and export 
authorizations. The Board wishes to reiterate its call to 
all Governments that have not yet done so to consider 
the issuing of import and export authorizations in two 
languages including one of the official languages of the 
United Nations. By doing so, Governments of 
importing and exporting countries will help to improve 
effective monitoring and control over international 
trade in controlled substances without unduly delaying 
legitimate trade. 
 
  National control measures regarding international 
trade 
 
92. Reports from the Government of Turkey indicate 
that minor quantities of psychotropic substances were 
imported, most likely for reference or forensic 
purposes, using couriers and through the mail without 
the authorization documents required by Turkish law. 
The Board wishes to draw the attention of the 
Governments concerned to the fact that those practices 
are not in compliance with the relevant Economic and 
Social Council resolutions and that exporting countries 
must respect the national legislation of the importing 
countries. 
93. The Board notes with appreciation that in 2006, 
the Democratic People’s Republic of Korea extended 
the system of import and export authorizations to 
include all substances in Schedules III and IV of the 
1971 Convention. At present, export and import 
authorizations are required by national legislation for 
all substances in Schedules III and IV in more than 
150 countries and territories. In approximately 
20 additional countries and territories, import and 
export authorizations are mandatory for at least some 
of those substances. 
__________________ 
 16  Arabic, Chinese, English, French, Russian or Spanish. 
94. The Board requests the Governments that do not 
yet control the import and export of all psychotropic 
substances through the system of import and export 
authorizations to introduce such controls. Experience 
has shown that countries that are centres of 
international commerce but do not have such controls 
are at particular risk of being targeted by drug 
traffickers. Governments should carefully examine the 
table showing the countries in which national 
legislation requires the issuing of import authorizations 
for the import of substances of Schedules III and IV of 
the 1971 Convention, which is circulated twice a year 
to all Governments and update the entries for their 
respective countries as appropriate. Exporting 
countries will not issue export authorizations without 
import authorizations from those countries which have 
indicated to the Board that import authorizations are 
required. 
95. The Board urges all other States concerned, 
irrespective of whether or not they are parties to the 
1971 Convention, such as Andorra, the Bahamas, 
Bhutan, Brunei Darussalam, Burkina Faso, Cape 
Verde, the Congo, Equatorial Guinea, Gabon, Guinea-
Bissau, Ireland, Lesotho, the Libyan Arab Jamahiriya, 
Myanmar, the Niger, Singapore and Zimbabwe, to also 
introduce such controls for all substances listed in the 
1971 Convention. 
96. Another important tool for preventing diversions 
is the verification, by exporting countries, of whether 
the quantities ordered by importing countries are 
within the assessments established by the authorities. 
In 2005, several exporting countries received import 
authorizations for quantities of psychotropic 
substances in excess of the corresponding assessments 
established by the authorities of the importing 
countries. In 2005, about 12 countries issued import 
authorizations for substances in Schedules II, III or IV 
of the 1971 Convention, without established 
assessments for the substances concerned. Moreover, 
about 36 countries issued import authorizations for 
substances in Schedules II, III or IV in quantities 
exceeding their respective assessments. The Board 
appreciates the support received from some major 
exporting countries, including France, Germany, India 
and Switzerland, which have consistently reminded 
importing countries of any failure to comply with the 
assessment system. The Board notes that the number of 
countries issuing such authorizations for quantities 
above assessments has declined in recent years. The 
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Board reiterates its request to all Governments to 
establish a mechanism for ensuring that their 
assessments correspond to their actual legitimate needs 
and that no imports exceeding the assessments are 
authorized. 
 
  Prohibition of imports according to article 13 of 
the 1971 Convention 
 
97. The Board notes that the Government of India has 
invoked article 13 of the 1971 Convention for the 
following substances: aminorex, brotizolam and 
mesocarb. At present, the import of one substance in 
Schedule III (flunitrazepam) and 27 substances in 
Schedule IV is prohibited in India according to the 
provisions of article 13. Information on the prohibition 
of, and restrictions on, export and import pursuant to 
article 13 is published annually by the Board in its 
technical report on psychotropic substances. 
 
  Voluntary submission of details on trade in 
substances in Schedules III and IV of the 
1971 Convention 
 
98. In accordance with Economic and Social Council 
resolutions 1985/15 of 28 May 1985 and 1987/30 of 
26 May 1987, Governments should, in their annual 
statistical reports, provide the Board with details of 
trade in substances in Schedules III and IV of the 
1971 Convention. Such details should include the 
identification of countries of origin for imports and 
countries of destination for exports. Complete details 
of trade movements in 2005 were submitted by 
110 Governments. With few exceptions, all of the 
major manufacturing and exporting countries furnished 
such information. However, some 36 parties to the 
1971 Convention failed to provide that information, 
which may indicate deficiencies in their national 
reporting systems. The Board encourages the 
Governments of the countries concerned to improve 
their data collection systems to ensure the submission 
of details of trade in their future annual statistical 
reports. 
 
  Ensuring the availability of psychotropic 
substances for medical purposes 
 
  Consumption of buprenorphine 
 
99. Buprenorphine is a potent opioid analgesic that 
has been under control in Schedule III of the 
1971 Convention since 1989. For many years, its main 
use has been as an analgesic. Buprenorphine in higher 
doses has lately been used for the detoxification and 
substitution treatment of persons dependent on opiates. 
Since new preparations containing high doses of 
buprenorphine (Subutex®) or buprenorphine with 
naloxone (Suboxone®) have been introduced in several 
countries for the treatment of drug addicts, global 
manufacture and consumption of buprenorphine have 
increased substantially in recent years.  
100. During the five-year period 2001-2005, global 
consumption of buprenorphine has more than 
tripled (from 420 million to 1.5 billion defined daily 
doses for statistical purposes (S-DDD)), averaging 
1.4 billion S-DDD in the three-year period 2003-2005. 
France and Germany have been the main users of the 
substance. The two countries together account for 60 
per cent of the total annual imports of buprenorphine 
(in quantities of more than 1 kg) reported by 43 
countries in the period 2001-2005. Other countries that 
have increased domestic consumption of bupre-
norphine in recent years are Belgium, Italy, Malaysia, 
Portugal, Spain, Switzerland and the United States. 
101. In France, buprenorphine has become the leading 
substance used for the 80 per cent of cases involving 
substitution treatment for persons dependent on 
opiates. Diversion of buprenorphine preparations 
prescribed to opiate addicts has been reported in a 
number of countries. To prevent such diversions, the 
Board encourages Governments to ensure that control 
measures are fully applied in all facilities where 
buprenorphine is dispensed for substitution treatment 
(see para. 84 above and paras. 187-195 below). 
 
  Use of stimulants in Schedule II for the treatment 
of attention deficit disorder 
 
102. Methylphenidate, amphetamine and dex-
amphetamine, substances included in Schedule II of 
the 1971 Convention, are used mainly for the treatment 
of ADD (also called attention deficit/hyperactivity 
disorder (ADHD) in the United States) and narcolepsy. 
While the Board recognizes the usefulness of 
stimulants in the treatment of ADD when prescribed on 
the basis of careful and appropriate diagnosis and 
proper treatment evaluation, it reiterates its concern 
that the significant increase in the use of stimulants for 
ADD treatment in many countries could be attributed 
to possible overdiagnosis and overprescription. The 
Board has also noted that in some countries high 
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prescription levels of stimulants used for the treatment 
of ADD have led to the diversion of those substances. 
103. The use of methylphenidate for medical purposes 
increased significantly in the period 2002-2005. Global 
calculated consumption of the substance increased 
from 18.5 tons in 2001 to 30.4 tons in 2005. That large 
increase was mainly a result of developments in the 
United States, where the substance is advertised in the 
media, directly to potential customers. It is frequently 
prescribed for the treatment of ADD, primarily in 
children. The Board has also noted that since the late 
1990s, the use of methylphenidate has risen sharply in 
many other countries as well, mainly Canada, Israel 
and Norway. In Norway, the substance was the 
preferred treatment for adults diagnosed with ADD. 
104. The Board requests the competent authorities of 
countries with an increasing level of consumption of 
stimulants in Schedule II of the 1971 Convention to 
remind health-care professionals of the need for proper 
diagnosis of ADD and appropriate prescription 
practice, in accordance with article 9, paragraph 2, of 
the 1971 Convention, as well as the need for secure 
storage and distribution of such substances. In 
addition, the Board urges the Government of the 
United States to prohibit public advertisement of 
psychotropic substances, including stimulants in 
Schedule II used for the treatment of ADD, in 
accordance with article 10 of the 1971 Convention. 
 
  Stimulants in Schedule IV used as anorectics 
 
105. The stimulants listed in Schedule IV of the 1971 
Convention are mainly used as anorectics. The highest 
per capita consumption of stimulants in Schedule IV 
has traditionally been in the Americas. While the 
consumption of such stimulants continues to be on the 
increase in the Americas, their consumption in Asia, 
Europe and Oceania has decreased markedly since 
2000. In 2005, the highest rates of calculated use per 
1,000 inhabitants per day of stimulants in Schedule IV 
of the 1971 Convention were reported in Brazil 
(12.5 S-DDD), Argentina (11.8 S-DDD), the Republic 
of Korea (9.8 S-DDD) and the United States 
(4.9 S-DDD). 
106. The Board has regularly requested the 
Governments concerned to devote adequate attention to 
those elevated consumption levels. The Governments 
of some countries, including Chile, Denmark and 
France, introduced special measures to control the 
inappropriate use of stimulants, which have resulted in 
a significant decrease in the use of stimulants in those 
countries. In other countries, however, in particular, 
Argentina, Australia, Brazil, the Republic of Korea and 
Singapore, per capita consumption of anorectics has 
risen significantly. 
107. In the past, the use of phentermine in the United 
States declined significantly as a result of the 
withdrawal of preparations containing both 
phentermine and fenfluramine. However, since 2000, 
consumption of phentermine in the United States has 
again been rising. Moreover, measures introduced in a 
number of countries in South America to control the 
inappropriate use of some stimulants led to a decrease 
in global consumption levels of that group of 
substances. Since 2000, however, the consumption of 
other stimulants in Schedule IV has markedly 
increased mainly in two countries in the Americas 
(Argentina and Brazil). The Board is concerned that 
the increasing availability of stimulants in Argentina 
and Brazil may lead to conditions that are conducive to 
their abuse and diversion. 
108. Attempts to divert stimulants listed in 
Schedule IV, such as amfepramone, from licit 
distribution channels and cases involving illicit 
trafficking in the substance have been reported in 
several countries in Asia and Europe in recent years. 
The Board recommends that the authorities in those 
countries monitor the situation closely for 
overprescribing of anorectics while ensuring adequate 
measures of control over domestic distribution 
channels. 
 
 
 C. Precursors 
 
 
  Status of adherence to the United Nations 
Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988 
 
109. As at November 2006, the number of States 
parties to the United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances 
of 198817 stood at 180. The 1988 Convention was also 
formally confirmed by the European Community 
(extent of competence: article 12), bringing the total 
number of parties to the Convention to 181. Currently, 
__________________ 
 17  United Nations, Treaty Series, vol. 1582, No. 27627. 
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92 per cent of all States in the world are parties to the 
Convention. The Board welcomes the accession of 
Gabon, Montenegro and Vanuatu to the 1988 
Convention.  
110. All of the world’s major manufacturing, 
exporting and importing States are now parties to the 
1988 Convention. Of the remaining 14 States that have 
yet to become parties to it, 3 are in Africa (Equatorial 
Guinea, Namibia and Somalia), 2 are in Asia (the 
Democratic People’s Republic of Korea and 
Timor-Leste), 2 are in Europe (the Holy See and 
Liechtenstein) and 7 are in Oceania (Kiribati, the 
Marshall Islands, Nauru, Palau, Papua New Guinea, 
Solomon Islands and Tuvalu).  
111. The Board calls on those 14 States which have 
yet to become parties to the 1988 Convention to 
implement the provisions of article 12 and to become 
parties to the Convention without further delay.  
 
  Cooperation with Governments 
 
112. As at 1 November 2006, a total of 126 States and 
territories, as well as the European Commission, on 
behalf of its member States, had provided the Board 
with the required information for 2005 on substances 
frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances. The rate of 
submission remained the same as for previous years. 
The Board urges those States parties to the 1988 
Convention which have not yet submitted that 
treaty-required information to do so without further 
delay. Among those States are Kuwait, Lesotho, the 
Niger, Serbia, the Sudan and Zimbabwe, which have 
not complied with their reporting obligations for at 
least five years.  
113. While 45 Governments have reported seizures of 
precursors effected in 2005, only a few of them have 
supplemented that information with additional data 
required on non-scheduled chemicals, methods of 
diversion and stopped shipments. More often, the 
information provided was in figures and did not 
provide sufficient details. The Board calls on all 
Governments effecting seizures or intercepting 
shipments of precursors to investigate those cases and 
to report the results to enable the Board to identify new 
and emerging trends in illicit drug manufacture and 
trafficking in precursors. 
 
  Annual submission of information on the licit 
trade in and uses of substances in Tables I and II 
of the 1988 Convention  
 
114. Since 1995, the Board, in accordance with 
Economic and Social Council resolution 1995/20 of 
24 July 1995, has requested the supply of data on licit 
trade in, uses of, and requirements for, substances in 
Tables I and II of the 1988 Convention. The provision 
of such data on form D is voluntary.  
115. As at 1 November 2006, a total of 107 States and 
territories had reported data for 2005 on the licit 
movement of precursors and 96 Governments had 
furnished information for 2005 on licit uses of and 
requirements for such substances. As in previous years, 
the European Commission has furnished information 
representing submissions from all 25 States members 
of the European Union. Most of the States and 
territories that submitted form D for 2005 furnished 
data on imports of and licit requirements for scheduled 
substances. The number of States and territories 
providing information on licit requirements of 
ephedrine and pseudoephedrine increased to 71 and 68, 
respectively. 
116. In particular, all of the major manufacturing and 
importing countries except Pakistan provide data on 
licit trade in scheduled substances. Pakistan, which 
imports significant quantities of substances in Table I 
of the 1988 Convention, has yet to provide data on its 
licit trade in and requirements for scheduled 
substances. The Board wishes to encourage Pakistan to 
furnish the requested data without further delay. 
 
  Prevention of diversion of precursors into the 
illicit traffic 
 
117. Practical and effective mechanisms for the rapid 
verification of transactions in precursor chemicals, 
particularly through the system of pre-export 
notifications, continue to be a priority for 
Governments, as well as the Board, as such 
mechanisms remain the most effective way to address 
diversion of and trafficking in chemicals. The 
international initiatives Project Prism and Project 
Cohesion, which focus on key precursor chemicals 
used in the illicit manufacture of amphetamine-type 
stimulants (ATS), heroin and cocaine, remain key 
elements of the international precursor control system.  
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118. Within the framework of those projects, the 
Board has assisted national authorities in monitoring 
thousands of shipments of chemicals in international 
trade and, in numerous cases, in preventing their 
diversion into illicit channels. During the current 
reporting period, the Board has assisted Governments 
in identifying and preventing the diversion of 
controlled chemicals in 55 cases. The Board is pleased 
that 126 States and territories have designated central 
national authorities for Project Prism and encourages 
all those that have not yet designated their national 
authorities to do so without delay and to start 
participating in that initiative. 
119. With regard to Project Cohesion, the Board 
invites participating Governments to bolster their 
activities under the project by considering the launch 
of activities in precursor chemicals that target 
trafficking in relevant regions, such as in Operation 
Trans-shipment. In particular, it would be useful for 
authorities in the Americas to devise a similar activity 
to address trafficking in potassium permanganate. The 
Board anticipates that, by following such an action, 
success in countering criminal networks trafficking in 
chemicals used to manufacture heroin and cocaine will 
be achieved. Governments should continue to place the 
utmost importance on investigations into stopped or 
seized shipments of precursor chemicals and follow up 
on information provided on attempted diversions of 
such chemicals. Intelligence driven investigations and 
backtracking investigations have proved particularly 
useful in the identification of those responsible for 
trafficking in and diversion of precursors. 
120. Detailed information on the activities of 
Governments and the Board in the area of precursor 
control is contained in the 2006 report of the Board on 
the implementation of article 12 of the 1988 
Convention.18 
 
__________________ 
 18  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2006 on the Implementation of 
Article 12 of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (United Nations publication, Sales 
No. E.07.XI.12). 
  Control measures 
 
121. During the current reporting period, Governments 
of a number of countries (Australia, Bhutan, China, the 
Gambia, the Philippines, the United States and Yemen) 
have adopted new, or strengthened existing, legislation 
and administrative controls over precursors. In 
particular, Australia, the Philippines and the United 
States have recently strengthened controls over 
preparations containing ephedrine and pseudo-
ephedrine. 
122. As controls over international trade in precursor 
chemicals improve, traffickers develop new methods 
and routes of diversion, utilizing in particular domestic 
distribution channels. For example, in Africa, many 
countries lack the infrastructure to control precursors 
effectively at the national level. The Board is 
concerned that Africa is being increasingly used for the 
diversion of precursors, as evidenced by the attempted 
large-scale diversion of ephedrine and 
pseudoephedrine in 2006. The Board urges all parties 
to take all the measures necessary to monitor the 
manufacture and distribution of scheduled substances 
within their territories, pursuant to article 12, 
paragraph 8 (a), of the 1988 Convention. 
 
  Advisory Expert Group and assessment of 
substances 
 
123. In 2006, the Board convened its Advisory Expert 
Group: (a) to determine whether information is 
available that would require the transfer of 
phenylacetic acid from Table II to Table I of the 1988 
Convention; (b) to evaluate the limited international 
special surveillance list of non-scheduled substances; 
(c) to examine the current status of control of safrole 
and the safrole-rich oils to provide, if necessary, a 
definition of safrole; and (d) to identify possible 
courses of action to address current attempts to divert 
ephedra from licit trade for use in the illicit 
manufacture of drugs.  
124. Based on the findings of the Advisory Expert 
Group, the Board has recommended the transfer of 
phenylacetic acid from Table II to Table I of the 1988 
Convention. With regard to the limited international 
special surveillance list of non-scheduled substances, 
the Board has emphasized that the monitoring 
measures associated with the list should be applied 
through voluntary cooperation with the chemical 
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industry. As in the past, the Board will continue to 
distribute the list directly to competent authorities. 
125. In response to Commission on Narcotic Drugs 
resolution 49/7, entitled “Promoting a consistent 
approach to the treatment of safrole-rich oils”, the 
Board prepared a definition of safrole/safrole-rich oils 
that will be communicated to the Commission at its 
fiftieth session. Following attempts to divert ephedra 
and its extracts from international trade, the Board also 
carried out a review of the information currently 
available on that substance. The Board concluded that 
more data were required before a decision could be 
made regarding possible changes to the tables of the 
1988 Convention.  
 
  Online system of pre-export notifications 
 
126. The system of pre-export notifications is the 
cornerstone of international precursor control. 
Exporting countries now regularly send pre-export 
notifications for shipments of scheduled precursor 
chemicals. That information has proved to be valuable 
in the identification of numerous suspicious 
transactions. In Project Prism and Project Cohesion, 
the system of pre-export notifications has greatly 
facilitated the successful verification of the legitimacy 
of individual transactions. 
127. In March 2006, the Board officially launched Pre-
Export Notification Online (PEN Online), a new 
electronic system for the exchange of pre-export 
notifications. As at 1 November 2006, 71 States and 
territories had registered in the new automated system 
and over 2,800 transactions had been communicated to 
importing countries and the Board through PEN 
Online. The system is being used by a growing number 
of States, including many major chemical exporters. 
More importantly, it has helped in the identification of 
new patterns and trends in both trafficking and licit 
trade in precursors, as highlighted in the 2006 report of 
the Board on the implementation of article 12 of the 
1988 Convention.19 The Board encourages all 
Governments to register and use the PEN Online 
system for the quick and efficient exchange of data. 
 
__________________ 
 19  Ibid. 
  Estimates of legitimate requirements for 
precursors  
 
128. In its report for 2005, the Board encouraged 
Governments to estimate their licit requirements for 
precursors used in the illicit manufacture of ATS and 
submit those data to it.20 In its resolution 49/3, the 
Commission on Narcotic Drugs: (a) noted that the 
precursor chemicals 3,4-methylenedioxyphenyl-2-
propanone, ephedrine, pseudoephedrine and 1-phenyl-
2-propanone were important for the illicit manufacture 
of “ecstasy”, methamphetamine and amphetamine; 
(b) requested Member States to inform the Board of 
their estimated licit requirements for those precursors 
and estimated requirements for imports of preparations 
containing those chemicals; and (c) requested Member 
States to permit the Board to share with national 
authorities, taking care not to impede legitimate 
commerce, shipment information on those preparations 
so that measures could be taken to prevent or intercept 
those shipments.21 
129. In response, some States have estimated their 
annual legitimate requirements for those chemicals and 
that information has been published by the Board in its 
2006 report on the implementation of article 12 of the 
1988 Convention. It is expected that many more States 
will be able to provide such information. Competent 
authorities of each country are invited to inform the 
Board of any methodology that they find useful for 
estimating their country’s legitimate requirements. 
Each Government is also invited to review the 
legitimate requirements published for its country and, 
where necessary, adjust them and inform the Board of 
the changes to be made. 
 
__________________ 
 20  Report of the International Narcotics Control Board for 
2005 …, para. 648, recommendation 12. 
 21  Official Records of the Economic and Social Council, 
2006, Supplement No. 28 (E/2006/28), chap. I, sect. C, 
resolution 49/3. 
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  Diversion of and trafficking in substances used in 
the illicit manufacture of amphetamine-type 
stimulants: Project Prism 
 
130. Data gathered under Project Prism on seizures 
and cases of diversion and attempted diversion 
highlight the magnitude of the problems related to 
preventing the illicit manufacture of ATS and 
particularly methamphetamine. As international 
controls over ephedrine and pseudoephedrine, traded as 
raw materials, are improving, traffickers are 
increasingly trying to obtain those substances in other 
forms, such as pharmaceutical preparations and natural 
products such as ephedra. Trafficking organizations are 
also trying to exploit situations where controls over 
such commodities at the domestic manufacture and 
distribution levels are less stringent or absent. In this 
connection, more than 30 cases of attempted diversion, 
involving over 2,100 tons of ephedra, have been 
reported to the Board since the beginning of 2005. 
131. During the current reporting period, over 
2,100 transactions involving licit international trade in 
ephedrine and pseudoephedrine have been monitored 
under Project Prism. The Board has issued a number of 
special alerts on trends in diversion, and it greatly 
appreciates the feedback received from Governments 
on those alerts. Activities under Project Prism have 
assisted Governments and the Board in identifying new 
trends, such as the diversion of raw materials from 
South Asia, Africa, Central America and West Asia and 
ephedra shipments from East Asia to Canada and 
countries in Europe and the smuggling of 
pharmaceutical preparations into and within Africa, 
Central and South America and West Asia. The 
diversion of raw ephedrine and pseudoephedrine to 
countries in North America, in particular to Mexico, 
seems to have declined, while diversion attempts in 
Central and South America continued throughout 2006. 
Several Governments of countries in the Americas 
have discovered attempts at diversion of pharma-
ceutical preparations in large quantities. The Board is 
particularly concerned that Africa and West Asia are 
starting to be used by organized criminal networks as 
trans-shipment points for consignments of ephedrine 
and pseudoephedrine destined for the illicit manu-
facture of methamphetamine. For example, multi-ton 
shipments of pseudoephedrine for use in the 
manufacture of pharmaceutical preparations, to be re-
exported to Mexico, have been ordered in West Asia. 
132. The Governments of importing countries in the 
above-mentioned regions are urged to take appropriate 
measures to monitor the manufacture, distribution and 
export of preparations containing ephedrine and 
pseudoephedrine, to ensure that the end-users are 
legitimate and to prevent accumulation of those 
preparations in quantities exceeding the licit 
requirements. As the diversion of precursors used in 
the illicit manufacture of methamphetamine is a global 
problem, the Board has recommended specific 
measures to be adopted by all Governments, in 
particular the use of pre-export notifications for 
pharmaceutical preparations as well as the estimation 
of licit requirements for ephedrine, pseudoephedrine 
and preparations containing those two substances. 
133. At its meetings during 2006, the Project Prism 
Task Force examined the latest developments related to 
diversion of, and trafficking in, precursors, in 
particular ephedra, used in the illicit manufacture of 
ATS. The Task Force noted the following: new 
legislation in the United States aimed at addressing the 
methamphetamine problem in that country; the 
measures against diversion of ephedrine and 
pseudoephedrine and the ban on ephedra adopted by 
the Mexican authorities; and the latest trends in 
suspicious shipments, including shipments to Africa, 
Central and South America and West Asia. The Task 
Force also focused its attention on trends and 
developments in Oceania. The Task Force held a 
special meeting with the main countries involved in the 
exporting and trans-shipment of ephedrines. Following 
that, the Task Force decided on operational measures to 
be carried out during the period 2006-2007 to address 
concerns regarding the diversion of large amounts of 
raw materials and preparations containing ephedrine 
and pseudoephedrine.  
 
  Diversion of and trafficking in substances used in 
the manufacture of heroin and cocaine: Project 
Cohesion 
 
134. Project Cohesion is a global initiative aimed at 
assisting countries in addressing the diversion of acetic 
anhydride and potassium permanganate by providing a 
platform from which time-bound regional operations 
can be launched, investigations into seizures and 
stopped shipments can be coordinated and licit trade 
can be monitored. Currently, 82 competent national 
authorities are participating in Project Cohesion. The 
Board invites all Governments that have not yet done 
  23 
 
 E/INCB/2006/1
so to join the initiative in order to prevent traffickers 
from identifying new routes of diversion and avoid 
controls. 
135. During 2006, the monitoring of licit international 
trade in precursors continued. More focused efforts are 
required in the investigation of cases and the launching 
of specific time-bound operations to counter trafficking 
at the subregional level, such as Operation Trans-
shipment, carried out in Central Asia to identify and 
seize consignments of acetic anhydride smuggled into 
Afghanistan. The operation was the first of its kind in 
the Central Asian subregion. It involved all five 
countries in that subregion: Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan and Uzbekistan. The 
operation, which was held in July 2006, resulted in 
seizures of sulphuric acid, as well as opium, “hashish” 
(cannabis resin) and heroin from Kazakhstan, 
Kyrgyzstan and Tajikistan. Although no acetic 
anhydride was seized during the operation, the Board 
trusts that the lessons learned will be used to launch 
similar activities involving, wherever possible, other 
countries in the region of West Asia, including 
Afghanistan. 
136. Based on the evaluation of the results of 
Operation Trans-shipment, Governments should 
continue operations to identify and dismantle the 
criminal networks involved. Afghanistan made a major 
seizure of acetic anhydride (1,250 litres) in May 2006. 
However, hardly any of the countries bordering 
Afghanistan reported seizures of acetic anhydride 
during 2005 and 2006. The lack of evidence linking 
seizures of acetic anhydride to diversion directly from 
international trade raises concern over the control 
exercised by Governments of neighbouring countries 
with a view to preventing the diversion of precursors 
from domestic distribution channels.  
137. Activities following the example of Operation 
Trans-shipment may also be useful in regions other 
than West Asia. For instance, fewer attempts to divert 
from international trade potassium permanganate, a 
key chemical used in the manufacture of cocaine, have 
been uncovered recently. That may indicate that 
traffickers have developed new methods and routes of 
diversion, possibly utilizing domestic distribution 
channels in third countries not usually associated with 
the illicit manufacture of cocaine. As large seizures of 
potassium permanganate were reported for 2005 – 
141 tons of the substance were seized in Colombia 
alone – it would be useful for authorities in the 
Americas to devise activities to address trafficking in 
potassium permanganate similar to the ones used to 
address trafficking in acetic anhydride. In particular, 
Colombia and its neighbouring States should urgently 
launch investigations to identify the sources and routes 
used for smuggling potassium permanganate into areas 
where the illicit manufacture of cocaine takes place. 
 
 
 D. Evaluation of overall treaty compliance 
by selected Governments 
 
 
138. Pursuant to its mandate under the international 
drug control treaties, the Board reviews, on a regular 
basis, the drug control situation in various countries 
and Governments’ overall compliance with the 
provisions of those treaties. The review covers various 
aspects of drug control, including the functioning of 
national drug control administrations, the adequacy of 
national drug control legislation and policy, measures 
taken by Governments in combating drug abuse and 
illicit trafficking and Governments’ fulfilment of their 
reporting obligations as required under the 
international drug control treaties.  
139. The Board, while reviewing the drug control 
situation in various countries, adopts, when necessary, 
positions on particular drug control issues. Those 
positions are conveyed to the Governments concerned 
and, when appropriate, made public by the Board 
through its annual report. 
140. In 2006, the Board reviewed the drug control 
situation in Papua New Guinea and Switzerland, as 
well as measures taken by the Governments of those 
two countries for the implementation of the 
international drug control treaties. In so doing, the 
Board paid particular attention to new developments in 
drug control in those two countries that might endanger 
the aims of the treaties. 
 
  Papua New Guinea 
 
141. In recent years, Papua New Guinea has 
experienced increasing problems of illicit cannabis 
production and abuse. Despite those acute problems, 
national drug control efforts are undermined by a lack 
of coordination within the Government and inadequate 
legislation. The country also suffers from inadequate 
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law enforcement capacity, and the rule of law is 
generally lacking. 
142. Drug control legislation in Papua New Guinea is 
out of date. It provides inadequate penalties for drug-
related offences. Though new legislation was drafted in 
the early 1990s, it has still not been adopted.  
143. Despite the existence of the National Narcotics 
Bureau, the national coordinating body for drug 
control, the Government of Papua New Guinea has 
failed to comply with its reporting obligations under 
the international drug control treaties for the past 
10 years. The Government has also failed to respond to 
the Board’s queries for information regarding the drug 
control situation in the country. 
144. The Board underlines that the chain of 
international drug control is as strong as its weakest 
link. If even one State fails to fulfil its obligations 
under the international drug control treaties, there is 
the danger that it might be exploited by drug 
trafficking organizations. The Board urges the 
Government of Papua New Guinea to take effective 
measures to remedy the situation without delay. 
 
  Switzerland 
 
145. For many years, Switzerland was one of the few 
European States that had not become a party to the 
1988 Convention, though it had cooperated closely 
with the Board by regularly providing data on 
precursor chemicals. After some years of dialogue with 
the Board on that issue, Switzerland acceded to the 
1988 Convention in 2005 and it is now a party to all 
three international drug control treaties. 
146. Drug injection rooms remain in operation in 
various parts of Switzerland. Some of the drug 
injection rooms also appear to provide facilities – 
generally known as inhalation rooms – where drug 
abusers can abuse drugs by inhalation. The Board has 
stated on numerous occasions, both to the Government 
of Switzerland and in its annual reports, that such 
rooms are in violation of the international drug control 
treaties. The Board urges the Government to provide 
adequate services and facilities to those in need of 
treatment in accordance with the international drug 
control treaties, instead of providing injection and 
inhalation rooms (see paras. 175-179 below). 
 
 
 E. Evaluation of the implementation by 
Governments of recommendations 
made by the Board subsequent to its 
country missions 
 
 
147. In discharging its mandate under the international 
drug control treaties, the Board undertakes an average 
of 20 country missions a year to maintain a direct 
dialogue with competent national authorities on 
matters relating to the implementation of the 
provisions of the treaties. Furthermore, as part of its 
ongoing dialogue with Governments, the Board 
conducts an annual evaluation of the implementation of 
its recommendations pursuant to its country missions. 
Selected countries are requested to provide information 
on progress made in the implementation of the Board’s 
recommendations, including any achievements made 
and difficulties encountered. 
148. In 2006, the Board selected five countries to 
which it had sent missions in 2003: Algeria, Cambodia, 
Fiji, Germany and Peru. The Board expresses its 
appreciation for the information provided by the 
Governments of Cambodia, Germany and Peru. Their 
cooperation enabled the Board to conduct a meaningful 
assessment of the drug control situation in those 
countries and the progress made by the Governments in 
addressing drug problems. Information provided by the 
Government of Algeria was received too late to be 
reviewed by the Board and is therefore not presented 
below. 
149. The Board notes with concern that no information 
was received from the Government of Fiji. The Board 
underlines the importance of the review of its country 
missions and requests the Government of that country 
to ensure that the required information is provided to it 
without further delay. 
 
  Cambodia 
 
150. Since the late 1990s, Cambodia has increasingly 
been used as one of the major trans-shipment points for 
consignments of ATS, mainly methamphetamine. In 
addition, methamphetamine has illicitly been 
manufactured in the country. The geographical location 
of the country, its limited national law enforcement 
capacity and a general lack of the rule of law have all 
contributed to a worsening situation with regard to 
drug trafficking and abuse. Inadequate control of the 
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licit movement of controlled substances has also 
resulted in the abuse of some psychotropic substances. 
151. Despite its lack of capacity, the Government of 
Cambodia has cooperated closely with the Board and 
some progress has been made in the implementation of 
the Board’s recommendations following its 2003 
mission to that country. In particular, Cambodia 
acceded to the three international drug control treaties 
in 2005 and has revised its national legislation to 
ensure compliance with its obligations under those 
treaties. 
152. In addition, the Government of Cambodia has 
established a national network to collect data on 
patterns of drug abuse, a first step towards systematic 
assessment of the scope of drug abuse in the country, 
and has adopted a national drug control plan. However, 
the Government has not been able to implement the 
plan fully because of inadequate funding. In addition, 
there appears to have been no significant progress in 
controlling psychotropic substances at the retail level 
and in preventing the abuse of those substances. The 
Board appeals to Cambodia’s partners to provide 
adequate financial and technical support to enable the 
Government to implement its drug control plan. 
 
  Germany 
 
153. Pursuant to its 2003 mission to Germany, where 
the Board visited drug injection rooms (called “drug 
consumption rooms” in Germany) and some drug 
abuse treatment establishments, the Board reiterated to 
the Government its view that such rooms violate the 
international drug control treaties and recommended 
that the Government take immediate measures to 
ensure compliance with its international obligations. 
154. The Board remains concerned that the policy of 
the Government of Germany in this area has not 
changed, and that rooms for the “consumption” of 
drugs, including by injection, continue to be in 
operation in the country. The Board urges the 
Government to take the steps necessary to ensure that 
the provisions of the international drug control treaties 
are fully implemented in the country and that the 
operation of such rooms is brought to a halt. The Board 
encourages the Government to continue its efforts to 
ensure that adequate services are made available to 
those in need of treatment, rehabilitation and social 
integration, in conformity with the international drug 
control treaties, rather than establishing such rooms. 
  Peru 
 
155. Peru is one of the world’s largest producers of 
coca leaf, with cultivation of coca bush taking place 
for purposes that are neither medical nor scientific. The 
Board has, on various occasions, brought to the 
attention of the Government its treaty obligations and 
urged it to take measures to remedy the situation. 
156. The Board notes that, pursuant to its dialogue 
with the Government, a declining trend has been 
observed in the total area under coca bush cultivation 
in Peru, as a result of the Government’s efforts in 
promoting manual eradication and sustainable legiti-
mate alternative development in the most affected 
areas. Though some regional authorities had adopted 
laws permitting coca bush cultivation, in September 
2005 the Tribunal Constitucional del Perú 
(constitutional tribunal of Peru) made a decision nulli-
fying those laws. The Government has also 
strengthened controls over precursor chemicals, in 
particular those precursors used in the illicit 
manufacture of cocaine hydrochloride. 
157. The Board notes that the Government of Peru 
conducted a national survey on drug abuse in 
secondary schools in 2005 and is carrying out a general 
population survey in 2006. However, the measures 
undertaken to combat drug abuse through treatment 
and rehabilitation are not keeping pace with the 
increasing demand for those services. The Board urges 
the Government to take the necessary measures so that 
progress can be made in those areas as well. 
 
 
 F. Measures to ensure the implementation 
of the international drug control 
treaties 
 
 
  Action of the Board taken pursuant to article 14 
of the 1961 Convention and article 19 of the 
1971 Convention 
 
158. Since 1997, the Board has invoked article 14 of 
the 1961 Convention and article 19 of the 1971 
Convention, which contain measures to ensure the 
execution of the provisions of the two conventions, 
with respect to a limited number of countries. The 
objective of the Board has been to promote compliance 
with those conventions when other means had failed. 
The Board notes that most of the States took remedial 
measures; consequently, the Board decided to 
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terminate any action pursuant to those articles vis-à-vis 
those States. 
159. The Board is concerned that one State, for which 
measures under article 14 of the 1961 Convention and 
article 19 of the 1971 Convention remain invoked, has 
so far made no sustainable progress. Should that State 
fail to take immediate steps to remedy the situation, the 
Board will have no choice but to take further action, 
pursuant to article 14 of the 1961 Convention and 
article 19 of the 1971 Convention, and bring the matter 
to the attention of the parties, the Economic and Social 
Council and the Commission on Narcotic Drugs. 
 
  Consultation with the Government of 
Afghanistan pursuant to article 14 of the 
1961 Convention 
 
160. The Board invoked article 14 of the 1961 
Convention vis-à-vis Afghanistan in 2000, in view of 
the fact that that country had become by far the world’s 
largest illicit producer of opium and was seriously 
endangering the aims of the 1961 Convention. The 
Board has since then followed closely the drug control 
situation in Afghanistan and has maintained an ongoing 
dialogue with the Government to ensure that progress 
is made in drug control in that country. 
161. The Board notes with concern that the drug 
control situation in Afghanistan is deteriorating despite 
the commitment of the Government of Afghanistan, as 
reiterated by the President of Afghanistan on various 
occasions, and despite the assistance provided to the 
Government by the international community over the 
past five years. There has been little progress in drug 
control in the country, in particular with regard to the 
elimination of illicit opium poppy cultivation and 
opium production. 
162. As evidenced by the UNODC report entitled 
Afghanistan: Opium Survey 2006,22 the area under 
illicit opium poppy cultivation reached a record level 
in 2006, with potential opium production estimated at 
about 6,100 tons, an increase of nearly 50 per cent over 
the figure for 2005. The alarming scale of that illicit 
activity, in which 2.9 million persons (12.6 per cent of 
the population) are engaged, constitutes a major 
obstacle to achieving peace, security and development 
__________________ 
 22  United Nations Office on Drugs and Crime, Afghanistan: 
Opium Survey 2006 (September 2006). 
in Afghanistan and poses a continuous threat to 
countries in the neighbouring area and beyond.  
163. Progress in eradicating illicit opium poppy 
cultivation in Afghanistan has often been impeded by 
corruption prevailing throughout the country. The 
Board stresses that, unless the Government of 
Afghanistan takes serious and firm measures to address 
this problem, the Government’s efforts in drug control 
will be undermined, further hindering political 
progress, economic growth and social development in 
the country.  
164. The Board regrets that five years after the 
Government’s issuance of a ban on opium production, 
illicit opium poppy cultivation in Afghanistan has not 
been contained but has instead reached a record high 
level. Today, one third of the Afghan economy remains 
opium-based, which contributes to the widespread 
corruption in the country. The elimination of illicit 
drug activities, in particular the illicit cultivation of 
opium poppy, is crucial to the efforts of the 
Government of Afghanistan to comply with its 
obligations under the international drug control 
treaties. The Government of Afghanistan should be 
held accountable for eradicating opium poppy 
cultivation and should take firm measures against 
corrupt officials involved in illicit drug activities. 
165. Illicit opium poppy cultivation is not the only 
drug control problem that has hindered the progress of 
the Government of Afghanistan in fulfilling its 
obligations under the international drug control 
treaties. Control of licit activities related to narcotic 
drugs, psychotropic substances and precursors in 
Afghanistan remains extremely weak. In particular, 
there is an absence of adequate drug control 
regulations and mechanisms, resulting in a 
proliferation of unregulated retail outlets selling 
controlled substances, many of which have been 
smuggled into the country.  
166. Drug abuse continues to increase in Afghanistan, 
as evidenced by the findings of the first nationwide 
survey on drug abuse conducted by UNODC and the 
Government of Afghanistan in 2005. Cannabis abuse is 
widespread: cannabis abusers account for 2.2 per cent 
of the total population of Afghanistan. Although drug 
abuse by injection appears to be a relatively new 
phenomenon, the number of heroin abusers has been 
increasing over the past five years. The Board urges 
the Government to pursue its action plan on demand 
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reduction, paying particular attention to raising public 
awareness and educating the population, especially 
women and young people about drug abuse prevention. 
167. The Board notes that the Government of 
Afghanistan established the Drug Regulation 
Committee in August 2006. The Committee is 
entrusted with the task of regulating licit activities 
related to controlled substances, an important step 
towards ensuring Afghanistan’s full compliance with 
the provisions of the international drug control treaties. 
The Board requests the Government to take the steps 
necessary to ensure effective functioning of the Drug 
Regulation Committee. 
168. Pursuant to a decision by the Board, a training 
seminar on the control of licit activities related to 
narcotic drugs, psychotropic substances and precursors 
was organized jointly by UNODC and the Board in 
Kabul in July 2006. The seminar, the first of its kind in 
Afghanistan, focused on the relevant provisions of the 
international drug control treaties and the obligations 
of the Government of Afghanistan under those treaties, 
with a view to strengthening the Government’s 
capacity to prevent diversion and ensure the 
availability of those substances for legitimate purposes. 
The Board urges UNODC to provide the necessary 
funding for the implementation of further training 
programmes aimed at increasing the capacity of 
Afghanistan to fulfil its treaty obligations.  
169. The Board notes that the year 2006 witnessed 
increased efforts by the international community to 
assist the Government of Afghanistan in establishing 
the rule of law throughout the country, which is 
essential to drug control efforts and to the success of 
the broader reconstruction process. Increased efforts 
have also been made to develop new intelligence 
structures and to build the capacity of drug law 
enforcement and criminal justice agencies. Those 
efforts are starting to show results. Since August 2005, 
there has been an increase in the number of drug 
traffickers convicted and a significant increase in drug-
related seizures and the destruction of illicit drug 
laboratories. 
170. The Board wishes to emphasize that achieving 
peace, security and development in Afghanistan is 
closely linked to solving the drug control problem, 
which requires the full support and cooperation of the 
international community. The Board calls upon the 
international community, particularly donor countries, 
to continue to assist the Government of Afghanistan in 
its efforts to eliminate the drug problem, thereby 
achieving the goals set out in the National Drug 
Control Strategy. The Government, for its part, should 
redouble its efforts to remove impediments to the rule 
of law. 
 
 
 G. Special topics 
 
 
  Bolivia 
 
171. The situation in Bolivia, which for many years 
has not been in conformity with that State’s obligations 
under the international drug control treaties, continues 
to be a matter of particular concern to the Board. 
Bolivia is a major producer of coca leaf, and national 
legislation allows the cultivation of coca bush and the 
consumption of coca leaf for non-medical purposes, 
which are  not in line with the provisions of the 1961 
Convention. 
172. In addition, some of the coca leaf produced in 
accordance with national legislation in Bolivia is 
diverted and used for the illicit manufacture of cocaine. 
There is also information indicating increase in the 
illicit manufacture of and trafficking in cocaine base 
and cocaine hydrochloride in recent years, as well as 
an increase in trafficking in precursor chemicals used 
in cocaine manufacture. 
173. The Government of Bolivia has indicated its 
intention to review existing national drug control 
legislation, with a view to using coca leaf for a wide 
range of products, some of which might be exported. 
The Board has followed closely the developments in 
Bolivia and has communicated to the Government its 
concern that some of the measures that the Government 
is about to take are not in line with the provisions of 
the international drug control treaties, particularly the 
1961 Convention. The Board is also concerned that 
policy developments in Bolivia could have 
repercussions in other countries in South America. 
174. In March 2006, the President of the Board, in a 
meeting with the Bolivian delegation attending the 
forty-ninth session of the Commission on Narcotic 
Drugs to discuss the issue, underlined the importance 
of a forthcoming mission of the Board to Bolivia to 
continue the dialogue. The Board urges the 
Government once again to ensure that all national 
legislation and policies, including possible 
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amendments to the Constitution, are in full compliance 
with the provisions of the international drug control 
treaties, to which Bolivia is a party. 
 
  Rooms for the abuse of drugs, including by 
injection 
 
175. The Board notes with concern that, despite its 
ongoing dialogue with the Governments concerned, 
drug injection rooms, where drug abusers can abuse 
with impunity drugs acquired on the illicit market, 
remain in operation in a number of countries, including 
Australia, Canada, Germany, Luxembourg, the 
Netherlands, Norway, Spain and Switzerland. The 
Board regrets that no measures have been taken to 
terminate the operation of such facilities in the 
countries concerned, and, in some cases, the number of 
such rooms has increased. Some of the facilities in 
those countries also provide areas for abusers to inhale 
drugs, as well as to inject drugs. 
176. The Board wishes to reiterate that the provision 
of rooms for the abuse of drugs, regardless of whether 
they are under the direct or indirect supervision of the 
Government, are contrary to the international drug 
control treaties, particularly article 4 of the 1961 
Convention, which obligates State parties to ensure 
that the production, manufacture, import, export, 
distribution of, trade in, use and possession of drugs 
are limited exclusively to medical and scientific 
purposes. 
177. The Board believes that any national, state or 
local authority that permits the establishment and 
operation of rooms or any outlet to facilitate the abuse 
of drugs, by injection or any other route of 
administration, also provides an opportunity for illicit 
drug distribution. The Board would like to emphasize 
that Governments have an obligation to combat illicit 
drug trafficking in all its forms and that parties to the 
1988 Convention are required, subject to their 
constitutional principles and the basic concepts of their 
legal systems, to establish as a criminal offence the 
possession and purchase of drugs for personal non-
medical use.  
178. In some jurisdictions, local authorities have 
encouraged or promoted the establishment of rooms for 
the abuse of drugs. The Board would stress that it is the 
Government that is responsible for ensuring 
compliance with the country’s obligations under the 
international drug control treaties. 
179. The Board encourages all Governments to ensure 
that efficient measures are taken to address drug abuse 
and the spread of HIV/AIDS, in compliance with their 
obligations under the international drug control 
treaties. The Board urges the Governments of countries 
where rooms for the abuse of drugs are in operation to 
provide adequate services to those in need of treatment 
and rehabilitation, in accordance with the provisions of 
the international drug control treaties, rather than 
providing such rooms. 
 
  Increasing trafficking in and abuse of fentanyl 
 
180. The Board is concerned about the increasing 
trafficking in and abuse of fentanyl and its analogues, 
which have been reported particularly in North 
America and in some parts of Europe. The very high 
potency of those synthetic drugs increases the risk of 
their overdose and other health problems related to 
opioid abuse. In the first half of 2006, the United 
States experienced a high number of deaths related to 
the abuse of fentanyl (see paras. 344-345 below). In 
Europe, authorities in Estonia reported that fentanyl 
and one of its analogues, 3-methylfentanyl, had 
replaced heroin as the main opioid of abuse in that 
country. The abuse of, and trafficking in, fentanyl and 
its analogues were also reported in Ukraine and in 
some cities in the Russian Federation. 
181. Fentanyl and its analogues are sold on the illicit 
market under various street names. In addition, they 
are also sold by traffickers as an imitation or as an 
adulterant of other illicit drugs, in particular heroin. In 
the United States, fentanyl has also been offered to 
drug abusers in tablets whose shape and logo resemble 
illicit MDMA tablets and in counterfeit tablets, 
purported to be OxyContin® tablets. The illicit market 
is supplied by the diversion of prescription drugs and 
by clandestine laboratories. 
182. Global consumption of fentanyl for medical 
purposes has more than tripled since 2000, mainly as a 
result of the increasing use of transdermal patches in 
the treatment of severe pain. Fentanyl is also available 
in injectable or lozenge form. The methods used to 
divert fentanyl from licit distribution sources include 
theft, fraudulent prescriptions and illegal distribution 
by patients, physicians or pharmacists. The Internet 
provides information on methods that can be used to 
tamper with pharmaceutical preparations containing 
fentanyl, including guidance on circumventing the 
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time-release properties of transdermal patches. The 
Board calls on all Governments to implement effective 
measures, in cooperation with the pharmaceutical 
industry and health-care professionals, to prevent the 
diversion and abuse of pharmaceutical preparations 
containing fentanyl. 
183. Fentanyl and its analogues manufactured in 
clandestine laboratories are increasingly being found 
on the illicit market. In 2006, several significant 
seizures of illicitly manufactured fentanyl were 
reported by the law enforcement agencies in the United 
States. In May 2006, a large clandestine laboratory 
supplying the illicit market in the United States was 
dismantled in Mexico. In recent years, clandestine 
laboratories manufacturing fentanyl have also been 
dismantled in Ukraine, where the drug is either abused 
locally or smuggled into other countries in Europe. In 
2004, a clandestine laboratory manufacturing fentanyl 
was dismantled in Austria. 
184. The Board notes that the authorities in the United 
States are examining the possibility of controlling 
precursor chemicals used in the illicit manufacture of 
fentanyl. The Board invites the Governments of 
countries where the illicit manufacture of fentanyl or 
fentanyl analogues takes place to exchange information 
on the synthetic routes used by clandestine laboratories 
and any other information that may facilitate the 
dismantling of such laboratories. 
185. The Board is concerned that many countries may 
not be in a position to quickly counteract the 
smuggling and abuse of fentanyl and its analogues, 
since they do not systematically collect data that would 
enable them to assess the extent of the problem. In 
most countries, the authorities are faced with 
difficulties in obtaining such data due to inadequate 
laboratory analysis and/or reporting. The Board 
encourages Governments to ensure that forensic 
laboratories include analyses of fentanyl and its 
analogues in their programmes so that they are able to 
determine whether fentanyl is trafficked in their 
countries and, if so, to what extent. In particular, 
countries where a sudden increase in opioid overdoses 
occurs should determine whether those overdoses were 
caused by the abuse of fentanyl and its analogues. The 
Board invites the relevant international organizations 
to support Governments in such efforts. The Board also 
wishes to remind all Governments of their obligation to 
report on abuse, seizures and illicit manufacture of 
fentanyl and its analogues to the Board and relevant 
international organizations, in accordance with the 
international drug control treaties. 
186. The Board wishes to alert all Governments that 
trafficking in and abuse of fentanyl and its analogues 
may become a fast-growing problem in their countries 
and reconfirms its concern about the possible 
replacement of illicit opiates with synthetic opioids. 
 
  Diversion of substances from substitution 
treatment 
 
187. Consumption of opioids prescribed for 
substitution treatment of drug dependency has 
increased in several countries in recent years. There is 
some evidence that such opioids, in particular, 
buprenorphine and methadone, have been diverted and 
abused in many countries. However, data on the extent 
of such diversion have been limited and are not 
comparable between countries. The Board sent a 
questionnaire in 2006 to Governments of 54 selected 
countries where opioids were prescribed for 
substitution treatment, in order to obtain information 
on the effectiveness of the control measures applied to 
those substances to prevent their diversion into illicit 
channels and to obtain current information on the 
diversion and abuse of those opioids in the countries 
concerned. In addition, information was obtained from 
other sources, such as seizure statistics, statistics on 
cases involving death, the Internet and government 
reports to complement the results obtained through the 
questionnaire. 
188. The replies to the questionnaire indicate that, in 
many countries, the control measures currently being 
applied are not adequate. More than half of the 
42 Governments that sent replies reported diversion of 
those substances from substitution treatment. One of 
the most frequently identified method of diversion was 
sales by patients. 
189. Most Governments reported that the trend in 
diversions from substitution treatment is stable or 
increasing. The estimated proportion of the diverted 
quantity to the total amount of opioids prescribed for 
substitution treatment, as reported by Governments, 
was as high as 15 per cent for methadone (in Croatia) 
and was even as high as 25 per cent for buprenorphine 
(in France). The Governments concerned indicated that 
only a small portion of the patients in substitution 
treatment were responsible for the diversions that 
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occurred. Governments of countries that applied less 
stringent controls to opioids used in substitution 
treatment reported the largest proportion of diverted 
quantity to the total quantity prescribed. 
190. The illicit market for buprenorphine and 
methadone in many countries is supplied by diversion 
from substitution treatment. For example, according to 
a government report, in the Czech Republic the price 
of Subutex® (buprenorphine) on the illicit market is 
three times higher than in a pharmacy. In Croatia, the 
street price of methadone is 15 times higher than the 
regular price in pharmacies; drug abusers in 
substitution treatment are selling some of the drug they 
receive in treatment in order to obtain their preferred 
drug of dependence, such as heroin. 
191. Opioids used in substitution treatment are also 
diverted in some countries for subsequent smuggling 
into other countries. In France, an increase in the 
activities of criminal groups smuggling diverted 
buprenorphine into Finland and Georgia has been noted 
since 2004. In Finland, 95 per cent of the 
buprenorphine found on the illicit market has been 
smuggled into the country. Israel and Slovakia are also 
experiencing problems with buprenorphine smuggled 
from abroad. For methadone, preparations diverted 
from substitution treatment are smuggled out of 
Central Europe and some Balkan countries into 
neighbouring countries, where they are abused. 
192. Cases involving death attributable to the abuse of 
buprenorphine and methadone have been reported in 
several countries. In the United Kingdom of Great 
Britain and Northern Ireland, methadone alone or in 
combination with other drugs was implicated in 173 
drug-related deaths in 2005.23 
193. Several Governments have recently taken or are 
considering steps to strengthen their control measures 
applicable to opioids used in substitution treatment, 
with a view to preventing their diversion. The 
measures which have been found to be effective 
include supervised consumption, application of 
appropriate conditions for drugs to be taken at home, 
treatment according to clinical standards, prescription 
monitoring systems and mandatory training of health-
care professionals. 
__________________ 
 23  National Programme on Substance Abuse Deaths, Drug-
Related Deaths in the UK: Annual Report 2006 (London, 
St. George’s, University of London, 2006). 
194. The Board requests the Governments of countries 
where opioids are used for substitution treatment to 
take all measures necessary to prevent their diversion 
into illicit channels while making those substances 
available for legitimate treatment. In this connection, 
the Board notes with concern that some of those 
Governments which responded to its questionnaire 
indicated that information on the diversion and abuse 
of opioids used in substitution treatment was not 
available to the competent authorities. The Board again 
requests all Governments concerned to establish a 
mechanism for the systematic collection of information 
on the diversion and abuse of drugs prescribed for 
substitution treatment, using, inter alia, statistics on 
emergencies related to drug abuse and statistics on 
drug-related deaths. Such a mechanism will help 
Governments to identify problems as soon as possible 
and to take appropriate countermeasures before such 
problems increase. 
195. The Board notes that, in response to Economic 
and Social Council resolution 2004/40 of 21 July 2004, 
WHO, in collaboration with UNODC, is developing 
the guidelines for psychosocially assisted 
pharmacotherapy for the management of opioid 
dependence. The Board trusts that the guidelines will 
remind all those involved in the provision of 
substitution treatment of their obligation to implement 
the provisions of the international drug control treaties 
and national legislations regarding opioids and that the 
guidelines will provide specific guidance on preventing 
the diversion of opioids used in pharmacotherapy. 
 
  Information on the specific requirements for 
travellers who carry medical preparations 
containing controlled substances for personal 
use 
 
196. The Commission on Narcotics Drugs, in its 
resolutions 44/15, 45/5 and 46/6, encouraged 
Governments to notify the Board of restrictions 
currently applicable in their territory to travellers under 
medical treatment with preparations containing 
controlled substances. As at 1 November 2006, 
73 Governments had provided such information to the 
Board, including information on relevant legal 
provisions and/or administrative measures in force in 
their countries applicable to travellers carrying medical 
preparations with narcotic drugs or psychotropic 
substances for personal use. The Board calls on all 
Governments that have not yet done so to submit to it 
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that information without delay. The Board will ensure 
the wide dissemination of the information so that 
Governments will be able to advise travellers on the 
requirements needed in countries of destination.24 
 
  Requirement for drug reference standards 
 
197. In order to facilitate the obtaining of reference 
standards of narcotic drugs, psychotropic substances 
and/or precursors required for the proper and reliable 
identification and analysis of controlled drugs and 
precursors, the Board has developed guidelines for use 
by national drug-testing laboratories and national 
competent authorities for the import and export of drug 
and precursor reference standards. 
198. The guidelines were prepared in order to assist 
national laboratories and other relevant scientific 
institutions in obtaining in a timely manner the 
reference standards they require. The guidelines 
contain some of the most frequently encountered 
difficulties and provide guidance on how obstacles 
may be overcome. The guidelines will be made 
available on the website of the Board (www.incb.org). 
 
  Ketamine 
 
199. During the past several years, the Board has 
noted with concern reports of the abuse of, and 
trafficking in, ketamine, a substance currently not 
under international control.25 In its report for 2005, the 
Board drew the attention of Governments to the 
problem of widespread abuse of ketamine, particularly 
among youth, in East and South-East Asia and 
trafficking in ketamine in that region and in other 
regions, including the Americas.26 
200. The abuse of and trafficking in ketamine continue 
unabated, particularly in a number of countries in East 
and South-East Asia, in South Asia and in Oceania, 
including Australia, Bangladesh, Cambodia, China 
(including the Hong Kong Special Administrative 
Region (SAR)), India, Malaysia, Singapore, Thailand 
and Viet Nam. In China, for instance, authorities seized 
__________________ 
 24  Report of the International Narcotics Control Board for 
2005 …, paras. 214 and 215. 
 25  See, for example, Report of the International Narcotics 
Control Board for 2004 (United Nations publication, 
Sales No. E.05.XI.3), para. 390. 
 26  Report of the International Narcotics Control Board for 
2005 …, paras. 385, 431, 468, 471 and 641. 
2.6 tons of ketamine in 2005. The Hong Kong SAR of 
China has reported a significant increase in seizures of 
ketamine in 2005: a total of 409 kg of the substance 
were seized in 921 individual seizure cases. Other 
seizures of ketamine have been reported in Canada, 
El Salvador, Indonesia, the Russian Federation and the 
United States and illicit ketamine laboratories have 
been dismantled in Mexico and the Philippines. 
Ketamine has become one of the most abused drugs 
among adolescents (persons aged 11-20 years old) in 
the Hong Kong SAR of China. The abuse of ketamine 
has also been reported in some countries in the 
Americas, such as Argentina, Canada and Costa Rica. 
201. In the light of those developments, the 
Commission on Narcotic Drugs adopted resolu-
tion 49/6, entitled “Listing of ketamine as a controlled 
substance”, in which it called upon Member States to 
consider controlling the use of ketamine by placing it 
on the list of substances controlled under their national 
legislation, where the domestic situation so required. 
202. At the same time, ketamine was subject to critical 
review by the WHO Expert Committee on Drug 
Dependence in March 2006. The Committee concluded 
that the information presented to it was not sufficient 
to warrant its international scheduling. Therefore, the 
Committee requested the secretariat of WHO to 
produce an updated version of the critical review 
document, to be submitted to it at its next meeting. 
203. The Board welcomes the adoption of Commission 
on Narcotic Drugs resolution 49/6 and calls on all 
Governments to implement that resolution without 
delay. In particular, the Board encourages all 
Governments concerned to take steps to determine the 
size of the population abusing ketamine and, wherever 
warranted, to place ketamine under their national drug 
control legislation. Furthermore, the Board urges all 
Governments to provide to it and to WHO all available 
information on the abuse of ketamine in their 
countries, in order to assist the WHO Expert 
Committee on Drug Dependence, at its next meeting, 
in its efforts to assess ketamine for possible scheduling 
under the 1971 Convention. 
204. The Board requests all Governments to furnish it 
with all relevant information on the national regulatory 
measures that have been put in place in their countries, 
in compliance with Commission on Narcotic Drugs 
resolution 49/6, in particular import and export 
authorization requirements relating to ketamine. In that 
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connection, the Board notes with appreciation that such 
information has already been provided to it by the 
Governments of Israel, Myanmar, the Philippines and 
the United Kingdom. Information on national controls 
in place in individual countries will assist the 
Governments of exporting countries, and the Board, in 
rapidly verifying the legitimacy of individual 
transactions involving trade in ketamine, without 
unduly delaying licit trade. The Board will maintain 
and update an inventory of that information, for 
distribution to all Governments on a regular basis. 
 
  Illegal sale of controlled substances through the 
Internet 
 
205. Despite successes achieved in a number of 
countries, available information indicates that the illicit 
sale of pharmaceuticals containing controlled narcotic 
drugs and psychotropic substances via the Internet and 
the illicit distribution of such substances by mail have 
continued unabated.27 
206. Many pharmaceutical preparations containing 
controlled substances continue to be sold by illegally 
operating Internet pharmacies and distributed to 
customers by mail. The Board notes with appreciation 
that smuggling by mail is increasingly recognized by 
national authorities as a method of drug trafficking and 
constitutes a major problem for law enforcement 
authorities. In 2005, 80 individual consignments of 
psychotropic substances that had been smuggled by 
mail were seized in Australia, New Zealand and 
Thailand. Most of those cases (32 seizures made in 
Thailand) involved diazepam. In 2006, four 
consignments of phenobarbital smuggled by mail from 
the Democratic Republic of the Congo were seized in 
Belgium. Three consignments of ATS were seized in 
New Zealand. 
207. In view of the global nature of the use of the mail 
for illicit drug trafficking, concerted action by the 
international community is urgently required. In 
particular, there is a need to establish a mechanism that 
will ensure the sharing of experiences and the rapid 
exchange of information on specific cases, as well as 
the standardization of data collected. The Board, 
__________________ 
 27  Report of the International Narcotics Control Board for 
2004 …, paras. 170-184; and the Report of the 
International Narcotics Control Board for 2005 …, 
paras. 219-242. 
therefore, in July 2005, requested all Governments to 
identify focal points for activities related to illegally 
operating Internet pharmacies, to provide details of 
legislation and regulations on Internet services and 
sites and on the use of the mail for individual 
shipments of controlled drugs. As at 1 November 2006, 
45 countries had provided the requested information to 
the Board. The Board encourages all Governments that 
have not yet done so to provide the requested 
information without further delay. 
208. The Board notes with appreciation that each of 
the responding Governments has nominated a focal 
point to be contacted in cases involving suspected 
illegal sales by Internet pharmacies. Forty per cent of 
the responding Governments reported having in place 
legislation for dealing with illegal Internet pharmacies. 
While six Governments reported that the purchase of 
controlled drugs through Internet pharmacies was 
allowed under their national legislation, 87 per cent of 
all the responding Governments confirmed that 
purchasing controlled drugs through Internet 
pharmacies was prohibited under their national 
legislation and 33 per cent confirmed that their 
national legislation included licensing/registration 
conditions that required Internet service providers to 
close down illegally operating Internet sites. Nine of 
the responding Governments reported that the use of 
the mail for importing and exporting controlled drugs 
was allowed, provided that the transactions had been 
duly authorized by the competent authorities. However, 
56 per cent of the responding Governments considered 
that their national legislative provisions did not provide 
adequate sanctions against the diversion and illegal 
sales of controlled drugs by Internet pharmacies, and 
only 9 per cent reported having in place a mechanism 
for voluntary cooperation between the competent 
authorities and manufacturers and wholesalers. 
209. Ten Governments (over 20 per cent of those 
responding) reported having practical experience in the 
control and investigation of illegal Internet pharmacies. 
Of those, the Government of the United States had the 
greatest experience in identifying and dismantling 
international drug trafficking through the Internet. The 
United States authorities concluded two major 
investigations in 2005, resulting in the dismantling of 
two trafficking networks operating in Australia, 
Canada, Costa Rica, India and the United States and 
the seizure of 13.5 million tablets of narcotic drugs 
(codeine, hydrocodone, morphine and oxycodone) and 
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psychotropic substances (alprazolam, amfepramone, 
buprenorphine, diazepam, methylphenidate and 
phentermine), as well as tramadol and ketamine 
(105 kg), substances currently not under international 
control. 
210. Other Governments that reported having closed 
down at least one illegal Internet pharmacy included 
the Governments of Costa Rica, Mexico, South Africa 
and Switzerland. While the court cases in South Africa 
and Switzerland are still pending, Mexico reported that 
a veterinary pharmaceutical laboratory in Cuernavaca 
that was manufacturing large quantities of ketamine 
and selling them over the Internet to persons in the 
United States had been dismantled. As a result, arrests 
had been made in both Mexico and the United States. 
211. The substances most commonly traded over the 
Internet were psychotropic substances, mainly 
benzodiazepines and stimulants. With regard to 
narcotic drugs, sales of codeine and 
dextropropoxyphene were also reported to have been 
sold over the Internet. 
212. The Board notes with appreciation the steps taken 
by the Governments of a number of countries, 
including France, the Netherlands, Sweden, the United 
Kingdom and the United States, to issue guidelines or 
adopt new legislation to counteract such illegal 
activities and encourages all Governments that have 
not yet done so to take action, as appropriate. 
 
  Control status of dronabinol (delta-9-
tetrahydrocannabinol) 
 
213. Pursuant to article 2, paragraph 4 (b), of the 1971 
Convention, a substance is placed under international 
control when there is sufficient evidence that the 
substance is being or is likely to be abused so as to 
constitute a public health and social problem. 
However, four different types of control 
(Schedules I-IV) are applied on the basis of the extent 
or likelihood of abuse, the degree of seriousness of the 
public health and social problem and the degree of 
usefulness of the substance in medical therapy. 
214. Substances in Schedule I of the 1971 Convention 
have the strictest form of control, while substances in 
Schedule IV have the least stringent control measures. 
Experience has shown, however, that where less 
stringent control measures are in place for 
psychotropic substances the level of diversion from 
licit distribution channels into illicit channels is higher. 
215. Dronabinol, being one of the stereochemical 
variants of delta-9-tetrahydrocannabinol (delta-9-
THC), was initially controlled in Schedule I of the 
1971 Convention, but delta-9-THC was transferred 
with its stereochemical variants to Schedule II in 1991 
by the Commission on Narcotic Drugs in its decision 2 
(XXXIV), on the grounds that dronabinol had some 
medical usefulness. The quantity of dronabinol 
currently used for medical purposes is limited and it is 
prescribed in only a few countries. 
216. Dronabinol continues to be available in the few 
countries for the treatment of medical conditions for 
which it has been approved or for clinical research. 
Despite the present control of dronabinol in 
Schedule II of the 1971 Convention and its limited use 
in a few countries, there have been reports of its abuse 
in a country in which it is prescribed most. The Board 
is concerned about the possibility of dronabinol, the 
active principle of cannabis, being transferred to a 
schedule with less stringent control. The adoption of 
control measures that may lead to a proliferation of 
dronabinol preparations and their use may result in 
increased diversion of such preparations into the illicit 
traffic and increased abuse of such preparations. The 
Board is of the view that the control measures 
envisaged for substances in Schedule II make it 
possible for dronabinol to be available either for 
treatment or for research purposes, as is the case for 
other substances in the same schedule, such as 
amphetamines and methylphenidate. 
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III. Analysis of the world situation 
 
 
 A. Africa 
 
 
  Major developments 
 
217. The cultivation and production of cannabis are on 
the rise in Africa, despite a marked reduction in 
cannabis production in Morocco (the world’s largest 
producer of cannabis resin) over the past few years and 
intensive eradication efforts undertaken by the 
authorities of countries in the entire region. Likewise, 
Africa’s share of global trafficking in cannabis has 
been increasing continuously, as corroborated by a 
number of multi-ton seizures of cannabis herb and 
resin that were effected in Africa during the past year. 
Cannabis remains the major drug of abuse in the 
region. As health-care facilities often lack the 
necessary resources, many African countries face 
serious difficulties in providing adequate treatment and 
rehabilitation for persons abusing cannabis. 
218. Pharmaceutical preparations containing 
controlled substances are easily obtained on 
unregulated markets throughout Western, Central and 
Northern Africa. Misuse and abuse of those 
preparations are reported to be taking place among 
persons in all social strata. Those products, which are 
usually diverted from domestic distribution channels, 
are sold without prescription in pharmacies and other 
retail outlets. While drug control legislation prohibiting 
such practices is in place in most countries, it is often 
not adequately implemented and enforced. Due to 
insufficient funds, there is a shortage of trained 
pharmacists and pharmacy inspectors in many 
African countries, which is often exacerbated by a lack 
of funds to fill vacancies resulting from natural 
attrition and emigration (“brain drain”). There is 
concern that the problem of controlled drugs and 
counterfeit drugs being sold via illegally operating 
Internet pharmacies may soon spread to urban centres 
in Africa. 
219. One particularly worrisome development in 
Africa is the large-scale trafficking in cocaine. Taking 
advantage of the weak interdiction capacities in Africa, 
drug trafficking networks are using the region as a 
transit area for smuggling cocaine from South America 
through Western, Central and Southern Africa. In 
addition, heroin from West and South-East Asia is 
smuggled through Eastern Africa, to be shipped to 
illicit markets in Europe and, to a lesser extent, 
North America. The trafficking in cocaine in Africa is 
fuelled by rising demand for, and abuse of, cocaine in 
Europe. Both the number of couriers apprehended and 
the volume of bulk seizures of cocaine in Africa 
have increased significantly. As a spillover effect of the 
ongoing transit trafficking in heroin in the subregion, 
the abuse of heroin has become a problem in 
Eastern Africa. In addition, heroin is now also being 
smuggled by groups from Western Africa to that 
subregion, in exchange for cocaine that is smuggled 
into South Asia, where the abuse of cocaine appears to 
have spread. 
220. Efforts by Governments of African countries to 
deal with those problems are impeded by a lack of 
adequate drug control mechanisms and skilled human 
resources. It is feared that, if left unchecked, the 
problem of drug trafficking in Africa might further 
exacerbate existing social, economic and political 
problems. 
 
  Regional cooperation 
 
221. The Board notes the efforts made by the 
Economic Community of West African States 
(ECOWAS) to coordinate drug control activities in 
Western Africa. At a conference held in Abuja in July 
2006 the coordinators of inter-ministerial drug control 
committees of ECOWAS member States carried out a 
final evaluation of the implementation of the 1997 
Regional Plan of Action for the Control of Drugs in 
West Africa. Based on the recommendations of the 
evaluation, the member States agreed to develop a new 
regional plan of action on drugs and crime. Other 
issues discussed at the conference included the status 
of the regional training academy for drug control in 
Jos, Nigeria, and the regional drug training centre in 
Grand-Bassam, Côte d’Ivoire. 
222. The Board welcomes the establishment of the 
West African Drug Regulatory Agencies Network, a 
subregional body of drug regulators aimed at 
combating counterfeit and fake drugs. The Network 
was created at an international conference held in 
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Abuja in March 2006.28 It is chaired by the head of the 
National Agency for Food and Drug Administration 
and Control of Nigeria. The Board calls upon IMPACT, 
the newly established task force of WHO, to cooperate 
with the Network, as appropriate. 
223. The WHO Regional Committee for Africa held its 
fifty-sixth session in Addis Ababa from 28 August to 
1 September 2006. The session was attended by the 
ministers of health of 46 WHO member States in 
Africa, as well as representatives of the United Nations 
and its specialized agencies, intergovernmental and 
non-governmental organizations and bilateral donor 
agencies. The Board notes, with appreciation, that the 
WHO Regional Committee dealt with drug regulatory 
matters, urging Governments that had not yet done so 
to accede to the international drug control treaties and 
stressing the importance of training national drug 
control authorities to establish a sound drug regulatory 
system to ensure adequate availability of controlled 
substances for medical needs. At the occasion of that 
session, the Secretary of the Board met with a number 
of ministers of health of African countries and officials 
from the WHO Regional Office for Africa with a view 
to developing a collaborative programme to strengthen 
drug regulatory systems in Africa and made 
contributions to the development of future drug control 
action plans.  
224. The Sixteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Africa, was held in 
Nairobi from 25 to 29 September 2006. Issues dealt 
with at the Sixteenth Meeting included alternative 
development and cannabis, the increased trafficking in 
cocaine in Africa, the control of precursor chemicals, 
controlled deliveries, drug abuse and HIV/AIDS, the 
illegal street sale of medicines, and psychotropic 
substances and synthetic drugs. 
225. In view of the rapid increase in the smuggling of 
cocaine from South America via Western Africa to 
Europe using commercial airliners, Interpol hosted an 
operational working group meeting on the subject at its 
headquarters in Lyon, France, in May 2006. At that 
__________________ 
 28  The international conference, entitled “Combating 
Counterfeit/Fake Products in West Africa: a Need for a 
Unified Approach”, was attended by representatives of 
Burkina Faso, Côte d’Ivoire, Ghana, Guinea, Guinea-
Bissau, Liberia, the Niger, Nigeria, Senegal, Sierra 
Leone and Togo. 
meeting, participants29 decided on measures for 
operational coordination and cooperation, including 
improved exchange of information and analysis of 
intelligence related to cocaine seizures. 
226. In Western Africa, successful joint operations 
continue to be carried out by drug law enforcement 
authorities from Cape Verde, Ghana and Senegal. The 
Board notes the good interaction involving 
international drug liaison officers in those countries 
and local law enforcement agencies in gathering and 
sharing intelligence. 
227. A memorandum of understanding was signed by 
the anti-narcotics general administrations of Egypt and 
the Libyan Arab Jamahiriya, with a view to 
strengthening cooperation at their joint border control 
points. 
228. A regional meeting of national prison authorities 
held in Nairobi in November 2005 was attended by 
authorities from Kenya, Mauritius, Uganda and the 
United Republic of Tanzania. The discussion focused 
on the current situation with regard to drug abuse and 
HIV/AIDS in prisons in those countries and on the best 
ways to address them.  
229. In 2006, assistance provided under the UNODC 
project to develop the drug interdiction capacity of law 
enforcement agencies at selected ports in Southern and 
Eastern Africa was extended to include the ports of 
Beira and Nacala in Mozambique. Similarly, the 
Government of Senegal and UNODC officially 
launched a container control project in the port of 
Dakar in early 2006. 
230. The Windhoek Declaration on a new partnership 
between the Southern African Development 
Community (SADC) and its international cooperating 
partners was adopted in Windhoek on 27 April 2006. In 
the Declaration, a number of areas, including efforts to 
counter drug trafficking, are identified for cooperation 
between SADC and multilateral and bilateral donors. 
231. South African authorities, with the support of the 
Government of France, organized in Roodeplaat, South 
Africa, in January 2006 a 14-day operational training 
course on the fight against drug trafficking and the 
__________________ 
 29  Law enforcement authorities from Belgium, Côte 
d’Ivoire, France, Germany, Ghana, Ireland, Italy, 
Morocco, the Netherlands, Portugal, Spain, Switzerland, 
the United Kingdom and the United States. 
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diversion of precursor chemicals. During the course, 
law enforcement officials from 14 African countries,30 
were provided with skills and expertise related to drug 
identification and interdiction, monitoring of chemicals 
required for drug manufacture, controlled deliveries 
dealing with clandestine drug laboratories, and 
surveillance of containers, parcels and persons. The 
Government of South Africa also hosted in 
Johannesburg, South Africa, from 22 to 24 August 
2006 the SADC Regional Seminar on Chemical 
Monitoring Programmes for member States. The 
seminar was attended by representatives of five SADC 
member States,31 as well as members of the chemical 
and pharmaceutical industries. In view of the 
increasing trafficking of drugs and precursor chemicals 
through Africa, the Board encourages all Governments 
concerned to support similar initiatives in Africa. 
 
  National legislation, policy and action 
 
232. Despite efforts to improve drug control in Africa, 
many countries on the continent still lack appropriate 
and updated legislation, qualified human resources and 
well-structured drug control mechanisms. As a result, 
drug control policy and action continue to have limited 
impact.  
233. The Government of Egypt continues to pursue a 
comprehensive drug control strategy that was 
developed in 1998. In Egypt, the Anti-Narcotics 
General Administration, the Ministry of the Interior, 
the coast guard, the customs service and selected 
military units cooperate in task forces designed to 
interdict illicit drug shipments. 
234. The Government of the Libyan Arab Jamahiriya 
has established a new drug control committee under 
the supervision of the Minister of the Interior. The 
committee makes recommendations to the Ministry of 
the Interior and the Anti-Narcotics General 
Administration of the Libyan Arab Jamahiriya. 
Currently, the Administration, in collaboration with 
other agencies in the country, is designing the national 
drug control strategy and action plan. 
__________________ 
 30  Angola, Botswana, Egypt, Ghana, Kenya, Morocco, 
Mozambique, Namibia, the Niger, Seychelles, South 
Africa, Togo, the United Republic of Tanzania and 
Zambia. 
 31  Botswana, Mozambique, Namibia, South Africa and the 
United Republic of Tanzania. 
235. The Government of Kenya has stepped up efforts 
aimed at drug abuse prevention and treatment. Access 
to treatment for drug abuse was significantly increased 
by the establishment of specialized units run by the 
Ministry of Health and competent non-governmental 
organizations. Drug abuse by injection and its 
relationship to HIV/AIDS continued to be highlighted 
in several ways. In Kenya, more than 7,000 drug 
abusers made use of an outreach project in one year; 
more than half of them were referred for voluntary 
counselling and testing. 
236. In October 2006, a new law on drug abuse has 
been submitted to the Parliament of Namibia. The new 
legislation, called the Combating of the Abuse of 
Drugs Bill, will ban trafficking in and sale, possession 
and consumption of dangerous, undesirable and 
dependence-producing substances and will provide for 
mandatory prison sentences. The new law, together 
with the Financial Intelligence Bill, submitted to 
Parliament earlier, and the Prevention of Organized 
Crime Act of 2004, is expected to pave the way for 
Namibia to accede to the 1988 Convention. 
237. The Board notes that the Government of South 
Africa approved in October 2006 the national drug 
control master plan for the period 2006-2011. The new 
master plan places emphasis on ensuring adequate 
standards for centres for the treatment and 
rehabilitation of drug abusers. In Nigeria, the 
Government is currently reviewing its national drug 
control master plan. New drug control laws have been 
drafted and are pending approval by the parliament in 
Ghana and Sierra Leone. 
238. The Board notes the efforts by the Government of 
Nigeria to combat unregulated markets. The 
Government of that country, which, according to 
Interpol, used to be the nucleus of the illicit traffic in 
pharmaceuticals in Africa, has markedly reduced the 
incidence of counterfeit drugs within the past few 
years, through improved control, inspection of 
distribution outlets and public destruction of 
counterfeit and substandard products. The Board calls 
upon all Governments concerned to improve the 
efficiency and effectiveness of their drug regulatory 
authorities with a view to preventing illicit distribution 
practices or counterfeiting while, at the same time, 
facilitating the access of their populations to the 
medication they require. 
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239. In Malawi, the inter-ministerial committee for 
drug control convened in November 2005 a broad-
based stakeholders meeting to solicit support for the 
Government’s new drug control master plan, drug 
control policy and drug abuse bill. 
240. The Government of Morocco, following the 
positive results of eradication efforts in 2005 and as 
part of its comprehensive national drug control 
strategy, has launched a new eradication initiative 
aimed at making the Province of Taounate free of 
cannabis by the end of 2006. The initiative is 
complemented by various socio-economic programmes 
and alternative development projects, including pilot 
projects involving rural development in the areas 
affected by illicit cannabis production. 
241. On 26 June 2006, the Ministry of Education of 
South Africa launched a new programme on substance 
abuse in schools. The programme places emphasis on 
the relationship between drug abuse, risky sexual 
behaviour and HIV/AIDS and is being implemented in 
schools and other educational institutions in 
cooperation with the Ministry of Education and the 
Ministry for Social Development. The Government is 
also in the process of reviewing and updating its 
current law relating to the prevention and treatment of 
drug dependence. The new legislation will promote 
more community-based services, place greater 
emphasis on preventive services and be more sensitive 
towards the needs of drug-dependent children. 
242. The Board is pleased to note that a number of 
Governments of African countries have taken measures 
against money-laundering. Legislation against money-
laundering was adopted in Cameroon, Malawi, the 
Niger and Sierra Leone. The Board also notes that the 
Financial Action Task Force on Money Laundering has 
removed Nigeria from the list of countries and 
territories considered to be “non-cooperative” in efforts 
to counter money-laundering or to have critical 
deficiencies in their systems for countering money-
laundering. Furthermore, the initiative to counter 
money-laundering in Western Africa was strengthened 
by ECOWAS by allocating substantial funds to the 
Intergovernmental Action Group against Money 
Laundering in West Africa (GIABA), the body 
responsible for coordinating efforts to counter money-
laundering at the subregional level. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
243. In Africa, the main drug of abuse remains 
cannabis, which is trafficked at the national, 
subregional, regional and international levels. Egypt, 
Morocco, Nigeria and South Africa remain important 
sources of cannabis herb. Africa accounts for almost 
one third of global seizures of cannabis herb. While 
Morocco continues to be a major producer of cannabis 
resin, cultivation of cannabis and production of 
cannabis resin reportedly declined in 2004 and 2005. 
According to the 2005 cannabis survey,32 conducted 
jointly by the Government of Morocco and UNODC, 
the total area under cannabis cultivation decreased by 
40 per cent from 2004 (120,500 hectares) to 2005 
(72,500 hectares), and the production of cannabis resin 
declined by 62 per cent (to 1,066 tons) in 2005. The 
decrease in Morocco was the result of unfavourable 
weather conditions combined with a successful 
eradication campaign, including awareness-raising and 
mechanical eradication of the cannabis crop (in 
Larache Province). From 2003 to 2004, seizures of 
cannabis resin in Morocco decreased from 96 tons to 
87 tons, while seizures of cannabis herb increased from 
69 tons to 319 tons. In Algeria, the volume of cannabis 
resin seized was reported to have increased from 8 tons 
to 12 tons. Overall, however, seizures of cannabis resin 
in North Africa decreased, from 115 tons in 2003 to 
103 tons in 2004. The increase in cannabis production 
in Africa was accompanied by an increase in the abuse 
of that drug. While the abuse of cannabis resin is 
largely confined to Northern Africa, the abuse of 
cannabis herb takes place throughout Africa. 
244. Cannabis herb continues to be the drug that is 
most widely smuggled within Africa. It is also 
smuggled out of the region, mainly into Europe. 
Africa’s share of global cannabis seizures increased 
from 16 per cent at the beginning of the 1990s to over 
30 per cent in 2004. In Africa, the largest seizures of 
cannabis herb in 2004 were effected in Nigeria and 
South Africa, while Morocco accounted for 6 per cent 
of global seizures of cannabis resin. In 2005, 78 tons of 
cannabis herb and 1.5 tons of cannabis resin were 
reported to have been seized in Egypt, and 14.3 tons of 
__________________ 
 32  United Nations Office on Drugs and Crime, Maroc: 
enquête sur le cannabis 2005 (November 2006). 
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cannabis herb were reported to have been seized in 
Ghana. In Morocco, in 2005, almost 18 tons of 
cannabis were seized at the port of Tangiers alone, and 
247 persons involved in international drug trafficking 
were arrested. Bulk shipments of cannabis (1-6 tons 
each) destined for countries in Europe, particularly the 
United Kingdom, continue to be seized by South 
African authorities. In May 2006, a record seizure of 
22.5 tons of cannabis originating in Pakistan and 
destined for Canada was effected by Canadian 
authorities on a vessel on the high seas 320 kilometres 
off the coast of Angola. In a joint operation involving 
police from Lesotho and South Africa in July 2006, 
47 tons of cannabis herb were seized. 
245. African countries are being targeted for trans-
shipment of cocaine. The smuggling of cocaine from 
South America into Europe through Africa continues 
unabated, with countries in Western and Central Africa 
being used as transit and storage areas for cocaine 
destined for Europe. Cocaine is trafficked from South 
America in large shipments along maritime routes 
leading predominantly to the countries surrounding the 
Gulf of Guinea, where it is re-packaged and smuggled 
by air by couriers into Europe or dispatched via parcel 
post. The most affected countries are Benin, Cape 
Verde, Ghana, Guinea-Bissau, Nigeria and Togo, while 
Ghana is serving as a major trans-shipment area and 
logistics base. Increasingly, Guinea-Bissau is being 
used by criminal groups from Latin America for the 
trans-shipment of cocaine. In September 2006, police 
in Guinea-Bissau seized 674 kg of cocaine and arrested 
two suspected smugglers, together with arms and radio 
and other equipment. Senegal has also become a transit 
country. Another matter of concern is that criminal 
organizations from South America involved in cocaine 
trafficking are reportedly linking with criminal groups 
involved in cannabis trafficking in Morocco and Spain. 
246. During the past two years, there have been major 
seizures of cocaine in Africa. In Ghana, 558 kg of 
cocaine were seized in Tema in January 2004, 580 kg 
of cocaine were seized in Accra in November 2005 and 
1.9 tons of cocaine hidden on a vehicle were seized on 
the Ghanaian coast in May 2006. In Kenya, 1.1 tons of 
cocaine were seized in late 2004. In addition, 3 tons of 
cocaine were seized on the high seas near Cape Verde 
in February 2006 on a vessel registered in 
Guinea-Bissau. In June 2006, over 14 tons of a mixture 
of cocaine and white cement was seized in Nigeria at 
the port of Lagos on board a vessel from Peru. The 
seizure in Lagos was the result of successful 
collaboration involving drug law enforcement 
authorities from Nigeria, South Africa, the United 
Kingdom and the United States. 
247. In addition, growing numbers of couriers with 
cocaine are being arrested at airports in Western Africa 
and Europe. There has been a spillover effect of such 
transit traffic: increased abuse of cocaine, including 
“crack” cocaine, in countries in Western Africa, 
including in Senegal and Sierra Leone. 
248. Sizeable quantities of cocaine continue to be 
seized in South Africa, mainly at the international 
airport at Johannesburg. In South Africa, the abuse of 
cocaine also appears to be on the increase, as reflected 
by significantly increasing demand for treatment for 
cocaine abuse. Courier mail seems to be frequently 
used as a means of smuggling cocaine originating in 
South America, according to seizure reports from 
Angola, the Democratic Republic of the Congo, 
Mozambique and Zambia. To a lesser extent, cocaine is 
smuggled by air into Europe via cities in Eastern 
Africa, mainly Nairobi. 
249. The Board urges the Governments of African 
countries affected by such transit traffic to step up 
surveillance of their territorial waters and points of 
entry to detect suspicious activities and to develop 
adequate mechanisms for cooperation in drug 
interdiction and intelligence-sharing. To that end, the 
provision of adequate assistance by the international 
community will be essential.  
250. Heroin from South-West Asia and South-East 
Asia continues to be smuggled through African 
countries, intended for illicit markets in Europe and, to 
a lesser extent, North America. While increased heroin 
seizures throughout Africa, particularly in Western and 
Central Africa, have been reported in 2004, the last 
year for which global figures are available, the total 
quantity of heroin seized in Africa is still small 
compared with the global figure. One new 
development is the reported smuggling of heroin from 
India into Western African countries, mainly Nigeria, 
in exchange for cocaine trafficked by Western African 
criminal groups. As a result, a gradual increase in 
cocaine abuse has been noticed in cities in India, such 
as Delhi, Mumbai, Bangalore and Goa (see paras. 500-
501 below). 
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251. Significant seizures of heroin continue to be 
made at international airports in Ethiopia (at Addis 
Ababa), Kenya (at Nairobi), Mauritius (at Port Louis) 
and the United Republic of Tanzania (at Dar es 
Salaam). In addition, a case of smuggling of heroin by 
sea freight containers has been reported: as a result of a 
controlled delivery, 42 kg of heroin from Pakistan 
smuggled via the United Arab Emirates and Kenya 
were seized in Uganda and five persons were arrested. 
As a spillover effect of the smuggling of heroin 
through those Eastern African countries, the abuse of 
that substance is also occurring in those countries. 
Heroin abuse also occurs in South Africa and in some 
countries in Western Africa. The South African 
Community Epidemiological Network on Drug Use has 
reported increased availability of “cheap heroin”, a 
mixture of heroin and cannabis that is popular among 
young people. 
 
  Psychotropic substances 
 
252. The availability and abuse of prescription drugs 
containing controlled substances is increasingly 
becoming a major problem in many countries 
throughout Africa (see also chap. I above). The abuse 
of preparations containing ephedrine33 and diazepam 
(Valium) continues to be reported, particularly in 
Western and Central Africa. Prescription drugs can be 
obtained without prescription through over-the-counter 
dispensing at licensed pharmacies and are sold by 
street vendors, health-care providers and 
neighbourhood shops. The problems are often 
exacerbated by a proliferation of illegal retail outlets. A 
recent study34 conducted by UNODC, in cooperation 
with the Government of Egypt and WHO, indicated 
that psychotropic substances were available in Cairo 
without prescription and revealed consumption patterns 
relating to inappropriate use. 
__________________ 
 33  Ephedrine is controlled under the 1988 Convention. 
However, under the national legislation of many African 
countries, ephedrine is subject to the same controls as 
are applied to psychotropic substances controlled under 
the 1971 Convention. 
 34  The exploratory study on the patterns of use and the 
misuse of prescription psychotropic substances in Cairo 
in 2006, conducted by the UNODC Regional Office for 
the Middle East and North Africa, in cooperation with 
the Ministry of Health and Population of Egypt and the 
WHO Regional Office for the Eastern Mediterranean. 
253. The illicit manufacture of psychotropic 
substances in Africa, notably methaqualone (Mandrax), 
methamphetamine, methcathinone and MDMA 
(“ecstasy”) remains limited to South Africa and some 
countries in Southern and Eastern Africa, where those 
substances are abused as well. That is corroborated by 
a substantial increase in the number of clandestine drug 
laboratories that have been dismantled, including a 
major methaqualone laboratory that was detected and 
dismantled by the Kenyan authorities in Nairobi in 
January 2006. 
254. In South Africa crystalline methamphetamine has 
now emerged as the main substance of abuse among 
patients in treatment for drug abuse in the Western 
Cape area. In addition, the abuse of psychotropic 
substances has been reported in Egypt. In 2005, 
Egyptian authorities seized over 325,000 tablets 
containing flunitrazepam (Rohypnol). Furthermore, 
significant increases in both the volume and number of 
seizures of buprenorphine have been reported in 
Mauritius. According to the authorities of that country, 
because of the current shortage of heroin, traffickers 
and abusers are now increasingly turning to 
buprenorphine.  
255. As most countries in Africa do not have the 
legislation and institutional framework in place to 
combat trafficking in precursors, such chemicals 
continue to be diverted through the region. Of 
particular concern are the ongoing diversion and 
attempted diversion of ephedrine and pseudoephedrine 
through African countries. While those substances are 
often destined for local abuse as a mild stimulant, there 
is some concern that parts of those consignments may 
be used for the illicit manufacture of methamphetamine 
and methcathinone elsewhere. That concern has been 
exacerbated by a series of diversions and attempted 
diversions of multi-ton consignments of 
pseudoephedrine to Angola, the Democratic Republic 
of the Congo, Ghana, Kenya and Rwanda that have 
been detected during the last year under Project Prism, 
the Board’s international initiative to address the 
diversion of precursors of ATS.35 
__________________ 
 35  Project Prism is being carried out by about 130 national 
authorities in cooperation with Interpol, the World 
Customs Organization, UNODC and the European 
Commission. 
E/INCB/2006/1  
 
40  
 
256. The seizure in Belgium in July 2006 of 300 kg of 
pseudoephedrine in a shipment from the Democratic 
Republic of the Congo that was destined for Mexico, 
corroborates suspicions that international trafficking 
networks have been operating in African countries, 
notably the Democratic Republic of the Congo, using 
those countries for the diversion of pseudoephedrine to 
be used for the illicit manufacture of methamphetamine 
in Mexico. Furthermore, the report that an 
African country had been used for smuggling into 
Europe a precursor of MDMA (“ecstasy”) was 
confirmed by a recent seizure effected in France of 
4 tons of 3,4-methylenedioxyphenyl-2-propanone from 
Madagascar and destined for the Netherlands (see the 
2006 report of the Board on the implementation of 
article 12 of the 1988 Convention).36 
257. The Board calls upon the Governments of all 
countries in Africa to establish adequate mechanisms 
for the monitoring and control of the substances listed 
in Tables I and II of the 1988 Convention. At the same 
time, the Board encourages the relevant authorities in 
North America and Europe to extend the necessary 
cooperation and support to their counterparts in Africa 
to prevent the diversion of precursor chemicals through 
that region. In that connection, the Board also 
welcomes the launching of a new Interpol project, 
named Project Drum, which entails the establishment 
of an African operational network for combating 
trafficking and diversions of synthetic drugs and 
precursor chemicals.  
 
  Substances not under international control  
 
258. Khat continues to be cultivated in countries in 
Eastern Africa, mainly Ethiopia and Kenya and to a 
lesser extent the Comoros, Madagascar and the United 
Republic of Tanzania, and is commonly chewed as a 
stimulant in that subregion and parts of the Arabian 
peninsula. Though khat consumption is associated with 
health risks and may have detrimental social 
consequences, khat is only prohibited in some 
countries in the subregion, such as Eritrea, Rwanda and 
the United Republic of Tanzania, in some countries in 
Europe and in Canada and the United States. In 2006, 
members of a smuggling ring were arrested in the 
__________________ 
 36  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2006 ..., chap. III. 
United States on charges of having smuggled 25 tons 
of khat from Eastern Africa into the United States over 
the past few years. 
 
  Missions 
 
259. The Board sent a mission to Djibouti in January 
2006 to review the drug control situation in that 
country and the Government’s compliance with the 
international drug control treaties. 
260. The Board notes that the national drug control 
legislation is not fully in line with main international 
drug control treaties. It therefore calls upon the 
Government of Djibouti to take steps to update and 
amend its drug control law as a matter of priority. If 
necessary, UNODC may be requested to provide 
technical assistance. 
261. The Board notes with concern that the currently 
existing mechanisms for the monitoring and control of 
internationally controlled substances in Djibouti do not 
function adequately. While a multidisciplinary national 
drug control committee has already been established in 
the office of the Prime Minister, the required 
administrative structures for the implementation of its 
aims and objectives have not yet been put in place. The 
Board is particularly concerned about the serious 
weaknesses in the control of licit narcotic drugs and 
psychotropic substances, including donated drugs, and 
the lack of control over precursor chemicals. The 
Board urges the Government of Djibouti to establish 
and maintain an appropriate drug control mechanism 
that is in compliance with the requirements of the 
international drug control treaties. 
262. As the actual extent of drug abuse in Djibouti is 
not known, the Board encourages the competent 
authorities of that country to carry out, if necessary 
with the support of WHO and UNODC, an assessment 
of the situation in order to be able to plan adequate 
control and preventive measures. 
263. In May 2006, the Board sent a mission to the 
Gambia, to assess the progress made by the 
Government in implementing the recommendations 
made by the Board pursuant to its mission in 1995 to 
that country. The Board appreciates the commitment of 
the Government to international drug control, which is 
reflected in the accession of the Gambia in 1996 to the 
1961 Convention, the 1971 Convention and the 1988 
Convention, the ongoing updating of the national drug 
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control legislation and the adoption of a national drug 
control master plan. 
264. The legal framework for drug control in the 
Gambia is comprehensive and generally in compliance 
with the provisions of the three main international drug 
control treaties, although some further updating might 
be warranted. The Board is concerned, however, that 
the controls exercised over licit narcotic drugs, 
psychotropic substances and precursor chemicals are 
not adequate and that the Government’s compliance 
with its mandatory reporting obligations pursuant to 
the treaties has not been satisfactory. The Board urges 
the Government to take all steps necessary to enhance 
coordination and cooperation among the institutions 
and agencies, both regulatory and law enforcement, 
that are responsible for drug control issues, and to 
ensure full implementation of its treaty obligations, as 
a matter of priority.  
265. The Board notes with appreciation the efforts of 
the newly established multidisciplinary drug control 
administration in the Gambia to combat the smuggling 
of drugs through the country, and its active role in 
fostering and supporting cooperation in the field of 
drug control at the national, regional and international 
levels. The Board encourages the Government to 
allocate the necessary resources to that administration 
to further strengthen its capacity to fight drug 
trafficking and abuse and calls upon UNODC to 
provide assistance in that regard. 
266. In August 2006, a mission of the Board visited 
Malawi. The Board notes that the Government is 
committed to addressing all aspects of the drug 
problem. A survey on drug abuse and HIV/AIDS and a 
survey on cannabis were carried out in 2004 to assess 
the magnitude of the drug problem in the country. The 
National Drug Control Master Plan, 2005-2009, 
approved by the Inter-Ministerial Committee on Drug 
Control in 2005, provides the administrative 
framework to counter drug abuse and covers a range of 
measures for supply and demand reduction, including 
alternative development programmes. As the national 
drug control legislation currently in force is not fully in 
line with the international drug control treaties, the 
Board encourages the Government to enact without 
delay the draft drug control policy and the drug abuse 
bill, and to resume its reporting obligations pursuant to 
the international drug control treaties. 
267. Illicit cannabis cultivation takes place throughout 
Malawi. More than 50 hectares of illicitly cultivated 
cannabis were eradicated in 2006. The detection 
capacities and drug control activities of the national 
law enforcement authorities, however, are hampered by 
a lack of financial and technical resources. The Board 
encourages the Government to strengthen its efforts to 
counter the illicit cultivation of cannabis plants and to 
introduce alternative development programmes, in 
cooperation with other countries in Africa and with the 
support of the international community, where 
possible. 
268. The Board notes that the availability of opioids, 
their selection and quantities available for the control 
of pain do not always meet the requirements of the 
medical institutions in Malawi. The Board recommends 
that the Government accurately assess the national 
medical and/or scientific requirements for narcotic 
drugs and psychotropic substances and to take all steps 
necessary to ensure that those substances are available 
for treatment purposes. 
 
 
 B. Americas 
 
 
  Central America and the Caribbean 
 
 
  Major developments 
 
269. Central America and the Caribbean continues to 
be used as a major trans-shipment area for cocaine 
from South America destined for North America and 
Europe. The main smuggling routes are the maritime 
corridor of the Pacific Ocean, and the Caribbean Sea. 
Cocaine is, to a lesser extent, also smuggled by land 
across Central America along the Pan-American 
Highway and by air. Institutional weaknesses and 
corruption seriously undermine efforts by the 
Governments of countries in Central America and the 
Caribbean to combat the drug problem. The link 
between local drug trafficking and organized crime 
perpetrated by youth gangs or maras in several 
countries in the region, especially El Salvador, 
Guatemala, Haiti and Honduras, continues to be a 
problem. The smuggling of arms and ammunition in 
exchange for drugs continues to prevail in the region, 
as reported in Honduras and Panama.  
270. Trafficking in precursors of ATS is becoming a 
problem in Central America and the Caribbean. 
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Because of the lack of controls, there have been cases 
where a large amount of pharmaceutical preparations 
containing controlled precursors, such as ephedrine and 
pseudoephedrine, has been legally imported into a 
country in the region and then smuggled into North 
America or South America, to be used for the illicit 
manufacture of drugs. 
 
  Regional cooperation 
 
271. The Inter-American Drug Abuse Control 
Commission (CICAD) of the Organization of American 
States (OAS) has developed a regional framework for 
drug control plans and policies, as well as an 
evaluation system for the region. The Multilateral 
Evaluation Mechanism enables OAS member States to 
assess their own policies and those of other OAS 
member States and make recommendations to improve 
them. 
272. CICAD has also developed hemispheric 
guidelines on school-based prevention programmes37 
aimed at standardizing interventions for preventing 
drug abuse in schools. The guidelines deal with issues 
such as the political framework, theoretical 
foundations, principal characteristics of a plan and 
examples of existing prevention programmes. 
273. To tackle the problem of maritime drug 
smuggling, Governments of countries in Central 
America and the Caribbean signed in 2003 the 
agreement concerning cooperation in suppressing illicit 
maritime and air trafficking in narcotic drugs and 
psychotropic substances in the Caribbean area. 
However, the agreement has yet to be ratified by 
several countries in the region.  
274. In order to prevent the smuggling of drugs by 
land, the United States has assisted Central American 
States in improving their border inspection facilities by 
establishing mobile inspection and law enforcement 
teams. Moreover, a database called the regional 
information and intelligence-sharing system is being 
developed to collect data on the movement of persons 
in Central America and the Caribbean. It will connect 
the 24 countries and territories that are part of the 
Association of Caribbean Commissioners of Police, 
facilitating the screening of arrival and departure of 
__________________ 
 37  Organization of American States, CICAD Hemispheric 
Guidelines on School-Based Prevention (Washington, 
D.C., 2005). 
travellers, and will be also linked to Interpol. 
Furthermore, the ministers of defence of El Salvador, 
Guatemala, Honduras and Nicaragua agreed on a 
cooperative control framework that will include 
information-sharing and the review and updating of 
national and regional legal systems. 
275. Representatives from Mexico and countries in 
Central America held a meeting in San Salvador in 
September 2006 to discuss the creation of a regional 
centre to fight drug trafficking. During the meeting, 
experts from various national drug control agencies 
discussed the terms of reference of the centre and the 
functions that it should have. The centre would be 
established in El Salvador and would be operated by 
prosecutors, police officers and military personnel 
from Central American countries and Mexico. 
276. During a regional workshop organized by 
UNODC in Panama City in March 2006, national 
experts and government representatives from Belize, 
Costa Rica, El Salvador, Guatemala, Honduras, 
Mexico, Nicaragua and Panama developed a strategy 
for Central America and the Caribbean based on 
national studies of the services available for the 
treatment, rehabilitation and social reintegration of 
drug-dependent persons in the region. The strategy 
enables countries to work together on particular topics 
such as training to reinforce common issues, in order to 
improve the services for drug-dependent persons. 
277. After testing the methodology in Barbados and 
Jamaica in 2004, UNODC has since mid-2005 
expanded its computer-based training programme in 
the Caribbean to include eight additional countries: 
Antigua and Barbuda, Dominica, Grenada, Guyana, 
Saint Kitts and Nevis, Saint Lucia, Saint Vincent and 
the Grenadines and Trinidad and Tobago. The aim of 
the computer-based training programme is to 
implement self-sustaining training programmes to 
counter drug trafficking and organized criminal 
activity affecting island States. 
 
  National legislation, policy and action 
 
278. In the Bahamas, the Cabinet is currently 
preparing new legislation to improve controls and 
ensure compliance with standards and regulations for 
preventing the diversion of pharmaceutical products 
containing controlled substances. 
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279. Belize started to participate with other Central 
American countries in a cooperative national 
information exchange system. The system helps to find 
and intercept civilian aircraft and facilitates the 
detection of drug trafficking routes and the arrest of 
drug traffickers. A new act for the control of 
pharmaceuticals is expected to be enacted in Belize by 
the end of 2006. The Ministry of Health has set up a 
unit to monitor and control pharmaceutical products. 
280. Costa Rica has implemented a national database 
system, which, together with complementary computer 
programs, will make possible the cross-checking of 
sales reported by distributors of controlled substances 
and pharmacies, as well as prescriptions written by 
doctors for medicine distributed in pharmacies. 
Moreover, the Government has enacted the Regulations 
on Granting and Oversight of Licenses to Handle 
Psychotropic Substances and Narcotics in the context 
of the national drug control plan for the period 2005-
2007. 
281. In Cuba, as part of Operation Aché III, efforts to 
counter drug trafficking are being further strengthened 
by increasing air, sea and radio reconnaissance and the 
number of border troops. Those efforts are helping to 
consolidate the success of Operation Aché III in 
preventing maritime drug trafficking, seizing a large 
volume of illicit drug consignments and maintaining 
information exchange with regional drug control 
agencies. 
282. In Dominica, the draft pharmacy bill on the 
control of pharmaceutical products has yet to be 
adopted, but it is anticipated that the bill will be 
enacted in 2007. 
283. Joint cooperation between the Governments of El 
Salvador and the United States has led to the 
imprisonment of a former Salvadoran legislator, 
extradited to the United States for drug trafficking. The 
Government of El Salvador is introducing more 
comprehensive approaches to prevention, education, 
public safety and the development of life skills, in 
order to deal with the persistent problem of youth 
gangs. 
284. In Guatemala, high-level police officials were 
arrested in November 2005 and charged with 
conspiracy to import cocaine into the United States. 
The Government of Guatemala has restructured the 
procedures for approval of the production, import and 
sale of narcotic drugs and psychotropic substances and 
is working to update the customs communication 
network to control the imports of those products into 
the country.  
285. In Haiti, armed gangs continue to be a serious 
problem, mainly because they are linked to 
organizations involved in drug trafficking. The coast 
guard of Haiti has again begun to patrol the territorial 
waters of the country, achieving an important goal in 
the prevention of maritime drug trafficking. 
286. In Tegucigalpa, cooperation among the 
Government of Honduras, the private sector and 
different organizations continues to be given priority in 
order to ensure the consolidation of the UNODC 
“labour integration programme”, an innovative 
vocational scheme for youth at risk. Honduras must 
carry out a nationwide survey to assess the extent of 
drug abuse and approve the minimum standards of care 
for drug-dependent persons. 
287. In Jamaica, the Government-appointed Precursor 
Chemical Committee, which had worked on the 
preparation of subsidiary legislation to the Precursor 
Chemicals Act, 1999, has been re-established to 
finalize such regulations.  
288. In the Netherlands Antilles, efforts at the 
international airport at Curaçao focusing on detecting 
“mules” (passengers who hide illegal drugs inside their 
bodies) continued to produce results during 2006. 
However, there are indications suggesting that the 
“mules” may be shifting their activities to other 
airports in the territory. To prevent that, the 
Government is starting to carry out “anti-mule” 
operations in those airports. Following the 
recommendation of the Board, the territory has started 
to address the problem of the illegal sale of drugs 
through Internet pharmacies. 
289. In Nicaragua, the Government approved the 
Minimum Standards of Care for Users of Psychoactive 
Substances through ministerial agreement No. 41-2006 
of 3 February 2006. 
290. Panama has strengthened its controls over 
precursor chemicals. The Government passed on 
13 June 2005, the Special Chemicals Law (Law 
No. 19) and its regulations. In addition, a new project 
to evaluate and improve drug control in the Colón Free 
Zone is to be implemented during 2006. Despite the 
efforts of the Government, corruption is a persistent 
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problem in the country. In 2005, a high-level official of 
the counter-narcotics unit was detained and accused of 
corruption. 
291. The authorities of Trinidad and Tobago, in 
cooperation with United States authorities, have 
developed a computer system that will give the 
Ministry of Health the capacity to track chemical 
shipments, with a view to preventing their diversion 
for use in illicit drug manufacture. Moreover, the 
Government of Trinidad and Tobago appointed a 
special Precursor Chemical Team that has completed a 
review of the current legislation and is in the process 
of drafting a new law. 
292. The use of cash couriers and of money transfer 
services to pay for consignments of illicit drugs is 
increasing. Cash couriers have been detained in 
Antigua and Barbuda, El Salvador and Honduras. In 
addition, cash couriers from Antigua and Barbuda have 
been detained in other countries, particularly in Saint 
Vincent and the Grenadines, where links to drug 
traffickers have been established by the police. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
293. In spite of being used as major transit and trans-
shipment areas, all countries in Central America and 
the Caribbean, with the exception of El Salvador, have 
relatively low levels of drug abuse. The most 
commonly abused drug in the region is cannabis, 
followed by cocaine hydrochloride and “crack” 
cocaine. 
294. Central America and the Caribbean is not a main 
drug-producing area, although some countries in the 
region, such as Guatemala and Jamaica (see paras. 299-
300 below), are threatened by increasing production of 
illicit drugs. 
 
  Narcotic drugs 
 
295. About 90 per cent of the cocaine entering North 
America every year passes through Central America. 
Moreover, the Caribbean is situated along one of the 
main cocaine trafficking routes leading to Europe. The 
authorities of the Netherlands made about 40 per cent 
of their total seizures in the waters of the Netherlands 
Antilles in 2004. Jamaica and Martinique continue to 
play an important role in the trans-shipment of cocaine 
to the United Kingdom and France, respectively. 
296. In El Salvador, law enforcement authorities 
seized over three times more illicit drugs during the 
period 2000-2005 than during the previous five-year 
period. Six out of 10 Salvadorans have abused an illicit 
drug at least once in their lifetime, particularly during 
adolescence. Between January and November 2005, 
2,394 persons in El Salvador were arrested for drug 
trafficking and the possession of drugs. 
297. In Nicaragua, a joint operation implemented in 
February 2006, involving the police and the army and 
coordinated by the prosecutor’s office, led to the 
seizure of 547 kg of cocaine that were being shipped 
from Costa Rica to Guatemala. 
298. In Costa Rica, the abuse of drugs, particularly 
“crack” cocaine, has increased; there has also been an 
increase in violent crime linked to drug trafficking and 
abuse. 
299. In Guatemala, almost 490 hectares of illicit 
opium poppy cultivation were eradicated in 2005, 
which represents an increase of more than 250 per cent 
compared with the figure for 2004 (181 hectares). 
During 2005, 6,400 persons were arrested for 
possession or illicit use of drugs, of whom 3,334 were 
young persons of between 15 and 25 years of age. In 
contrast, only 46 persons were arrested for drug 
trafficking during the same period. 
300. Jamaica is the main illicit producer and exporter 
of cannabis in Central America and the Caribbean. 
However, there is no precise estimate of the quantity of 
cannabis plant illicitly cultivated in the country. The 
illicit cultivation of cannabis plants, which was carried 
out on a large scale in the past, is now being done on 
smaller plots of land hidden in inaccessible 
mountainous areas. Cannabis is the most commonly 
abused drug not only in Jamaica but also in the region 
as a whole. 
301. Saint Vincent and the Grenadines is also an 
important illicit producer of cannabis in the Caribbean 
subregion. Illicit drug trafficking has penetrated the 
licit economy of Saint Vincent and the Grenadines, 
making parts of the population dependent on the illicit 
cultivation of cannabis plant and on trafficking in 
cannabis. 
 
  Psychotropic substances 
 
302. During the first half of 2006, law enforcement 
authorities of Costa Rica confiscated 3,450 tablets of 
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MDMA (“ecstasy”) that were being smuggled by 
Colombian nationals. That was the largest quantity of 
synthetic drugs ever seized by the police in that 
country. 
303. The Dominican Republic continues to be used as 
a major trans-shipment area for MDMA (“ecstasy”) 
from Europe destined for the United States. In 2005, a 
total of 280,000 MDMA tablets were seized. 
304. In Trinidad and Tobago, the National Alcohol and 
Drug Abuse Prevention Programme, which is 
responsible for the coordination of demand reduction 
initiatives, has reported evidence of the abuse of 
MDMA (“ecstasy”) in the country, in addition to the 
abuse of cocaine, cannabis and heroin. 
 
  Missions 
 
305. A mission of the Board visited El Salvador in 
August 2006. The Board notes that the Government is 
committed to combat drug trafficking and abuse and is 
making its best efforts towards those ends, as 
evidenced by a high degree of professionalism and 
good coordination among the state agencies in charge 
of drug control. However, some of those agencies, in 
particular the Supreme Council of Health, lack the 
financial and technical resources to fully carry out their 
mandate. The Board encourages the Government of El 
Salvador to join Project Prism. 
306. Control over the licit movement of narcotic drugs 
and psychotropic substances in El Salvador is, in 
general, satisfactory. Nevertheless, the availability of 
controlled substances for medical purposes is very low. 
The Board encourages the Government to take the 
necessary measures to ensure sufficient availability of 
controlled medicines for medical purposes. The Board 
notes that the problem related to the youth gangs or 
maras (criminal bands organized to commit all kinds of 
offences, including drug trafficking) (see para. 269 
above) is growing steadily. The Board encourages the 
Government to study the problem and to take the 
necessary measures to deal with it. 
307. A technical visit of the Board to Honduras took 
place in August 2006. The Board notes that Honduras 
ratified the 1971 Convention in May 2005 and has thus 
become a party to each of the three international drug 
control treaties. The Board also notes the commitment 
of the National Council against Drug Trafficking 
(CNCN), which is comprised of the highest-level 
officials in Honduras, to the fight against drug 
trafficking and abuse. However, inadequate resources 
and coordination among drug control agencies have 
hampered the Government’s efforts to combat drug 
trafficking effectively. 
308. The Board notes that the legal framework for 
drug control in Honduras is outdated. The Board 
requests the Government to enact a new, more 
comprehensive law, in line with the international drug 
control treaties, that will include the regulation of 
precursor chemicals and to fully implement the 1971 
Convention. The Board also notes that the Unit for the 
Regulation of Pharmaceutical Products, the competent 
authority in charge of the licit movement of drugs, 
lacks adequate resources to carry out its basic 
responsibilities. The Government should take the 
necessary measures to solve those problems as soon as 
possible. 
309. The Board notes that no surveys on the extent of 
drug abuse among the general population in Honduras 
have been conducted recently, and no minimum 
standards of care have been approved yet. The 
Government should take measures to deal with those 
problems. 
 
 
  North America 
 
 
  Major developments 
 
310. North America, comprising Canada, Mexico and 
the United States, continues to be one of the prime 
targets of drug traffickers. For more than 30 years, 
drug abuse and perceived risk of drug abuse among 
students in secondary schools in the United States have 
been monitored in the annual survey “Monitoring the 
Future”. According to the survey, the proportion of 
students using illicit drugs has been on the decline for 
four consecutive years; as a result, the annual 
prevalence rate for various drugs is currently 10-30 per 
cent lower than it was 10 years ago. There has been a 
significant decline in the percentage of students in 
secondary schools who reported lifetime use of 
cannabis; there have also been declines in their lifetime 
use of other drugs, such as methamphetamine, MDMA, 
cocaine and heroin. The Board notes that, according to 
the survey, those declines are largely related to a 
significant rise in the percentage of adolescents 
perceiving the abuse of amphetamines, cannabis, 
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“crack” cocaine, heroin and MDMA to be high-risk 
activities. However, the same survey reveals that the 
abuse of prescription drugs is increasing among 
students in secondary schools; for example, abuse of 
oxycodone preparations (OxyContin®) increased by 
almost 40 per cent from 2002 to 2005. 
311. Substance abuse remains a matter of serious 
concern in the United States, particularly with regard 
to the high level of abuse of prescription drugs by 
adolescents and adults. The gradual increase in the 
abuse of sedatives (including barbiturates), 
tranquillizers and narcotic drugs other than heroin 
among the general population has resulted in 
prescription drugs becoming the second most abused 
class of drugs after cannabis. The abuse of prescription 
drugs such as fentanyl, oxycodone and hydrocodone 
has lead to a rising number of deaths.  
312. The spread in the abuse of prescription drugs is 
also related to the increasing use of the World Wide 
Web as a global drug market. International law 
enforcement efforts closed down thousands of illegal 
Internet pharmacies involved in drug trafficking. 
Despite those efforts, there is an increasing number of 
such Internet sites selling medicines containing opioids 
and stimulants without prescriptions. 
313. Methamphetamine trafficking and abuse continue 
to be key problems in Canada and the United States. In 
some rural areas and a number of small cities in the 
United States, the abuse of methamphetamine has 
reached widespread proportions. Methamphetamine 
abuse has become a serious health, law enforcement 
and political concern and the fastest-growing drug 
threat: 58 per cent of counties rank it as their biggest 
drug problem. While United States drug law 
enforcement agencies have been successful in closing 
down illicit methamphetamine laboratories, domestic 
illicit manufacturers of methamphetamine have largely 
been replaced by transnational drug trafficking 
organizations, based in Canada and Mexico. In Canada, 
domestic illicit manufacturers account for the largest 
share of the trafficked methamphetamine. 
314. The Board notes the significant legislative efforts 
made by all three States in North America to counteract 
the surge of methamphetamine in the region. The 
United States has enacted new legislation (the Patriot 
Act), which inter alia, restricts the sale of ephedrine 
and medications containing pseudoephedrine. Limits 
on imports of pseudoephedrine and ephedrine have 
also been introduced in Mexico. Canada amended the 
2003 Precursor Control Regulations, strengthening, 
inter alia, import and export licensing procedures.  
315. The involvement of organized criminal groups 
has led to Canada being used as a source for cannabis, 
methamphetamine and MDMA sold on the illicit 
market in that country or in the United States. The 
importance of illicit methamphetamine exports to the 
United States has declined following the introduction 
of improved precursor controls in 2003.  
316. Mexican drug trafficking organizations and 
criminal groups control most of the organized 
wholesale drug trafficking in the United States, in 
particular trafficking in cocaine, cannabis, meth-
amphetamine and heroin that is illicitly manufactured 
in Mexico. They are expanding their control of drug 
trafficking to areas formerly under the influence of 
Colombian, Dominican and other criminal groups. 
 
  Regional cooperation 
 
317. The Governments of all three countries in North 
America have responded to the threat of drug 
trafficking operations, particularly those operations run 
by organized criminal groups, with increased 
cooperation and mutual support. The close cooperation 
between Mexico and the United States has included 
major institution-building initiatives, as well as 
financial and technical support, as evidenced by the 
provision of training courses for Mexican law 
enforcement personnel and prosecutors at the national, 
state and local levels. The Attorney General of Mexico 
and the Attorney General of the United States hold 
meetings on a regular basis to discuss bilateral 
cooperation and border violence.  
318. The extradition of drug criminals from Mexico to 
the United States is taking place more frequently. An 
increasing number of fugitives are being deported to 
the United States by Mexican police and immigration 
authorities. The Government of Mexico initiated 
Operativo México Seguro (Operation Secure Mexico) 
to counter violence that began in 2005 among criminal 
organizations fighting for control over smuggling 
routes in cities along the border of Mexico with the 
United States. The Governments of Mexico and the 
United States started in 2005 Operation Border Unity, a 
bilateral, multi-agency effort to address violence on 
both sides of the border in the Laredo/Nuevo Laredo 
area.  
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319. The involvement of criminal groups in drug 
trafficking between Canada and the United States is 
counteracted by close cooperation of the authorities of 
the two countries at the national, state (or provincial) 
and local levels. One example of that close cooperation 
is the Integrated Border Enforcement Team initiative, 
which has become one of the primary tools used to 
ensure that criminals cannot exploit international 
borders to evade prosecution. The Shiprider 
Agreement, concluded in 2006 between Canada and the 
United States, has strengthened law enforcement 
cooperation by providing transborder law enforcement 
authority to Canadian law enforcement officers 
operating along and across the border.  
320. Cooperation between Canada and the United 
States has also been used to combat drug trafficking in 
the transit zone from South America to North America. 
Canada deployed “Maritime Patrol Assets” in support 
of “Joint Interagency Task Force South”, of the United 
States, one of three such task forces conducting 
operations to counter drug trafficking.  
 
  National legislation, policy and action 
 
321. The Uniting and Strengthening America by 
Providing Appropriate Tools Required to Intercept and 
Obstruct Terrorism (USA PATRIOT) Improvement and 
Reauthorization Act of 2005, signed in March 2006, 
contains a number of important provisions to combat 
the illicit manufacture of and trafficking in 
methamphetamine. The provisions include: restrictions 
on the sale of medicines containing pseudoephedrine, 
ephedrine and phenylpropanolamine; increased 
criminal penalties for illicit manufacture of, trafficking 
in and smuggling of methamphetamine; and provisions 
for bilateral efforts at the border between Mexico and 
the United States.  
322. In addition, individual states in the United States 
have responded to the new challenge posed by 
methamphetamines and enacted additional state-level 
legislation on precursor control. States with the 
strictest laws on pseudoephedrine have seen a 
significant reduction in the number of seizures of 
methamphetamine laboratories. 
323. In November 2005, the Government of Canada 
enacted the first major amendments to the 2003 
Precursor Control Regulations, which provided for 
strengthened licensing procedures. Canada also moved 
methamphetamine to a more strictly controlled national 
schedule, increasing the maximum penalty for 
trafficking in or illicit manufacture of the substance 
(from 10 years of imprisonment to life imprisonment) 
and for possession (from three years of imprisonment 
to seven). 
324. The Government of Mexico introduced a policy 
limiting the importation of pseudoephedrine and 
ephedrine to manufacturers only, thereby reducing 
imports of those precursors by 40 per cent. Wholesale 
distributors are no longer allowed to import base 
pseudoephedrine and ephedrine. In addition, the 
quantity that can be imported in a single shipment is 
limited to 3,000 kg. Import quotas were tied to 
estimates of national needs.  
325. The Supreme Court of Mexico ruled in November 
2005 that sentencing a person to life in prison without 
the possibility of parole did not violate the Mexican 
Constitution, which prohibited cruel and unusual 
punishment. The ruling has removed a significant 
obstacle to the extradition of fugitives from Mexico 
facing life imprisonment in the United States for 
offences involving major drug trafficking and violent 
crimes.   
326. In November 2005, the Parliament of Canada 
passed the Proceeds of Crime Bill, which targets the 
illicit proceeds of organized crime, including serious 
drug offences, and authorizes the courts to order the 
forfeiture of property of those convicted of either 
membership in a criminal organization or certain drug-
related offences.  
327. The Board notes that the Government of Canada 
has decided not to pursue the proposed cannabis 
reform legislation that would have decriminalized 
possession of small quantities of cannabis.  
328. The Board is seriously concerned that several 
cities in Canada, in addition to the heroin injection site 
in Vancouver, have planned to distribute drug 
paraphernalia, including “crack” pipes, to chronic 
users. The Board has repeatedly mentioned in its 
annual reports38 that such programmes are in 
__________________ 
 38  Report of the International Narcotics Control Board for 
2005 (United Nations publication, Sales No. E.06.XI.2), 
para. 590; Report of the International Narcotics Control 
Board for 2004 (United Nations publication, Sales 
No. E.05.XI.3), para. 510; Report of the International 
Narcotics Control Board for 2003 (United Nations 
publication, Sales No. E.04.XI.1), paras. 325-326. 
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contravention of the international drug control treaties. 
The Board urges the Government to make available 
adequate services to drug abusers in need of 
treatment and rehabilitation, rather than providing drug 
injection rooms, in order to ensure full compliance 
with the provisions of the international drug control 
treaties. 
329. The Board welcomes the Drug Strategy 
Community Initiatives Fund, established by the 
Government of Canada, which supports efforts in 
demand reduction and treatment for drug abuse carried 
out at the local community level, in particular 
initiatives for preventing the abuse of cannabis and 
methamphetamine.  
330. The United States is responding to the increasing 
problem of abuse of prescription drugs, focusing on 
preventing the diversion of prescription drugs and 
providing treatment for abusers of such drugs. At the 
state level, the prescription-drug monitoring 
programme provides doctors, pharmacists and, when 
appropriate, law enforcement with information about 
patients’ prescriptions. In late 2005, a total of 25 states 
had operational programmes for monitoring 
prescription drugs or were in the process of 
implementing them.  
331. In Mexico, corruption continues to be a serious 
problem. The Agencia Federal de Investigación 
(federal investigative agency) is the central body 
coordinating efforts to fight corruption in the country, 
promoting professionalism and the effectiveness of law 
enforcement institutions. Mexico has taken a 
number of steps to reduce, if not eliminate, corruption 
among law enforcement and government officials, such 
as the establishment of a career path for investigators 
and the introduction of the concept of “culture of 
lawfulness” as part of the curriculum in schools. 
Authorities at the national, state and local levels have 
initiated training on the rule of law for police 
personnel. Investigations into possible misconduct by 
law enforcement officers and government employees 
are carried out regularly. The Board, while noting those 
efforts, again requests that Mexican authorities actively 
pursue the implementation of policies to counteract 
corruption. 
 
  Situation with regard to drug trafficking and 
abuse  
 
332. Cannabis continues to be the most commonly 
abused and trafficked illicit drug in the region. North 
America accounts for the largest part of illicit cannabis 
production worldwide. According to available 
information, in 2005 Mexico produced more than 
10,000 tons of cannabis and the United States produced 
nearly 4,500 tons. 
333. According to the latest Canadian Addiction 
Survey, annual prevalence of cannabis use among 
persons aged 15 and above increased from 6.5 per cent 
in 1989 to 14.1 per cent in 2004. Illicit cannabis plant 
cultivation has become a thriving illegal industry in 
Canada. In addition to outdoor cultivation, more 
sophisticated indoor crop-growing methods are 
increasingly being used to produce high-potency 
cannabis (cannabis with a high tetrahydrocannabinol 
(THC) content). On some of the plantations there are 
thousands of cannabis plants. Criminal groups are 
increasingly gaining control over the production and 
distribution of high-potency cannabis in Canada and 
have been identified as the principal suppliers of such 
cannabis to the United States. The total amount of 
Canadian cannabis seized by United States customs 
authorities was more than eight times greater in 2004 
(more than 19 tons) than in 2000. 
334. In Canada, cultivation of cannabis plants and 
trafficking in cannabis currently account for the bulk of 
the caseload of drug law enforcement authorities. Each 
year, approximately 1.3 million cannabis plants are 
seized; using that figure as a basis, Canadian law 
enforcement agencies estimate annual production of 
cannabis to be 1,070-2,676 tons. 
335. Cannabis remains the most commonly abused 
drug in the United States, but a steady decline in its 
abuse by adolescents has been noted for almost a 
decade. A large part of the cannabis products available 
in the United States are smuggled into the country by 
Mexican drug trafficking organizations and criminal 
groups. More than 580 tons of cannabis originating in 
Mexico were seized by United States customs 
authorities in 2004. In Mexico, the eradication of 
cannabis plants remained at the same level in 2005 as 
in 2004 (30,882 hectares). 
336. Mexican drug trafficking organizations have 
increased the size and sophistication of their cannabis 
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plant cultivation operations on public and private lands 
in the United States. New techniques are used on those 
well-protected cultivation areas to produce a larger, 
more potent outdoor cannabis crop with a THC content 
of at least 5 per cent and with an increased street value. 
Such higher-potency cannabis accounted for more than 
half of the total cannabis seized in 2005. 
Approximately 5.7 million cannabis plants were 
eradicated within the United States in 2005, which 
represents an increase of 1 million plants compared 
with the figure for 2004. 
337. Another major problem in North America is the 
increasing methamphetamine manufacture, abuse and 
trafficking, involving mainly the United States market. 
Amphetamine abusers accounted for 8 per cent of all 
drug abusers admitted for treatment in 2004, compared 
with 3 per cent in 1994. Methamphetamine abuse has 
gradually expanded from the western states of the 
United States to the eastern states. It is particularly a 
problem in rural areas and small cities in that country. 
338. While domestic illicit methamphetamine 
manufacture is still the main supplier of the United 
States market, it has declined in recent years as a result 
of law enforcement pressure and restrictions on the 
sale and use of pseudoephedrine and ephedrine. In the 
United States, the number of seizures of laboratories 
illicitly manufacturing methamphetamine, whether on a 
large or a small scale, declined significantly, from 
more than 10,200 in 2003 to less than 5,300 in 2005. 
The reduction in the manufacture of methamphetamine 
in the United States has been largely offset by sharp 
increases in the large-scale manufacture of that drug in 
Mexico, particularly in the western and north-western 
parts of the country. The latter trend has been 
confirmed by the increasing amount of meth-
amphetamine manufactured in Mexico and seized on 
the border between Mexico and the United States 
(2 tons in 2004).  
339. The prevalence of methamphetamine abuse is still 
relatively low among the general population in Canada; 
however, among youth, particularly among street youth 
and youth in the rave and club scenes, 
methamphetamine abuse is rising.  
340. Most of the methamphetamine trafficked in 
Canada is manufactured in clandestine laboratories in 
the country itself. The number of seizures of 
clandestine methamphetamine laboratories increased 
from 13 in 2001 to 40 in 2004. While there are many 
small methamphetamine laboratories operated by 
individuals in rural areas, there has been an increase in 
the number of “super laboratories” (manufacturing 
methamphetamine in excess of 5 kg per synthesis 
cycle). The level of sophistication of the laboratory set-
ups, as well as the involvement of organized criminal 
groups in methamphetamine manufacture, has 
increased. In some parts of Canada, such as Quebec, 
most of the methamphetamine trafficked is in tablet 
form. The shift from powder form to tablet form is in 
response to the growing number of users in the rave 
and club scenes. 
341. The Board is concerned about the increasing 
abuse in the United States of prescription drugs listed 
as controlled substances, including pain killers, 
stimulants, sedatives and tranquillizers. Levels of non-
medical use and abuse of pharmaceuticals are higher 
than levels of use for most illicit drugs, second only to 
the levels of cannabis abuse. Pharmaceuticals 
commonly abused in the United States include cocaine, 
codeine, fentanyl, hydrocodone, hydromorphone, 
methadone, methylphenidate, morphine, oxycodone, 
the amphetamine group and the benzodiazepine group. 
The abuse of several of those substances can have 
lethal effects, and there has been an increasing number 
of deaths related to such abuse in the United States. 
The Board calls on the United States authorities to 
raise public awareness and take more effective action 
with regard to the added risk for non-medical drug 
users who tamper with prescription drugs and 
formulations. The tampered medications include 
narcotic analgesics, stimulants and depressants.  
342. According to the National Survey on Drug Use 
and Health in the United States, 11 per cent of persons 
aged 12-17 reported lifetime non-medical use of pain 
killers. According to data from the study Monitoring 
the Future, OxyContin® abuse increased from 2002 to 
2005 by almost 40 per cent, to an annual prevalence of 
5.5 per cent among students in their final year of 
secondary school (aged 17-18). Hydrocodone 
(Vicodin®) is also widely abused: 7.4 per cent of 
college students (aged 18-22) abused that drug in 2005 
(see also para. 56 above). 
343. The Board wishes to draw to the attention of the 
United States authorities that the overall increase in the 
amount of prescription drugs abused appears to be 
related to an increase in sales of prescription narcotic 
drugs, depressants and stimulants. From 2000 to 2004, 
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the commercial distribution of pharmaceuticals in the 
United States increased by 109 per cent. One matter of 
particular concern is the sharp rise in sales of 
commonly abused pharmaceuticals such as 
hydrocodone and oxycodone. 
344. Another matter of particular concern to the Board 
is the noticeable increase in the abuse of fentanyl since 
May 2006 in the United States, and, to a lesser extent, 
in Canada. The abuse of fentanyl, a synthetic opioid 
80 times as potent as heroin, is particularly dangerous, 
as evidenced by the recent dramatic increase in the 
number of deaths from fentanyl overdoses registered 
on the eastern coast of the United States. The fentanyl 
is either sold as heroin or mixed with heroin. Fentanyl 
abusers are unable to judge the strength of the 
substance they are injecting. There have also been 
cases of the abuse of a mixture of fentanyl and cocaine.  
345. Fentanyl is diverted by means of pharmacy theft, 
fraudulent prescriptions and illicit distribution by 
patients, physicians and pharmacists. Lately, fentanyl 
preparations, in particular in the form of transdermal 
patches and lozenges, are becoming as popular as 
OxyContin® in pharmacy burglaries and robberies. Not 
all fentanyl found on the illicit market has been 
diverted. To date, over 12 different analogues of 
fentanyl have been manufactured clandestinely and 
identified in seizures of drugs trafficked in the United 
States. Recent developments involving large quantities 
of trafficked fentanyl, as well as raids of clandestine 
laboratories in Mexico and the United States, indicate 
the growing role of illicitly manufactured fentanyl in 
supplying the illicit market.  
346. Cocaine abuse in the United States is stable, with 
a slight decline in the number of persons who abused 
cocaine at least once in the past month. The proportion 
of persons admitted for treatment for cocaine abuse 
declined from 18 per cent in 1994 to 14 per cent in 
2004. Persons who smoked “crack” cocaine accounted 
for 72 per cent of all persons admitted for treatment for 
cocaine abuse in 2004. United States inter-agency and 
multinational forces in the transit zone from South 
America to North America (the Joint Interagency Task 
Force South) seized a record 254 tons of cocaine in 
2005, compared with 219 tons in 2004 and 176 tons in 
2003. However, the Board notes that, as traditional 
maritime routes of cocaine trafficking have been 
disturbed by joint law enforcement operations, drug 
traffickers have tried to evade interdiction efforts by 
moving fishing-vessel operations farther out in the 
Pacific, as far as the Galapagos Islands. Vessels or 
yachts carrying cocaine intended for illicit markets in 
Canada and the United States have been seized in 
locations even farther away, such as off the coast of 
Spain.  
347. The cocaine smuggled into the United States is 
derived from coca produced mainly in Colombia but 
also in Bolivia and Peru. Mexico continues to be used 
as the principal trans-shipment country for cocaine 
entering the United States. Cocaine abuse is increasing 
in Mexico.  
348. Demand for cocaine in Canada remains strong, 
and large-scale illegal importations of the drug 
continue. Law enforcement operations have revealed 
close relations between organized criminal groups from 
Canada and Colombian cartels attempting to import to 
Canada bulk shipments of cocaine (several hundred 
kilograms each) on a regular basis. The most common 
areas used as trans-shipment points for smuggling 
cocaine into Canada are Antigua, Haiti, Jamaica, Saint 
Lucia, Saint Martin, Trinidad and Tobago and the 
United States. According to the Canadian Addiction 
Survey, cocaine is the third most widely used illicit 
drug in Canada, after cannabis and hallucinogens (such 
as lysergic acid diethylamide (LSD) and 
phencyclidine). According to survey data, annual 
prevalence of abuse of powder and “crack” cocaine in 
Canada increased from 0.7 per cent in 1994 to 1.9 per 
cent in 2004.  
349. The Board regards the decrease in heroin abuse 
among adolescents in the United States as an 
encouraging sign: annual prevalence of such abuse was 
0.2 per cent in 2004, compared with 0.6 per cent in the 
mid-1990s. As the current perception that the risks of 
heroin abuse are high is expected to continue, the rate 
of past year abuse of heroin is expected to decrease 
even further.  
350. The total amount of heroin seized in the United 
States decreased from 2,773 kg in 2002 to 1,845 kg in 
2004. Most of the heroin abused in that country is 
manufactured from opium poppy grown in Colombia 
and Mexico, though opium production in those 
countries accounts for less than 4 per cent of global 
production. Expanded aerial eradication efforts, as well 
as upgraded security screening and increased seizures 
at United States airports, has led to a decrease in the 
availability of Colombian heroin; however, Colombia 
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is still the main supplier of heroin to the United States, 
accounting for 60-70 per cent of the heroin sold in the 
United States.  
351. In Mexico, opium poppy growers employ small, 
widely dispersed plots in remote, hard-to-access areas, 
hindering detection and eradication of crops. In 
addition, the favourable climate in 2005 permitted two 
or three opium poppy harvests. Opium poppy is mostly 
cultivated in areas on the Pacific coast and then 
transported to the centre and north of Mexico for 
processing. The eradication operations of the Mexican 
Army and the Attorney General’s Office usually 
destroy at least 80 per cent of the opium poppy grown 
in the country. In 2005, the total area of eradicated 
opium poppy crops increased to 20,464 hectares, an 
increase of 28 per cent over the previous year.  
352. In Canada, the total volume of heroin seized 
remained comparatively low (68 kg in 2004) but the 
volume of opium seized increased (from 27 kg in 2001 
to 84 kg in 2004). According to the Royal Canadian 
Mounted Police, consignments of opium and heroin 
from Afghanistan, India, Iran (Islamic Republic of) and 
Pakistan are usually routed through a European country 
or the United States to Canada. Since 2002, the total 
seizures of heroin originating in South-East Asia has 
somewhat declined, and the market share of Latin 
American heroin has been increasing. 
353. The sharp increase in MDMA trafficking in the 
United States noted five years ago (11 million tablets 
in the peak year 2001) has been halted: the total 
amount of MDMA seized in that country has declined 
to less than 3 million tablets in the last two years. The 
number of past-year abusers of MDMA (aged 12 and 
above) declined by 40 per cent between 2002 and 
2004. In Canada, significant seizures of MDMA from 
clandestine laboratories indicate the involvement of 
larger and more sophisticated operations involving 
organized criminal groups. Prior to 2004, MDMA 
arrived mainly in tablet or powder form from Europe. 
In 2004, importations of MDMA decreased as 
traffickers began to produce MDMA on a large scale 
within Canada. The total amount of seized MDMA 
increased to a record level of 15 million dosage units 
in 2004, compared with an annual average of less than 
2 million dosage units in the period 2000-2002. The 
number of seized clandestine laboratories nearly tripled 
(to 17) in 2004. Most of the clandestine laboratories 
are polydrug laboratories, manufacturing more than 
one single illicit drug (for example, a combination of 
methylenedioxyamphetamine (MDA) and MDMA, a 
combination of MDA and methamphetamine or a 
combination of MDMA and methamphetamine). 
Organized criminal groups are heavily involved in the 
illicit manufacture of and trafficking in such drugs.  
354. In Canada, MDMA, MDA and gamma-
hydroxybutyric acid (GHB) continue to be widely 
abused in the rave scene. The abuse of those drugs has 
spread to far broader user groups, including youth 
attending clubs, private parties, secondary schools, 
colleges and universities.  
 
  Substances not under international control 
 
355. Among students in their final year of secondary 
school in the United States, the proportion of students 
who abused inhalants in the past year was considerably 
lower in 2004 (4.2 per cent) than in the peak year 1995 
(8.0 per cent). The abuse of inhalants in the United 
States, however, is on the rise again. It appears that, 
among adolescents, inhalants are the third most widely 
used class of illicit drugs.  
356. In the United States, there have been reports on 
the abuse of high doses of dimenhydrinate, the active 
ingredient in Dramamine®, with dangerous or even 
fatal effects. 
357. Khat from various countries is smuggled into 
Canada, mainly via the United Kingdom, where it is 
not a prohibited substance. Under Schedule IV of the 
Controlled Drugs and Substances Act of Canada, khat 
is designated a “controlled substance” and as such it is 
a criminal offence to import, export or traffic in khat. 
 
 
  South America  
 
 
  Major developments 
 
358. The total area under coca bush cultivation in the 
Andean subregion increased slightly, from 158,000 
hectares in 2004 to 159,600 hectares in 2005, but the 
figure for 2005 still represented a decrease of 28 per 
cent compared with the figure for 2000. Slight 
decreases in the total area under coca bush cultivation 
in Bolivia and Peru were offset by an increase in 
Colombia despite intensified eradication efforts. The 
ability of coca bush growers to move their operations 
from one area to another adversely affected the results 
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of eradication efforts by the Government of Colombia. 
Potential cocaine manufacture in the Andean subregion 
decreased by 3 per cent. Cocaine continues to reach the 
principal markets of the United States and Europe 
through the main trafficking routes in Central America 
and the Caribbean, as well as through Africa, as 
evidenced by increased seizures in Western and Central 
Africa (see para. 401 below). 
359. With a view to monitoring the total area under 
coca bush cultivation, field research measuring coca 
leaf yields and cocaine yields from coca leaves was 
conducted in Colombia in 2006. The research confirms 
the findings of the Board that the cocaine yields are 
higher than reported in 2005. Those new findings are 
reflected in the 2005 figure for potential cocaine 
manufacture in Colombia (640 tons). In Peru, work to 
update the methods used to measure coca leaf and 
cocaine yields started in 2006 and will be applied in 
2007. A similar review is also expected in Bolivia. 
360. The Board notes that the Government of Bolivia 
is considering the introduction of a new drug control 
policy with a view to using coca leaf for a wide range 
of products, as evidenced by the inauguration in June 
2006 of a plant for processing coca leaf. The plant will 
manufacture packed coca tea, for local consumption 
and, according to proposals, also for export to other 
States parties to the 1961 Convention. 
361. The Board wishes to reiterate its position 
reflected in its report for 200539 and urges the 
Governments concerned to ensure the full 
implementation of the provisions of the 1961 
Convention as amended by the 1972 Protocol 
concerning the production of coca leaf, its industrial 
uses and international trade. The Board is concerned 
that that action could serve as a precedent and may 
send the wrong message to the public if it is allowed to 
stand. 
362. In Peru, coca bush growers are putting pressure 
on the new Government to stop manual eradication of 
coca bush and to remove coca leaf from international 
control. In Argentina, under current legislation, the 
possession of coca tea or coca leaf in a natural state for 
chewing purposes is not considered to be possession or 
personal use of a narcotic drug. The Board wishes to 
remind Governments that it is the responsibility of the 
__________________ 
 39  Report of the International Narcotics Control Board for 
2005 …, para. 394. 
States parties to the international drug control treaties 
to ensure that the provisions concerning the cultivation 
of coca bush and the possession and use of coca leaves 
are adhered to, and the Board is ready to assist 
Governments in their efforts to fulfil that 
responsibility. 
363. The implementation of measures aimed at 
countering drug trafficking, reducing illicit crop 
cultivation, preventing and fighting corruption related 
to drug trafficking and extraditing drug traffickers has 
met with resistance by violent groups in some 
countries in South America. The Board urges all 
Governments not to reduce their efforts to enforce their 
drug control policies, despite difficulties that they may 
be experiencing in that area. 
364. Large amounts of precursor chemicals required 
for the illicit manufacture of drugs continue to be 
seized in most countries in South America, which 
indicates the availability of those precursor chemicals 
to be used for such purposes. Measures to counter 
smuggling, including measures used in controlling 
domestic distribution networks and investigating 
diversions of precursor chemicals, need to be further 
strengthened. 
365. Cocaine abuse continues to account for most of 
the demand for treatment for drug abuse in South 
America, though the share accounted for by cocaine 
abuse has declined since the late 1990s. Several 
countries in the region carried out activities 
specifically aimed at the establishment of minimum 
standards of care for the treatment and rehabilitation of 
drug-dependent persons and the evaluation of the 
effectiveness of existing programmes for the treatment 
and prevention of drug abuse and conducted studies on 
the prevalence of drug abuse. 
 
  Regional cooperation 
 
366. To advance efforts in drug control and supply 
reduction, CICAD continued to provide its member 
States with support in the form of training and 
technical assistance. The establishment of a network of 
national drug observatories in South America, to 
ensure that Governments are supplied with high-
quality information on drug production, trafficking and 
abuse and related crime, was one of the priorities of 
CICAD. For example, in Peru, the Comisión Nacional 
para el Desarrollo y Vida sin Drogas (national 
commission for development and a drug-free lifestyle) 
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submitted to the Government in February 2006 a draft 
decree providing for the establishment of the 
Observatorio Peruano de Drogas (Peruvian drug 
observatory), which also received support from 
Belgium. 
367. The VIII High-Level Meeting of the Coordination 
and Cooperation Mechanism on Drugs between the 
European Union and Latin America and the Caribbean 
was held in Vienna on 6 and 7 March 2006. The 
mechanism is of particular importance within the 
framework of relations between the European Union 
and Latin America and the Caribbean, as it is an 
institutional forum at the interregional level for 
identifying new approaches and exchanging proposals, 
ideas and experiences in addressing illicit drug 
production, trafficking and consumption. 
368. At the Fifteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and 
the Caribbean, held in Santa Marta, Colombia, from 17 
to 21 October 2005, participants reported on the latest 
drug trafficking trends and distribution networks and 
links between drug trafficking and other forms of 
organized crime. The meeting recommended, inter alia, 
regular revision of the relevant legal instruments to 
counteract new trends in the use of technology by 
organized criminal groups and regulation of ownership 
of speedboats, a means of transportation frequently 
used by drug traffickers. 
369. Experts from countries in the Americas, the 
Caribbean and Europe participated in the Latin 
American conference on cocaine trafficking via 
maritime routes, held in Cartagena de Indias, 
Colombia, from 14 to 17 February 2006. The experts 
analysed maritime routes used for smuggling cocaine 
into the United States and Europe, the structures of the 
criminal organizations involved and interdiction 
operations in international waters. It was recommended 
that the capacity of law enforcement agencies be 
strengthened in particular through better utilization of 
investigative techniques such as controlled delivery. 
370. The Board notes that South American countries 
continued to adopt specific measures to strengthen the 
security of their borders. A pilot programme to identify 
cars and trucks in real time was developed at the land 
border crossing between Argentina, Brazil and 
Paraguay with a view to supporting the sharing of 
information among the law enforcement authorities of 
those countries. Argentina, Brazil, Colombia and 
Uruguay are among the countries that have been 
implementing the International Ship and Port Facility 
Security Code (ISPC Code) of the International 
Maritime Organization. 
371. South American countries continued to 
participate in regional projects, such as Drogas 
Sintéticas and Seis Fronteras, and in international 
projects initiated by the Board, such as Project 
Cohesion and Project Prism. Bolivia, Colombia, 
Ecuador, Peru and Venezuela (Bolivarian Republic of), 
the five countries participating in a project for the 
control of precursor products in Andean countries 
(PRECAN), which is financed by the European 
Commission, decided in October 2005 to establish a 
joint regional web portal for use by administrative 
control authorities. The portal is expected to be 
operational before the end of 2006. 
372. Colombia and Ecuador signed, in December 
2005, a joint declaration on the strengthening of border 
cooperation, which includes measures to counter 
trafficking in essential chemicals and arms. The 
Governments of the two countries also agreed on a 10-
kilometre buffer zone to protect the border of Ecuador 
from the effects of aerial spraying of illicit crops in 
Colombia; the agreement went into effect in January 
2006. 
373. The first international meeting of drug 
observatories of Europe, Latin America and the 
Caribbean was held in Caracas from 28 to 
30 November 2005. The Board is pleased to note that 
participants from more than 40 countries shared 
experiences in the field of drug demand reduction, 
information on recent trends in drug abuse and 
methodologies used for the processing and analysis of 
epidemiological data. The Board welcomes the first 
comparative study of drug abuse in secondary schools 
in South American countries, an initiative of the 
subregional system for drug abuse information and 
investigation, comprising Argentina, Bolivia, Chile, 
Ecuador, Peru and Uruguay, as well as CICAD and 
UNODC. The Board also welcomes a study on the 
human, social and economic costs of drugs in certain 
countries in the Americas, including Chile and 
Uruguay. 
 
  National legislation, policy and action 
 
374. New national drug strategy plans were adopted in 
Guyana in June 2005 and in Suriname in January 2006. 
E/INCB/2006/1  
 
54  
 
In Guyana, the national drug control master plan for 
the period 2005-2009 includes the implementation of 
school-based and occupation-based surveys to 
determine the prevalence of drug abuse in targeted 
areas. 
375. The Board notes that, in Ecuador, there is closer 
cooperation between the National Narcotic and 
Psychotropic Substances Control Board (CONSEP), 
the drug control directorate of the police and the 
customs authorities (see para. 405 below). 
376. In Bolivia, Ministerial Regulation 112/06 
(Reglamento de Circulación y Comercialización de la 
Hoja de Coca en su Estado Natural), adopted in June 
2006, allows coca producers to trade their coca on licit 
coca markets. Furthermore, two draft laws, one on coca 
in its natural state and the other on controlled 
substances, are being prepared to replace law No. 1008 
of 19 July 1988 on the Regimen de la Coca y 
Sustancias Controladas (regime applicable to coca and 
controlled substances). 
377. The Board notes that the Government of Bolivia 
intensified its interdiction efforts in 2006. The Board 
urges the Government to ensure that, in addition to 
strengthening its measures for countering drug 
trafficking, all provisions of the new drug control 
legislation, including those relating to the cultivation 
of coca bush and the use of coca leaf, are in line with 
the international drug control treaties. 
378. In October 2006, the Government of Peru decided 
on the decentralization of the national coca leaf 
enterprise. The Board urges the Government to ensure 
that that measure does not violate the provisions of the 
1961 Convention on establishing a government agency 
to control coca bush cultivation and coca leaf 
production and does not undermine efforts in Peru to 
combat illicit coca bush cultivation and drug 
trafficking. 
379. In Brazil, law No. 11.343 of 23 August 2006, 
which establishes the Sistema Nacional de Políticas 
Públicas sobre Drogas (national system of public 
policy on drugs), was promulgated in August 2006. 
The law also stipulates procedures related to the 
investigation of drug-related crimes and sanctions, as 
well as measures for the prevention of drug abuse. The 
law distinguishes between drug traffickers and drug 
users and establishes alternative sanctions for drug 
abuse without decriminalizing it. 
380. In Paraguay, decree No. 5213/05 was enacted, 
updating the list of controlled substances and providing 
for the control of prescriptions for narcotic drugs and 
psychotropic substances. 
381. In Ecuador, the Ley para reprimir el Lavado de 
Activos (law against money-laundering) was 
promulgated and a new Corte Suprema de Justicia 
(supreme court of justice) was established in October 
2005. The law defines money-laundering as a criminal 
activity, establishes a financial intelligence unit and 
includes provisions for mutual legal assistance and the 
exchange of information. 
382. In the Bolivarian Republic of Venezuela, law 
No. 38.281 (Ley Orgánica contra la Delincuencia 
Organizada) was enacted in September 2005, inter alia, 
establishing money-laundering as an offence. 
383. In several countries in South America, such as 
Argentina, Chile, Paraguay and Venezuela (Bolivarian 
Republic of), new laws on precursors and regulations 
establishing further control mechanisms, defining 
codes of conduct for precursor traders and providing 
for the exchange of information were adopted. 
384. In Peru, law No. 28305 (Ley de Control de 
Insumos Químicos y Productos Fiscalizados), which 
entered into force in October 2005, introduced controls 
over substances listed in the 1988 Convention over 
which there had previously been no control in the 
country. In addition, the Comité de Coordinación 
Interinstitucional was established by decree No. 053-
2005-PCM to coordinate and assess policies and action 
in the area of chemical control. 
385. In Colombia, the national drug regulatory 
authority initiated a survey on the access and 
availability of opioids in hospitals throughout the 
country. In addition, the results of a national study on 
the mental health of adults and adolescents and a 
national survey on drug use in schools have been 
completed in that country and are expected to be 
published in 2006. 
386. In accordance with the recommendations of the 
Multilateral Evaluation Mechanism of CICAD, 
countries in South America such as Guyana and 
Suriname have carried out activities aimed at the 
establishment of programmes for drug abuse 
prevention and the development of standards for 
programmes for the treatment of drug abuse. 
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387. In Guyana, where the programmes for the 
treatment of drug abuse that are currently available do 
not meet the national requirements, the minimum 
standards of care for the treatment and rehabilitation of 
drug abusers are currently being prepared and are 
expected to be ready for implementation in 2007. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
388. According to UNODC estimates, approximately 
18 per cent of global illicit cannabis herb production 
occurs in South America. Though illicit cultivation of 
cannabis to be sold on the local market continues to be 
detected in most of the countries in the region, 
cannabis grown in Paraguay, and to a lesser extent, 
Colombia is also being smuggled into other countries, 
both in South America and in other regions. Between 
2004 and 2005, the total volume of seizures of 
cannabis herb decreased in Argentina and Colombia, 
while in Bolivia it increased from 28.0 to 34.5 tons. 
389. Paraguay remains a major producer of cannabis 
in South America: the total area under cannabis 
cultivation in the country is estimated to be 
5,500-6,000 hectares. Owing to the weak economic 
situation, the high prices paid by traffickers for crops 
and the lack of effective drug control programmes, 
illicit cannabis production has spread to areas of the 
country previously not affected by such activity. In 
2004, the discovery of a new hybrid of cannabis that 
had been developed by traffickers and was capable of 
growing during the dry months of winter was reported 
in Paraguay. The Board is concerned that year-round 
cultivation of cannabis may contribute to an increase in 
potential cannabis production; for that reason, the 
Board urges the Government of Paraguay to implement 
programmes to eliminate illicit cannabis cultivation. 
390. In Brazil, cannabis is grown mostly in the north-
eastern part of the country. While there are still no 
accurate estimates of the total area under illicit 
cannabis cultivation and the potential cannabis 
production capacity, it is believed that most of the 
cannabis abused in Brazil originated in neighbouring 
countries. For example, according to the National Anti-
Drug Secretariat (SENAD) of Paraguay, approximately 
85 per cent of the cannabis produced in that country is 
smuggled into Brazil, 10-15 per cent is smuggled into 
other countries in the Southern Cone and only 2-3 per 
cent is for local consumption. 
391. In Peru, the illicit cultivation of cannabis, for 
local consumption, but also for illicit markets in Chile 
and Ecuador, increased in 2005. The Bolivarian 
Republic of Venezuela reported cannabis eradication 
operations at its border with Colombia. 
392. Though cannabis is regarded as the most widely 
abused drug in South America, data collected in the 
period 2001-2005 indicate significant differences in the 
annual prevalence of cannabis abuse by the population 
aged 15-64 in that region. For example, Chile, with a 
5.6 per cent prevalence rate, is regarded as the most 
affected country, and is the only country in the region 
reporting an annual level of cannabis abuse that is 
above the global average. Though cannabis is produced 
in Paraguay, that country has a prevalence rate of only 
0.5 per cent. In Argentina and Peru, an upward trend in 
the prevalence of abuse of cannabis herb was reported 
in the past year. According to a recent epidemiological 
study on drug abuse carried out by the Government of 
the Bolivarian Republic of Venezuela, cannabis is the 
drug most widely abused among persons aged 15-70 in 
that country. The study also indicated a major 
difference in lifetime prevalence of drug abuse (use of 
illicit drugs at least once in a person’s lifetime): the 
figure for males (3.9 per cent) was five times higher 
than the figure for females. 
393. In 2005, the majority of illicit coca bush 
cultivation continued to take place in the following 
countries, in descending order: Colombia, Peru and 
Bolivia. 
394. In Colombia, despite eradication efforts, the total 
area under illicit coca bush cultivation in 2005 
increased by 6,000 hectares to 86,000 hectares. That 
represents a decline of 47 per cent compared with the 
peak annual estimate of 163,300 hectares in 2000. 
Illicit coca bush cultivation in Colombia spread rapidly 
to areas where it had not been detected before. The 
most significant increase was noted in two areas 
bordering Ecuador and Venezuela (Bolivarian Republic 
of). A total of 170,070 hectares of coca bush were 
eradicated in Colombia in 2005, mainly through aerial 
spraying. The intensive eradication efforts in Colombia 
continued also in 2006. By mid-September 2006, 
150,600 hectares of illicitly cultivated coca bush had 
been eradicated in that country. 
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395. In Peru, the total area under illicit coca bush 
cultivation decreased by 4 per cent, to 48,200 hectares, 
between 2004 and 2005. The decline is attributable 
mainly to alternative development efforts in several 
valleys in which coca bush was grown and to manual 
eradication campaigns in other areas, most notably in 
parts of the Upper Huallaga valley (San Martín) and in 
San Gabán (Puno), where illicit coca bush cultivation 
dropped sharply, from 2,700 hectares in 2004 to 
292 hectares in 2005. The total area under illicit coca 
bush cultivation eradicated in Peru increased in 2005 
by 19 per cent, to 12,000 hectares. Between January 
and August 2006, an additional 8,000 hectares of coca 
bush were eradicated. 
396. In Bolivia, the total area under illicit coca bush 
cultivation dropped by 8 per cent, to 25,400 hectares, 
in 2005. The total area includes 12,000 hectares in the 
Yungas, where coca bush cultivation has been 
permitted under law No. 1008 for traditional uses, and 
an additional 3,200 hectares in the Chapare area, where 
such cultivation has been temporarily authorized by the 
Government. 
397. In the Bolivarian Republic of Venezuela, 
following the use of a satellite monitoring system for 
the detection of illicit crop cultivation, 80 hectares of 
coca bush were eradicated at the country’s north-
western border with Colombia during Operation Sierra, 
conducted in November 2005. 
398. In 2005, maceration pits and coca paste or coca 
base laboratories continued to be detected in all three 
illicit coca-producing countries in South America, 
whereas cocaine laboratories were found mainly in 
Colombia. The total amount of cocaine hydrochloride 
seized in Colombia (168 tons) was almost 50 times 
higher than the total amount seized in Bolivia and Peru 
together. 
399. According to the information available on 
disclosures of clandestine laboratories in South 
America, some illicit manufacture of cocaine continues 
to take place in non-traditional illicit cocaine 
manufacturing countries. For example, in Argentina, 
the number of clandestine laboratories manufacturing 
cocaine hydrochloride has increased since 2000. In 
2004, 16 cocaine laboratories and 4 coca paste or base 
laboratories were reported to have been dismantled. 
While the amount of cocaine illicitly manufactured in 
that country each year is still small, there are concerns 
that traffickers are moving their activities into that 
country. 
400. According to the European Police Office 
(Europol), every year almost 250 tons of cocaine enter 
the European Union, the second largest market for 
cocaine after the United States. Most of the cocaine is 
transported by sea from Argentina, Brazil, Colombia, 
Ecuador, Suriname and Venezuela (Bolivarian 
Republic of) to the main European seaports. Sizeable 
amounts of cocaine are also smuggled into Europe by 
air courier. 
401. Traffickers from South America and criminal 
groups from Central and Western Africa have been 
smuggling large shipments of cocaine by sea to Europe 
and the United States, as evidenced by the large 
quantities of cocaine seized in Lagos, Nigeria, in 2006 
(see para. 358 above). 
402. According to law enforcement agencies in South 
America, the organizations traditionally involved in 
drug trafficking are becoming more specialized, also 
offering their services to other criminal groups. 
Criminal organizations often exploit new technological 
developments in communication and transportation to 
prevent disclosure of their criminal activities. 
403. Criminal organizations also exploit certain 
vulnerable population groups. For example, in 
Ecuador, children have been used as street dealers. 
Increased drug trafficking in that country is also 
accompanied by waves of violent crime, including 
kidnapping and juvenile gang “warfare”. 
404. In Brazil, the total volume of cocaine seizures has 
doubled over the past year. The use of drug couriers for 
transporting drugs from Brazil to South Africa and 
from there to European countries and Australia has 
been identified. Since the introduction in 2005 of a 
new law permitting unidentified aircraft to be shot 
down in Brazil, drug trafficking using small aircraft in 
the Amazon area has decreased but there has been a 
substantial increase in drug seizures on boats and small 
ships in the river network. 
405. Drug traffickers from Colombia and Mexico 
continued to use Ecuador for stockpiling and 
redistributing cocaine destined for illicit markets in 
North America and Europe. In Ecuador, following the 
implementation of a programme by the Government to 
strengthen the control of containers at the port of 
Guayaquil, more than 40 tons of cocaine were seized in 
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2005, eight times more than in the previous year. The 
cocaine was found mainly in sea freight containers and 
on fishing vessels transferring their illicit 
consignments to mother vessels waiting in 
international waters. In the first quarter of 2006, an 
additional 11 tons of cocaine were seized during 
Operation Pacific Storm, which resulted in the 
dismantling of a major trafficking organization. 
Although no similar seizures have been reported since 
that operation, cocaine trafficking continued, using 
other routes and methods. 
406. Paraguay continues to be used to trans-ship 
cocaine consignments to other countries in South 
America and to Africa and Europe. Approximately 40-
60 tons of cocaine are smuggled each year through 
Paraguay by criminal organizations, most of which are 
controlled by nationals of Brazil. 
407. In the Bolivarian Republic of Venezuela, the total 
volume of cocaine seizures increased in 2005 by 87 per 
cent, to 58.4 tons; a further 23 tons of cocaine were 
seized in the first nine months of 2006. Most of the 
intercepted cocaine shipments were destined for Spain 
and the United Kingdom. 
408. According to UNODC data for the period 2004-
2005, the annual prevalence of cocaine abuse in South 
America in the population aged 15-64 was 0.7 per cent. 
In two countries in South America, Bolivia and Chile, 
the prevalence rate for cocaine abuse was higher than 
the regional average. In Peru, the prevalence of cocaine 
abuse increased over the past year. However, this was 
not the case for all forms of cocaine. In 2005, the 
declining prevalence of the abuse of cocaine base was 
offset by the increased abuse of cocaine hydrochloride. 
The abuse of “paco” (coca paste) has risen sharply in 
recent years in Argentina (see para. 420 below). 
409. According to the results of the sixth national 
study on the abuse of drugs among the general 
population in Chile, which was carried out in 2004, 
0.8 ton of cocaine base and 1.9 tons of cocaine are 
abused each year in the country. 
410. In Colombia, the total area under illicit opium 
poppy cultivation dropped by 49 per cent in 2005, to 
2,000 hectares, as a result of continued eradication 
efforts by the Government. During 2005, six heroin 
laboratories were destroyed and 745 kg of heroin were 
seized. A record 1.6 tons of raw opium were seized in 
Colombia in 2005, compared with 27 kg in 2003 and 
57 kg in 2004. Increasing amounts of heroin destined 
for North America and Europe continued to be trans-
shipped through Ecuador. On a smaller scale, 
trafficking in heroin originating in Colombia was also 
reported in Argentina. 
411. According to the Government of Peru, the total 
area under illicit opium poppy cultivation in the 
country in 2004 was estimated at 1,500 hectares. More 
than 92 hectares of opium poppy fields were eradicated 
in 2005, and a further 88 hectares were eradicated 
during the first eight months of 2006. 
412. In the Bolivarian Republic of Venezuela, illicit 
opium poppy cultivation areas larger than 100 hectares 
were identified during eradication operations in 2005. 
413. Heroin seizures have been reported in recent 
years in Argentina, Brazil, Chile, Colombia, Ecuador, 
Guyana, Peru, Uruguay and Venezuela (Bolivarian 
Republic of). The most significant increase in the 
volume of heroin seizures has been recorded in the 
Bolivarian Republic of Venezuela: in that country, 
heroin seizures rose steadily from 196 kg in 2000 to a 
record 658 kg in 2004. 
414. In South America, the prevalence rate for the 
abuse of opiates, in particular heroin (0.1 per cent of 
the population aged 15-64), is among the lowest in the 
world. In 2004, the latest year for which data are 
available, the abuse of opiates increased in Argentina 
(also in 2005), Colombia and Venezuela (Bolivarian 
Republic of). 
 
  Precursors 
 
415. Seizures of precursor chemicals, including 
potassium permanganate and acetic anhydride, were 
reported in South America. Furthermore, in 2005, 
16 laboratories manufacturing potassium permanganate 
were destroyed in Colombia and 2 such laboratories 
were dismantled in Bolivia. There has been increased 
use of substances not listed under the 1988 Convention 
as substitutes for precursor chemicals. Recycling 
chemicals that can be reused as many as five or six 
times is one of the methods used by traffickers to 
circumvent controls. The Board urges the Governments 
concerned to further foster, in cooperation with the 
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chemical industry, the existing controls, particularly at 
the domestic distribution level.40 
 
  Psychotropic substances 
 
416. Although the total amount of ATS seized in South 
America is not significant, drug abuse surveys indicate 
that the popularity of stimulants is increasing in some 
countries in the region, including Argentina and Peru. 
MDMA, mainly from the Netherlands, is the synthetic 
drug most commonly abused in Brazil. In the first half 
of 2006, more than 900 amphetamine tablets and 7,500 
“ecstasy” tablets were seized in the Bolivarian 
Republic of Venezuela. In 2005, “ecstasy” tablets were 
seized in Paraguay for the first time. 
417. Several countries in South America have reported 
a rising trend in the non-therapeutic use of sedatives 
and tranquillizers. In Argentina and Peru, the 
prevalence of the abuse of those substances is slightly 
higher among the female population than among the 
male population. In Brazil, the licit use of 
amfepramone and fenproporex, stimulants listed in 
Schedule IV of the 1971 Convention, is increasing. 
Zopiclone and ketamine, two substances not under 
international control, were found to have been diverted 
into illicit channels and abused in Argentina. 
418. Pharmaceutical preparations containing narcotic 
drugs and psychotropic substances are often smuggled 
into countries in South America, such as Ecuador, and 
sold over the counter in non-licensed outlets. 
 
  Missions 
 
419. The Board sent a mission to Argentina in May 
2006. The Board appreciates the commitment of the 
Government to combating illicit activities related to 
drugs. The Board found that existing laws and 
regulations on drug control are not always in line with 
the international drug control treaties and noted that 
changes in the legislative basis for drug control and 
related areas had been planned or already introduced. 
The Board urges the Government to implement 
measures to comply with the provisions of the 1961 
Convention concerning the use of coca leaf and to 
harmonize laws and jurisdiction between provinces 
__________________ 
 40  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2006 …, chap. III. 
with a view to sending a clear message to the public on 
the dangers of drug abuse. The Board notes that, in 
addition to drug trafficking, the illicit manufacture of 
cocaine from coca paste that has been smuggled into 
the country has been increasing in recent years. The 
Board is aware of the measures already taken to 
suppress those activities and encourages the 
Government to ensure concerted action at the federal 
and provincial levels involving the relevant 
government agencies, including the customs 
authorities. In that connection, the gathering and 
analysis of intelligence on drug-related crime should 
be improved, in order to assist in the investigation and 
prosecution of illicit activities related to drugs; to that 
end, additional resources should be provided. 
420. The mission of the Board found that the controls 
applied to the licit movement of narcotic drugs, 
psychotropic substances and precursors in Argentina 
appeared to be comprehensive. The Board welcomes 
the plan to establish a prescription monitoring 
programme to identify unusual consumption patterns 
and encourages the Government to continue to promote 
the rational prescription of narcotic drugs and 
psychotropic substances. In view of the continued 
diversion of precursor chemicals in Argentina, the 
Board requests the Government to remain vigilant and 
investigate all cases of diversion and attempted 
diversion, with a view to identifying new trends and 
detecting and arresting the traffickers involved. With 
respect to demand reduction, the Board notes with 
satisfaction the recent efforts to ascertain the extent 
and patterns of drug abuse in the country. Since it has 
been found that drug abuse, in particular the abuse of 
“paco” (coca paste), has been rising sharply in 
Argentina, the Board advises the Government to 
continue its efforts to improve the prevention of drug 
abuse and the treatment and rehabilitation of drug 
abusers. 
 
 
 C. Asia 
 
 
  East and South-East Asia 
 
 
  Major developments 
 
421. Since 2004, there has been an increase in seizures 
of cocaine in the Hong Kong SAR of China. 
  59 
 
 E/INCB/2006/1
422. Traffickers are attempting to arrange the illicit 
sale of drugs using the Internet and cellular phones. 
Recently, attempts to smuggle illicit drugs into Japan 
through the postal system have increased. 
423. In several countries in East and South-East Asia, 
including China and Japan, persons who until recently 
had abused a single type of drug have shifted to 
polydrug abuse. 
424. There is growing concern in the region regarding 
the illicit manufacture of, trafficking in and abuse of 
substances not under international control. 
425. Although the HIV epidemic remains concentrated 
among high-risk groups in East and South-East Asia, 
HIV infection continues to be a major problem in 
countries in the region where heroin is the drug of 
choice among persons who abuse drugs by injection. In 
Japan, the prevalence of HIV infection attributed to 
drug abuse by injection continues to be low. 
 
  Regional cooperation 
 
426. A memorandum of understanding was signed by 
the Secretary-General of the Association of Southeast 
Asian Nations (ASEAN) and the Secretary-General of 
the Economic Cooperation Organization in January 
2006. The areas of cooperation related to drug control 
include: the exchange of information on national 
legislation and activities to suppress illicit drug 
trafficking; the promotion of law enforcement 
cooperation; the promotion of increased public 
awareness of the dangers of drug abuse, the 
development of community-based drug abuse 
prevention and treatment programmes and the 
development of programmes for the reduction of illicit 
drug demand. 
427. The Beijing Congress Declaration, the updated 
ASEAN and China Cooperative Operations in 
Response to Dangerous Drugs (ACCORD) Plan of 
Action, 2005-2010, and the Special Initiative on 
Regional Joint Action against ATS-related Crimes were 
adopted at the Second International Congress of 
ASEAN and China Cooperative Operations in 
Response to Dangerous Drugs, held in Beijing in 
October 2005. Those initiatives are aimed at 
identifying further strategies and measures to be used 
for drug control cooperation in South-East Asia. 
428. The second Training Course on Precursor and 
Chemical Control for ASEAN Narcotics Law 
Enforcement Officers was held in Bangkok from 16 to 
22 May 2005. Law enforcement officers from ASEAN 
member States, as well as China and India, attended 
the course. The objective of the course was to provide 
an overview of the illicit traffic in precursor chemicals 
in countries in South-East Asia, China and India, as 
well as training in the use of investigative techniques. 
The Office of the Narcotics Control Board of Thailand 
and the Thailand International Development 
Cooperation Agency organized a training course on 
international drug law enforcement in Bangkok in 
August 2005. In 2005, China continued to provide law 
enforcement training for officers from the Lao People’s 
Democratic Republic and Myanmar. In addition, 
through its alternative development assistance, China 
provided training for 135 agricultural and medical 
workers and facilitated the cultivation of over 
330 hectares of food crops in northern Myanmar. 
429. In July 2005, cooperation between law 
enforcement officials from China and Myanmar led to 
the seizure of 100 kg of methamphetamine. In 
September 2005, China, the Lao People’s Democratic 
Republic, Myanmar and Thailand cooperated in an 
investigation that resulted in the arrest of two major 
drug dealers in the Lao People’s Democratic Republic 
and in the seizure of 496 kg of heroin in Shan State, 
the largest seizure ever made in Myanmar. 
430. UNODC regional activities involving laboratory 
assistance to strengthen regulatory and law 
enforcement control with respect to ATS and their 
precursors in East and South-East Asia became 
operational in early 2006. The aims of such assistance 
are to improve the integration of scientific support into 
national and regional drug control systems. Two 
regional meetings were held on the subject in Bangkok 
in May and September 2006. The meetings were 
attended by UNODC laboratory personnel, as well as 
law enforcement, health and regulatory authorities 
from Cambodia, China, India, Indonesia, the Lao 
People’s Democratic Republic, Malaysia, Myanmar, 
Philippines, Singapore, Thailand and Viet Nam. 
 
  National legislation, policy and action  
 
431. In Viet Nam, the master plan for drug control for 
the period 2005-2010 is currently being implemented. 
It is aimed at increasing public awareness of the 
harmfulness of drug abuse, preventing illicit crop 
cultivation and illicit drug manufacture and trafficking, 
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strengthening programmes for the treatment of drug 
abuse and reducing drug abuse by injection. The plan 
includes measures to eliminate the illicit cultivation of 
opium poppy and to prevent the use of precursor 
chemicals in the illicit manufacture of drugs. 
432. The National Narcotics Board of Indonesia 
launched its national strategy to combat drug abuse and 
illicit drug trafficking for the period 2005-2009. The 
strategy includes activities aimed at building the 
capacity of law enforcement agencies and 
strengthening programmes for the prevention of drug 
abuse and the treatment and rehabilitation of drug 
abusers. 
433. In line with the recommendations of the Board 
following its mission to Thailand in May 2004, the 
Board wishes to reiterate its recommendation to the 
Government of Thailand to undertake sustainable 
measures to address the problem of drug abuse, as well 
as to provide treatment and rehabilitation for drug 
abusers in Thailand. 
434. In China, a drug control bill was submitted to the 
national legislature for consideration in August 2006. 
The bill was drawn up to curb drug-related crime and 
the growing population of drug abusers in the country. 
The Ministry of Public Security of China has actively 
supported the bill. 
435. Several States in East and South-East Asia have 
taken action to deal with specific drug-related issues. 
For example, in June 2006, the National Assembly of 
Viet Nam adopted a comprehensive law on HIV/AIDS 
prevention and control that will enter into force in 
January 2007. The law includes provisions for harm 
reduction. The National Committee for AIDS, Drugs 
and Prostitution Prevention and Control held a meeting 
in Hanoi in March 2006 to review the national 
programme for the period 2001-2005. The Government 
of the Lao People’s Democratic Republic launched in 
2005 a national strategy calling for a balanced 
approach to eliminating opium in the country during 
the period 2006-2009. The main components of the 
strategy are alternative development, demand 
reduction, law enforcement and civic awareness. In 
August 2006, the Government of the Lao People’s 
Democratic Republic introduced a draft action plan 
targeting 1,000 former opium poppy cultivating 
villages that are most at risk of reverting to opium 
poppy cultivation. The Ministry of Education, Youth 
and Sport of Cambodia has incorporated drug 
awareness issues into the national curriculum for 
primary and secondary schools. 
436. In order to prevent the illicit manufacture of 
ketamine (currently not under international control), 
the Dangerous Drugs Board of the Philippines 
classified ketamine as a dangerous drug in October 
2005. 
437. A number of States in East and South-East Asia 
are taking steps to prevent money-laundering. In 
Viet Nam, decree No. 74/2005/ND-CP of 7 June 2005, 
aimed at preventing and combating money-laundering, 
entered into effect on 1 August 2005. Steps are being 
taken to establish a money-laundering information 
centre in the State Bank of Viet Nam, with a view to 
raising awareness within the financial sector and 
training police and other law enforcement officers. The 
Cabinet of the Government of Cambodia endorsed in 
July 2006 draft legislation to combat money-
laundering and the financing of terrorism; the draft 
legislation includes provisions on establishing a 
financial intelligence unit and, if adopted, would 
introduce measures to detect and prevent money-
laundering and the financing of terrorism. The 
Government of the Lao People’s Democratic Republic 
has trained banking officials as part of its efforts to 
tackle the problems of money-laundering and the 
financing of terrorism. 
438. The Financial Action Task Force on Money 
Laundering has welcomed the progress made by the 
Government of Myanmar in reforming its programme 
for countering money-laundering and has urged the 
Government to continue its efforts in that direction. 
Myanmar is the only country that remains on the list of 
countries and territories considered by the Financial 
Action Task Force to be “non-cooperative” in efforts to 
counter money-laundering. 
 
  Situation with regard to drug trafficking and 
abuse 
 
  Narcotic drugs 
 
439. The illicit cultivation of cannabis plants 
continued throughout the region, particularly in South-
East Asia. Cannabis plants are illicitly cultivated 
throughout the Philippines. The illicit cultivation of 
cannabis plants also continued in Thailand, particularly 
in the northern and north-eastern parts of the country. 
Illicit cannabis production in the Lao People’s 
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Democratic Republic takes place mainly in the 
lowlands, in the south and in areas near the Mekong. 
Cannabis plants are illicitly cultivated in the central 
and southern parts of Myanmar. There is limited illicit 
cultivation of cannabis plants in Cambodia in some 
provinces along its borders and the Mekong. Cannabis 
plants are also illicitly cultivated in some areas in 
Indonesia. 
440. Countries in East and South-East Asia continued 
their campaigns to eradicate cannabis plants. In 2005, 
12 tons of cannabis were seized in Thailand and the 
Government of the Philippines destroyed millions of 
cannabis plants. China, Indonesia, Japan and Myanmar 
also seized significant amounts of cannabis. Viet Nam 
reported a major increase in the volume of cannabis 
seizures. Most of the cannabis seized in the 
Hong Kong SAR of China originated in the Golden 
Triangle, Cambodia or countries in South Asia. 
441. Illicit opium poppy cultivation continued to 
decrease in almost all countries in East and South-East 
Asia. Most of the illicit cultivation of opium poppy in 
the region occurs in Myanmar; however, each year the 
Government of that country succeeds in reducing the 
level of such cultivation. Although illicit opium poppy 
cultivation in the southern and eastern parts of Shan 
State has increased, the total area under such 
cultivation declined to 21,500 hectares in 2006. In the 
Lao People’s Democratic Republic, all provinces and 
the special zone where opium poppy used to grow were 
declared by the Government in February 2006 to be 
opium-free; however, limited illicit opium poppy 
cultivation reportedly continues in several northern 
provinces of that country. In Viet Nam, the total area 
under illicit opium poppy cultivation was negligible. 
442. Seizures of opium continued to be reported in 
countries in East and South-East Asia. In 2005, 
Chinese law enforcement officers seized a total of 
2.3 tons of opium. Law enforcement officials in 
Viet Nam also reported seizures of opium. In addition, 
124 kg of morphine were seized in Yunnan Province of 
China in 2005. 
443. Since 2004, there has been an increase in seizures 
of cocaine in the Hong Kong SAR of China. In 
March 2006, law enforcement officers from China 
(including the Hong Kong SAR) and the United States 
cooperated with each other to uncover a cocaine 
trafficking syndicate based in Colombia. As a result of 
that cooperation, 142 kg of cocaine were seized and 
nine people were arrested. In 2005, small amounts of 
cocaine were seized in Cambodia and Thailand. 
Cocaine is smuggled into Thailand from South 
America, usually entering the country via Bangkok 
International Airport. Some of the cocaine has also 
been smuggled into Thailand via South Africa and 
Europe. Seizures of cocaine decreased dramatically in 
Japan, where 2.9 kg of cocaine were seized in 2005, 
compared with 85.4 kg in 2004. 
444. Heroin is illicitly manufactured in Myanmar. 
Illicit heroin manufacture in the Lao People’s 
Democratic Republic remains limited. Most of the 
heroin seized in the Lao People’s Democratic Republic 
has been smuggled through Myanmar. In 2005, China, 
Thailand and Viet Nam reported a large volume of 
heroin seizures. Heroin continues to be smuggled into 
Thailand over its northern, north-eastern and eastern 
borders. A total of 924 kg of heroin were seized in 
Thailand in 2005, the highest reported volume of 
heroin seizures in that country since 1998. Traffickers 
also continued to use Thailand as a transit point for 
heroin consignments. Most of the heroin seized in 
China was smuggled into that country from the Golden 
Triangle. The total volume of heroin smuggled into 
China from the Golden Triangle decreased in 2005 
compared with the previous year. Law enforcement 
officers in China continued to focus on strengthening 
drug control activities at the south-western border of 
that country. As a result, 66.8 kg of heroin were seized 
at the border between China and Viet Nam. In China, 
law enforcement officers from the autonomous region 
Xinjiang identified nine cases involving the smuggling 
of drugs from the Golden Crescent by air and seized a 
total of 14.5 kg of heroin. Small amounts of heroin 
were also seized in Cambodia, Indonesia and Japan in 
2005. Most of the heroin seized in the Hong Kong SAR 
of China originates in the Golden Triangle; the heroin 
is smuggled into Yunnan Province and is transported 
overland through the autonomous region Guangxi and 
Guangdong Province into the Hong Kong SAR. 
445. Cannabis continues to be abused in countries in 
East and South-East Asia, including Brunei 
Darussalam, China, Indonesia, Japan, Malaysia, 
Myanmar, the Philippines and the Republic of Korea. 
Heroin remains the drug of choice among drug abusers 
in most countries or areas in the region, such as China 
(including the Hong Kong SAR and the Macao SAR of 
China), Indonesia, Malaysia, Myanmar and Viet Nam. 
In Malaysia, morphine continues to be the drug abused 
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by almost one third of persons undergoing treatment 
for drug abuse. 
446. In 2004, there was an increase in HIV infection 
among persons who abuse drugs by injection in the 
Macao SAR of China; largely as a result of swift 
Government action to stem the spread of HIV 
infection, in 2005 there was a decrease in both the 
number and the proportion of persons who abused 
drugs by injection among newly reported HIV cases in 
the Macao SAR. In Viet Nam, the HIV epidemic 
remains concentrated among high-risk groups, and 
drug injection continues to be the main cause of HIV 
transmission: 53 per cent of newly detected cases of 
HIV infection were attributed to drug abuse by 
injection. In China, over 40 per cent of the 
135,630 registered HIV/AIDS patients contracted the 
disease through drug abuse by injection. In Myanmar, 
HIV prevalence among persons who abuse drugs by 
injection is estimated at 34 per cent. In Indonesia, 
Malaysia and Thailand, the prevalence of HIV among 
persons who abuse drugs by injection remains high. In 
Japan, HIV infection attributable to drug abuse by 
injection continues to be low (0.5 per cent). 
 
  Psychotropic substances 
 
447. Large-scale clandestine laboratories involved in 
the illicit manufacture of methamphetamine continued 
to be uncovered in East and South-East Asia. In 2005, 
seven clandestine laboratories involved in the illicit 
manufacture of methamphetamine were dismantled and 
11 kg of methamphetamine, precursor chemicals and 
equipment were seized in the Philippines. In China, 
police uncovered a large-scale drug smuggling, 
trafficking and manufacturing operation in Guangdong 
Province in May 2005; as a result, a clandestine 
laboratory manufacturing methamphetamine and 
another manufacturing 1-phenyl-2-propanone were 
dismantled and 46.7 kg of methamphetamine, 
1-phenyl-2-propanone and other precursor chemicals 
were seized. In June 2005, Chinese law enforcement 
officers uncovered a transnational operation involved 
in the illicit manufacture of and trafficking in 
methamphetamine; as a result, 42.5 kg of 
methamphetamine and tons of precursor chemicals, 
including ephedrine and acetic anhydride, were seized. 
In Thailand, two clandestine laboratories 
manufacturing methamphetamine were dismantled in 
2005. 
448. In 2005, large amounts of ATS continued to be 
seized in Cambodia, the Lao People’s Democratic 
Republic and Viet Nam. Many of the ATS tablets 
recently seized in the Hong Kong SAR of China 
originated not in Europe (which is often the case) but 
in Asia. Many countries in East and South-East Asia 
have reported a significant increase in the volume of 
methamphetamine seizures. In 2005, China, Indonesia, 
Malaysia and Thailand each reported an increase in 
seizures of methamphetamine tablets. In January 2006, 
the Anti-Narcotics Task Force of Myanmar arrested 
eight suspects and seized a large amount of 
methamphetamine tablets (worth an estimated 
US$ 10 million) in Tachilek, a town on the border of 
Myanmar with Thailand, near the Mekong. In 2005, 
there was increased smuggling of methamphetamine 
from the Lao People’s Democratic Republic into 
Cambodia. In 2005, Cambodian border patrol officers 
uncovered 128 cases of trafficking in 
methamphetamine and arrested 284 people and seized a 
significant amount of methamphetamine in connection 
with those cases. Attempts to smuggle 
methamphetamine into Thailand over its north-eastern 
and eastern borders continued to be detected. 
Methamphetamine is smuggled into the Philippines 
mainly through the shorelines of the Northern Luzon, 
Central Luzon and Southern Tagalog regions. A few 
countries in the region, including Japan and the 
Philippines, reported a considerable decrease in the 
volume of methamphetamine seized in 2005. 
449. The amount of methamphetamine smuggled into 
China increased in 2005 compared with the figure for 
2004. In 2005, law enforcement officials in Yunnan 
Province of China seized 2.62 tons of 
methamphetamine, accounting for almost 50 per cent 
of the total volume of such seizures in China. 
Methamphetamine from mainland China continues to 
be smuggled into the Hong Kong SAR of China. At the 
end of 2005, 192 kg of methamphetamine were found 
in a container in the Hong Kong SAR. Attempts to 
smuggle the drug were also detected in the northern 
border areas of Thailand. 
450. In January 2006, a clandestine laboratory that had 
been tabletting MDMA was dismantled in Kowloon, in 
the Hong Kong SAR of China; as a result of that 
operation, 60 kg of MDMA powder, a tabletting 
machine and a number of MDMA tablets were seized. 
Analysis of the ingredients of ATS seized in the Hong 
Kong SAR of China suggest that clandestine 
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laboratories may be moving away from the illicit 
manufacture of MDMA (“ecstasy”), in the direction of 
a mixture that includes methamphetamine. According 
to a recent analysis conducted in the Hong Kong SAR 
of China, 37 per cent of seized ATS tablets contained 
only MDMA, while 63 per cent contained a 
combination of MDMA and other ingredients such as 
amphetamine, caffeine, estazolam and diazepam. 
451. MDMA continued to be smuggled into Thailand 
across its border with Malaysia. In Myanmar, the total 
number of MDMA tablets seized increased from 5 in 
2004 to 3,981 in 2005. In 2004, an attempt to smuggle 
MDMA from China and the Russian Federation into 
Japan were detected for the first time. In 2005, Japan 
reported the largest volume of MDMA seizures since 
2001. However, several countries in East and South-
East Asia, including China, Indonesia, Malaysia and 
Thailand, reported a decrease in MDMA seizures in 
2005. 
452. In the Philippines, there was a significant 
increase in the amount of diazepam seized in 2005 
compared with previous years. 
453. In 2005, prescription drugs containing controlled 
psychotropic substances were smuggled from Thailand 
into Europe and the United States through air parcel 
services. Traffickers are attempting to arrange for the 
illicit sale of drugs using the Internet and cellular 
phones. Recently, attempts to smuggle illicit drugs into 
Japan using the postal system have increased. 
454. Precursor chemicals, including acetic anhydride, 
continued to be smuggled into the Golden Triangle. In 
2005, 158 tons of precursor chemicals were seized and 
34 clandestine laboratories were dismantled in China; 
all of the precursor chemicals found in the laboratories 
had been produced locally. Seizures of ephedrine in 
Myanmar increased significantly, to 1,283 kg, in 2006. 
After several years of increased seizures of ephedrine 
in the Philippines, there was a decline in such seizures 
in 2005. 
455. The abuse of ATS has emerged as a serious and 
fast-growing problem in the Lao People’s Democratic 
Republic. Methamphetamine is the drug of choice 
among drug abusers in Japan, accounting for 83.5 per 
cent of the arrests for drug-related offences. It also 
remains the drug of choice among drug abusers in the 
Philippines, the Republic of Korea and Thailand. Of 
the drug abusers undergoing treatment in the 
Philippines, 81 per cent reported having abused 
methamphetamine; some also reported having abused 
preparations for treating coughs and colds. 
Methamphetamine is also widely abused in Brunei 
Darussalam, Indonesia, Myanmar and Singapore. 
Methamphetamine is rapidly gaining in popularity in 
Malaysia: more than twice as many people abused 
methamphetamine in that country in 2005 (15 per cent) 
than in 2004 (7 per cent). Drug abusers in China are 
also increasingly abusing methamphetamine. In Japan, 
MDMA continues to be abused throughout the country. 
Drug abusers in China are increasingly abusing 
MDMA and triazolam. MDMA is the second most 
abused drug after ketamine among persons aged 11 to 
20 in the Hong Kong SAR of China. An increase in the 
abuse of GHB, LSD and nimetazepam (Erimin 5) has 
been noted in the Hong Kong SAR of China. 
456. Most methamphetamine abusers in Japan abuse 
the substance by injection. While no national figures 
are available, data suggest that there has been an 
increase in drug abuse by injection in Cambodia, 
especially in urban areas of the country. In Indonesia, 
56 per cent of drug abusers abuse drugs by injection. 
Limited abuse of ATS by injection has been reported in 
Cambodia, China, the Hong Kong SAR of China, 
Indonesia, the Lao People’s Democratic Republic and 
Thailand. 
 
  Substances not under international control 
 
457. The illicit manufacture of and trafficking in 
ketamine continued to be matters of concern in East 
and South-East Asia. In 2005, Chinese law 
enforcement officers seized 2.6 tons of ketamine. In 
the past, ketamine from mainland China was often 
smuggled into the Hong Kong SAR; however, in 2005, 
law enforcement authorities uncovered cases in which 
traffickers attempted to smuggle into the Hong Kong 
SAR of China through South-East Asia large 
consignments of ketamine originating in South Asia. In 
2005, there was a significant increase in seizures of 
ketamine in the Hong Kong SAR of China. A small 
quantity of ketamine was also seized in Thailand. 
Ketamine from Europe was smuggled through 
neighbouring countries into Thailand. Data suggest that 
the illicit manufacture of ketamine for export is taking 
place in the Philippines. During the period 2003-2005, 
five clandestine laboratories involved in the illicit 
manufacture or processing of ketamine were 
dismantled and ketamine hydrochloride and ketamine 
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powder were seized in the Philippines. Law 
enforcement officials in Viet Nam reported seizures 
and abuse of ketamine in the country in 2005. 
458. The abuse of substances not under international 
control is a matter of concern in China, the Hong Kong 
SAR of China, Japan and the Republic of Korea. In 
2005, Japan placed under national control as 
narcotic drugs 5-methoxy-N,N-diisopropyltryptamine, 
alpha-methyl-tryptamine, 2,5-dimethoxy-4-(n) propyl-
thiophenethylamine and N-methyl-1-(3,4-methylene-
dioxyphenyl)-2-butanamine. The main drug of abuse 
among persons aged 11-20 in the Hong Kong SAR of 
China is ketamine. Drug abusers in China are 
increasingly abusing ketamine. The abuse of ketamine 
has also been reported in the Macao SAR of China, 
Malaysia, the Philippines and Singapore. The abuse of 
dextromethorphan, fenfluramine and nalbuphine has 
been reported in the Republic of Korea. There have 
been reports of nalbuphine hydrochloride (sold under 
the brand name Nubain®) being abused by injection in 
the Philippines. 
 
  Missions 
 
459. The Board sent a mission to China in January 
2006. The Board commends the Government of China 
for its political will and commitment towards the 
implementation of the international drug control 
treaties, as evidenced by the adoption of new national 
legislation on the control of narcotic drugs, 
psychotropic substances and precursors in August 
2005. 
460. The Board notes that in China drug control is not 
only incorporated into the programme for national 
economic and social development, but is also made an 
important duty of governments at all levels. The Board 
welcomes the launch of the “People’s War on Drugs”, 
aimed at mobilizing the entire society to address its 
growing drug problem. The Board encourages the 
Government to take the measures necessary to ensure 
that progress is made in implementing the new laws, as 
well as in combating drug abuse and illicit trafficking 
in the country.  
461. China, which is a major producer of precursor 
chemicals, is facing a growing challenge in preventing 
the diversion of such chemicals from licit sources into 
illicit channels, particularly in view of the growing 
abuse problem of methamphetamine globally and in the 
region. The Board, while acknowledging the 
Government’s cooperation in providing pre-export 
notifications for exports of ephedrine and pseudo-
ephedrine, requests the Government to do the same for 
exports of pharmaceutical preparations containing 
those two substances and to put in place mechanisms 
for monitoring domestic distribution of the substances 
to ensure that no diversion takes place. 
462. The Board notes the increasing role played by 
China in drug control in East and South-East Asia. 
China has made achievements in various areas of drug 
control through bilateral and multilateral cooperation. 
However, the situation with regard to the illicit 
manufacture of ATS in the region remains serious. The 
Board encourages the Government of China to further 
strengthen its cooperation, particularly with 
neighbouring countries, and play a more active role in 
combating this problem. 
463. The Board sent a mission to the Democratic 
People’s Republic of Korea in June 2006. The Board 
notes that the Government remains fully committed to 
strengthening its cooperation with the Board in drug 
control, as evidenced by the progress made in the 
implementation of the Board’s recommendations 
pursuant to its last mission to that country in 2002. 
464. The adoption of new national drug control 
legislation and the establishment of the national 
coordinating committee for drug control are two 
important steps taken by the Government of the 
Democratic People’s Republic of Korea towards full 
compliance with the provisions of the international 
drug control treaties. The Board welcomes those 
developments and encourages the Government to take 
measures to ensure that further progress is made in 
drug control.  
465. The Board notes that there is adequate control 
over the licit movement of narcotic drugs and 
psychotropic substances in the Democratic People’s 
Republic of Korea. However, the Board is concerned 
that there is an insufficient amount of opiates for 
medical purposes. The Board acknowledges the 
difficulties that the Government has encountered in the 
implementation of the international drug control 
treaties and calls upon it to seek legal and technical 
assistance, particularly in developing regulations 
required for the implementation of the new national 
drug control legislation.  
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466. The Board notes that continuous efforts are being 
made by the Democratic People’s Republic of Korea 
towards acceding to the international drug control 
treaties. The Board trusts that the Government will take 
concrete steps to expedite the process of accession, 
thereby effectively integrating itself into regional and 
international efforts to fight drug abuse and illicit 
trafficking. The Board encourages the Democratic 
People’s Republic of Korea to cooperate with its 
neighbouring countries to combat the problem of ATS 
trafficking in East and South-East Asia. 
467. The Board sent a mission to Myanmar in October 
2006 to review the implementation of the international 
drug control treaties and maintain its ongoing dialogue 
with the Government on issues related to drug control. 
The Board notes the continued commitment of the 
Government to eradication of illicit opium poppy 
cultivation. The Board encourages the Government to 
continue its efforts to achieve the goal of complete 
eradication of illicit drug production, as set out in the 
15-year national plan. 
468. The Board also recommends to the Government 
of Myanmar to continue to cooperate with the 
Governments of neighbouring countries in 
strengthening law enforcement activities and, in 
particular, to make additional efforts to identify the 
sources and trafficking routes of precursor chemicals 
used for the illicit manufacture of ATS. 
469. With regard to the availability of narcotic drugs 
for treatment of pain in Myanmar, while recognizing 
that some traditional methods of pain management are 
used in the existing sociocultural situation, the Board 
recommends that the authorities should nevertheless 
examine the adequacy of the provisions of the current 
drug control law to ensure that the existing laws and 
regulations do not constitute obstacles to the adequate 
availability of controlled drugs for medical purposes. 
 
 
  South Asia  
 
 
  Major developments 
 
470. Trafficking in and abuse of opiates, in particular 
heroin, are serious problems in South Asia, which is 
geographically sandwiched between West and South-
East Asia, the two major producers of illicit opiates. 
Despite the strict controls imposed by Governments of 
countries in South Asia, an unknown quantity of 
opiates is diverted from licit opium poppy cultivation 
in India, to be either abused domestically or smuggled 
into other countries. 
471. In South Asia the abuse of heroin, as well as 
other drugs such as buprenorphine, often takes place 
through injection, and unsafe practices surrounding 
abuse by injection remain one of the key factors in the 
spread of HIV/AIDS in the region. Though that is 
particularly true in India and Nepal, Bangladesh also 
has the potential for an HIV/AIDS epidemic outside of 
the subpopulation of those who abuse drugs by 
injection, and for that reason Governments of countries 
in the region need to remain vigilant. 
472. Available information suggests an emerging trend 
of increasing abuse of and trafficking in cocaine in 
South Asia. In India in particular, there have been 
increasing seizures of cocaine, as well as evidence that 
the abuse of that drug is on the rise.  
473. In many countries in South Asia, in particular 
Bangladesh, India and Nepal, there continue to be 
long-standing problems with the licit control of 
pharmaceutical preparations containing controlled 
substances. That has led to widespread abuse of such 
preparations among all segments of the population. In 
general, pharmaceutical preparations are diverted from 
domestic distribution routes and are sold without 
prescription in pharmacies and various other retail 
outlets in the region.  
474. The Agreement on South Asian Free Trade Area41 
entered into force on 1 January 2006, creating a 
framework for the establishment of a free trade zone 
for the seven member States of the South Asian 
Association for Regional Cooperation (SAARC). The 
agreement stipulates measures to be taken by States to 
reduce import duties, depending on their stage of 
development. The Board urges the member States of 
SAARC to ensure that the implementation of the 
agreement does not hamper measures to combat drug 
trafficking within the region.  
 
  International cooperation  
 
475. The ministers of the interior of the member States 
of SAARC held a meeting in Dhaka on 11 May 2006 to 
review measures taken by SAARC member States 
against drug trafficking and terrorism. The ministers 
__________________ 
 41  A/58/716-S/2004/122, annex III. 
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recognized the rapid spread of drugs in the region, and 
decided to strengthen the resources of the SAARC 
secretariat in drug control. The ministers also decided 
to increase cooperation with other organizations, such 
as ASEAN and UNODC, and to share information on 
drug control efforts. 
476. The Fifth SAARC Conference on Cooperation in 
Police Matters was held in Dhaka on 9 May 2006. The 
police chiefs of SAARC member States who attended 
the conference agreed to work towards the 
establishment of a police forum, to be called 
SAARCPOL, that would enhance regional cooperation 
in the area of law enforcement, as well as to form a 
regional association of police chiefs. 
477. The countries of South Asia continued to conduct 
activities against drug abuse and trafficking under the 
umbrella of the Drug Advisory Programme of the 
Colombo Plan. The Drug Advisory Programme 
organized the International Conference of Faith-Based 
Organizations/Islamic Scholars on Drug Policies and 
Strategies in Jakarta from 27 February to 1 March 
2006. Participants at the conference reaffirmed their 
commitment to overcoming the drug problem by 
strengthening the role of religious leaders in reducing 
demand for drugs. It was also agreed that religious 
principles could be incorporated into demand reduction 
approaches in Islamic countries in the region. 
478. The Fifth Asian Youth Congress, held in Chiang 
Mai, Thailand, from 24 to 27 October 2006, discussed 
how participants could be empowered to prevent drug 
abuse in their communities. Asian Cities against Drugs, 
a network of cities from over a dozen countries 
modelled after European Cities against Drugs, has been 
established, bringing together mayors, city councillors 
and officials working in the field of drug control to 
exchange information and enhance skills in both 
supply and demand reduction. Both of those activities 
were established under the Drug Advisory Programme.  
 
  National legislation, policy and action 
 
479. Bhutan, with the assistance of UNODC, is 
currently building its capacity to implement the 
international drug control regime. Bhutan, which 
acceded to the 1961 Convention and the 
1971 Convention in August 2005 and thus became a 
party to the three international drug control treaties, is 
currently finalizing detailed regulations to implement 
new drug control legislation.  
480. All but one of the States in South Asia are now 
parties to the international drug control treaties. The 
one exception is Nepal, which has yet to accede to the 
1971 Convention. The Board reiterates its call to the 
Government of Nepal to accede to and implement the 
1971 Convention at the earliest opportunity.  
481. Maldives finalized its drug control master plan 
for the period 2006-2010. The Board welcomes the 
plan, which was prepared with the assistance of 
UNODC, and urges the Government to ensure its 
speedy and effective implementation, so as to address 
the growing drug control problem in the country. The 
Board also urges the international community to 
provide assistance to Maldives in this respect. 
482. The Board notes with concern that the monitoring 
of drug abuse patterns and trends in many countries in 
South Asia remains inadequate and, as a result, 
concrete data on drug abuse in those countries are 
scarce. The Board notes that a new national survey on 
drug abuse in India may be conducted soon, with the 
assistance of UNODC. The Board encourages 
Governments of countries in the region that have not 
yet done so to ensure that the extent of drug abuse can 
be measured and that adequate measures are taken 
against drug abuse. 
483. On 26 June 2006, the Government of India and 
UNODC launched the national awareness campaign, a 
nationwide drug abuse prevention campaign. The 
campaign utilizes a wide variety of media, including 
television, posters and the printed media, to convey the 
dangers of drug abuse, in particular to young persons. 
National youth organizations are also conducting peer 
awareness initiatives as part of the campaign. 
484. The Board notes with satisfaction the effective 
working relationship that exists between the 
Governments of many countries in South Asia and 
national and international non-governmental 
organizations in the field of drug control. That 
cooperation has enabled many of those organizations to 
play an effective role in complementing and 
strengthening the activities of the Government, 
particularly in the areas of treatment and prevention of 
drug abuse.  
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  Cultivation, production, manufacture, 
trafficking and abuse 
 
485. Though, in South Asia, trafficking in and abuse 
of opiates and pharmaceutical preparations usually 
command the most attention, cannabis is also a 
problem that should not be overlooked. In addition to 
growing wild in a number of countries in the region, 
including Nepal, cannabis plants are also illicitly 
cultivated in certain areas of India and Sri Lanka. 
486. In 2004, the last year for which detailed figures 
are available, over 46 tons of cannabis herb were 
seized in north-east India, accounting for over one 
third of the country’s total volume of seized cannabis 
herb (144 tons). 
487. In Sri Lanka, illicit cultivation of cannabis plant 
takes place mostly in the eastern and southern 
provinces of the country. Though the amounts have 
fluctuated over recent years, seizures of cannabis plant 
have remained significant, with 29 tons seized in 2005. 
Cannabis-related arrests also increased in Sri Lanka in 
2005. 
488. Despite stringent measures taken by the 
Government of India against the diversion of licitly 
cultivated opium, some opium and poppy husk 
continue to be diverted to illicit markets in India. 
Crude heroin manufactured from such diverted opium 
is trafficked and sold on illicit markets in India or is 
smuggled into other countries. Domestically 
manufactured heroin continues to be seized in India. 
Most of the illicit heroin laboratories dismantled in the 
country are near opium poppy cultivation areas. 
489. In addition to low-grade heroin manufactured 
using opium diverted from licit sources, heroin from 
South-West Asia continues to be smuggled into India 
and passes through the country on its way to other 
countries. Heroin in small quantities entering some 
north-eastern states of India from South-East Asia is 
mainly abused locally in those states. Evidence 
suggests that the State of Punjab has been emerging as 
a new hub for smuggling drugs into India, the 
traditional trafficking hubs being New Delhi and 
Mumbai. This recent development appears to be 
connected with the increase in the licit and illicit cross-
border flow of goods and persons between India and 
Pakistan. Most of the drugs, particularly heroin, that 
are smuggled into India through Punjab are 
subsequently taken to New Delhi or Mumbai before 
being transported further to other countries. 
490. The border between India and Nepal remains 
porous, and smuggling between the two countries, in 
particular the smuggling of cannabis from Nepal into 
India, continues.  
491. Seizure trends show significant increases in the 
smuggling of heroin into Maldives in recent years, 
though it remains at a low level. Nevertheless, it is a 
source of concern that seizures made by the authorities 
of Maldives remain small compared with the seizures 
made by Indian and Sri Lankan authorities of heroin 
destined for Maldives. Most seizures in Maldives in 
2005 occurred at that country’s airport, despite the fact 
that most drug addicts and law enforcement officials 
consider the country’s seaports to be the main entry 
points for trafficked drugs. 
492. Recent investigations by law enforcement 
authorities indicate that drug trafficking organizations 
have been using Bangladesh as a trans-shipment point 
for smuggling drugs into Europe. In April 2006, it was 
reported that consignments of heroin had been 
smuggled through Bangladesh into the United 
Kingdom, where they had been seized. It is believed 
that the heroin might have been smuggled from 
Afghanistan into Bangladesh through the border with 
India and then shipped to the United Kingdom from 
there. It is also reported that heroin destined for the 
United States has been smuggled through Bangladesh.  
493. Sri Lanka remains an important trans-shipment 
point for heroin from Afghanistan and India. The 
heroin is destined mainly for countries in other regions, 
but also stimulates the domestic market for the drug. 
Heroin enters the country mainly by sea from India 
and, to a lesser extent, by air from Pakistan. 
494. The abuse of opiates, including illicitly 
manufactured heroin and low-quality heroin base 
known as “brown sugar”, remains a problem in several 
countries in South Asia, including Bangladesh, India, 
Maldives, Nepal and Sri Lanka. There is also a 
continuing trend in the region to move rapidly from 
inhaling to injecting drugs (mainly heroin and 
buprenorphine).  
495. Drug abuse in Maldives has reached alarming 
levels, and, according to several ministers and high-
ranking officials, is now the most serious problem the 
country is facing. There are indications that, since a 
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rapid situation assessment was conducted in 2003, the 
situation has continued to worsen, with drug abuse 
spreading outside of the capital city and younger 
persons abusing drugs. Drug abuse is linked closely 
with the rising theft and robbery rates in Maldives, 
with prison authorities estimating the prevalence of 
drug abuse among inmates at 80 per cent. 
496. Preventive measures taken by the Government of 
Bangladesh appear to have resulted in a decrease in the 
abuse of buprenorphine and pethidine in that country. 
However, it also appears that this has resulted in an 
increase in the abuse of heroin. The Board urges the 
Government to monitor the situation closely and to 
take remedial measures as appropriate. 
497. In India, drug abuse by injection has been one of 
the main factors behind the spread of HIV in some 
areas. It has been well documented that drug abuse by 
injection has been one of the main driving forces 
behind the spread of HIV in the State of Manipur, in 
the north-eastern part of the country. 
498. In Bangladesh, the prevalence rate of HIV among 
persons who abuse drugs by injection in that country 
remains relatively low. However, a mission of the 
Board that visited Bangladesh in 2005 found that the 
proportion of persons abusing drugs by injection had 
been increasing steadily for years and that the HIV 
infection rate had reached epidemic levels in certain 
communities where people abused drugs by injection, 
such as those in the capital city of Bangladesh.  
499. In June 2006, the Indian authorities seized 200 kg 
of cocaine from a container in the port of Mumbai. It 
was the largest single seizure of cocaine in India, more 
than the total amount of cocaine seized in the country 
in over 10 years. The case is currently under 
investigation by the Indian authorities. Once the results 
of the investigation are available, it will be possible to 
make an assessment of the possibility of a newly 
emerging trafficking route for cocaine.  
500. The above-mentioned seizure seems to 
corroborate information that the abuse of cocaine is 
growing in India, particularly among the newly 
emerging wealthy population. Though the first ever 
national survey on drug abuse in India was released by 
the Government in 2004, data on cocaine abuse do not 
feature in the survey. It appears that data on the abuse 
of cocaine in the country have yet to be collected.  
501. The Board, concerned about the possibility of 
cocaine abuse growing in India, urges the Government 
to remain vigilant regarding that development. In 
addition, the Board is concerned about reports of 
growing abuse of and trafficking in cocaine in other 
countries in Asia, where cocaine has traditionally not 
been a major problem. The Board urges the 
Governments concerned to continue to monitor the 
situation and to take appropriate measures to combat 
the abuse of cocaine. 
502. For many years trafficking in and abuse of 
pharmaceuticals have been among the largest drug 
control problems in countries in South Asia, in 
particular in Bangladesh, India and Nepal. Many of the 
pharmaceutical preparations subject to abuse are 
manufactured in India. Though there are strict 
regulations in India and in most other countries, 
loopholes in enforcement mean that pharmaceutical 
preparations are subject to diversion at all levels of the 
supply chain. That has resulted in widespread abuse of 
pharmaceutical preparations, affecting all segments of 
the population, both rich and poor. 
503. Some of the main problem drugs include 
buprenorphine, which is the main drug of injection in 
most areas of India, and cough syrups containing a 
high level of codeine. Besides supplying local markets 
in India, cough syrups are also trafficked into 
Bangladesh and, in some cases, pharmaceuticals are 
also trafficked to Myanmar. 
504. The abuse of dextropropoxyphene in the north-
eastern states of India has also increased significantly 
in recent years. Dextropropoxyphene is a synthetic 
pain reliever and, although it is banned for sale in some 
of the north-eastern states, it is smuggled from other 
states and is easily obtained from street merchants. 
505. The Board notes with concern that ATS are also 
becoming an increasing problem in several countries in 
South Asia, in particular India. The abuse of MDMA 
and methamphetamine appears to be increasing in 
some parts of India. 
506. There are indications of ephedrine and 
pseudoephedrine being smuggled from India through 
the north-eastern states into Myanmar, where those 
substances are used for the illicit manufacture of 
methamphetamine. India produces a significant amount 
of ephedrine and pseudoephedrine every year, for licit 
use in industry. Large amounts of ephedrine (totalling 
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650 kg) were seized in New Delhi in August and 
September 2006. 
 
 
  West Asia 
 
 
  Major developments 
 
507. The Board remains concerned that the drug 
control situation in Afghanistan is worsening, despite 
efforts by the Government and the international 
community. Illicit opium poppy cultivation increased 
by 59 per cent in 2006 compared with 2005, and the 
level of production increased by nearly 50 per cent, 
reaching a record 6,100 tons. The Board again urges 
the Government and the international community to 
take effective measures to eradicate illicit opium poppy 
cultivation and to ensure that opium poppy farmers are 
provided with sustainable, legitimate livelihoods. The 
eradication of illicit opium poppy in Afghanistan is a 
long-term project, and the Board urges all those 
involved to continue their efforts. 
508. It is estimated that Afghan opiates are trafficked 
predominantly through Iran (Islamic Republic of), 
Pakistan and countries in Central Asia. As a result of 
continuing large-scale opium poppy production in 
Afghanistan, those countries are faced with a wide 
range of problems related to large-scale drug 
trafficking, such as organized crime, corruption and 
relatively high illicit demand for opiates. For example, 
the Islamic Republic of Iran has the highest rate of 
opiate abuse in the world. 
509. In addition, the abuse of ATS is spreading in 
various countries in West Asia, including Iran (Islamic 
Republic of), Turkey and several countries on the 
Arabian peninsula. 
510. Though drug seizures in Central Asia decreased 
significantly in 2005, it appears that there was no 
decrease in the amount of drugs trafficked through the 
subregion. In 2006, opium production in north-eastern 
Afghanistan increased, resulting in a rising level of 
drug trafficking in Central Asia. The abuse of drugs in 
Central Asia also continued to increase, and a rise in 
drug abuse by injection fuelled the spread of 
HIV/AIDS. 
511. Armenia, Azerbaijan and Georgia, which are 
situated in the southern Caucasus, which border Iran 
(Islamic Republic of), the Russian Federation and 
Turkey and which have coastlines along the Black Sea 
and the Caspian Sea, are experiencing an increase in 
drug trafficking and abuse. 
 
  Regional cooperation 
 
512. Afghanistan continued to receive assistance 
through several multilateral mechanisms. The 
Afghanistan Compact (S/2006/90, annex), a blueprint 
for sustained international engagement in the 
development of the country over a five-year period, 
was agreed upon at the Conference on Afghanistan 
held in London on 31 January and 1 February 2006, 
bringing together a wide range of stakeholders. The 
Compact, which was subsequently endorsed by the 
Security Council in its resolution 1659 (2006) of 
15 February 2006, is aimed at consolidating Afghan 
institutions, curbing insecurity, eliminating the illicit 
narcotics drug industry, stimulating the economy, 
enforcing the law, providing basic services to the 
Afghan people and protecting human rights. 
Representatives at the Conference pledged 
US$ 10.5 billion for the reconstruction of Afghanistan. 
513. Experts met at a round table on cross-border 
cooperation between Afghanistan and its neighbouring 
countries in Dushanbe on 10 and 11 April 2006. The 
experts recommended the exchange of drug liaison 
officers at additional border crossing points between 
Afghanistan and its neighbouring countries, the 
enhancement of law enforcement training, the 
harmonization of technical and communication 
equipment and the giving of greater priority, at the 
political and operational levels, to the control of 
precursors. The meeting in Dushanbe was part of a 
series of round tables held, pursuant to Paris Pact 
recommendations,42 to improve law enforcement 
coordination in countries affected by trafficking in 
heroin from Afghanistan. 
514. Central Asian States continue to cooperate in 
bilateral and multilateral efforts, including the Central 
Asian Drug Action Programme and the Border 
Management Programme in Central Asia of the 
European Union and the Central Asian Regional Drug 
Information Network. In February 2006, the parties to 
__________________ 
 42  The Paris Pact initiative emerged from the Paris 
Statement (S/2003/641, annex), which had been issued at 
the end of the Conference on Drug Routes from Central 
Asia to Europe, held in Paris on 21 and 22 May 2003. 
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the Memorandum of Understanding on Subregional 
Drug Control Cooperation (Azerbaijan, Kazakhstan, 
Kyrgyzstan, the Russian Federation, Tajikistan, 
Turkmenistan and Uzbekistan) agreed on the legal 
framework of the Central Asia Regional Information 
and Coordination Centre and signed a resolution for its 
establishment in Almaty, Kazakhstan. The 
Coordination Centre, staffed by law enforcement 
officials from the above-mentioned countries, will 
promote the sharing of border intelligence, training and 
effective coordination of supply reduction measures in 
Central Asia. 
515. In July 2006, the North Atlantic Treaty 
Organization (NATO)-Russia Council initiated a 
programme to strengthen law enforcement efforts in 
Central Asia and Afghanistan. Under the programme, 
mobile training teams from NATO member States and 
the Russian Federation visited Afghanistan and five 
Central Asian countries, providing specialized training 
in counter-narcotics operations to local law 
enforcement agencies. In October 2006, the first group 
of Afghan law enforcement specialists completed the 
training. The training complemented training already 
provided for those specialists in the Russian Federation 
and Turkey. 
516. The members of the operational group of the 
Russian Federal Security Service remaining in 
Tajikistan after the withdrawal of the Russian border 
guard troops in 2005 continued to provide advisory 
assistance to Tajik border guards in the effective border 
patrolling and training of recruits. The Government of 
Tajikistan has increased the border guard to over 
10,000 troops and, with the assistance of the 
Governments of the Russian Federation and the United 
States, has strengthened patrolling, security and 
customs control at border crossing points. 
517. China and Pakistan agreed in July 2006 to further 
strengthen bilateral cooperation against drug 
trafficking, as well as other forms of cross-border 
crime. China has also reportedly reinforced its 
exchange of drug trafficking information and law 
enforcement cooperation with Afghanistan. 
518. In July 2006, the Board and UNODC together 
launched Operation Trans-shipment, aimed at 
streamlining measures to prevent the smuggling of 
acetic anhydride through the Central Asian States to 
Afghanistan. In March 2006, the Board and UNODC 
had held a planning session for the Operation in 
Tashkent and training sessions for officials from the 
customs, border services and national security services 
and for drug control authorities were conducted at the 
Turkish International Academy against Drugs and 
Organized Crime in June 2006. 
519. The Board continues to be concerned that 
regional cooperation in drug control among the 
countries in the southern Caucasus remains inadequate, 
as there is no comprehensive framework that includes 
all countries in the subregion. The Board urges the 
Governments of countries in the southern Caucasus to 
participate actively in existing international projects 
and task forces aimed at promoting regional 
cooperation in drug control. 
520. In November 2005, Israel and the Palestinian 
Authority adopted a joint declaration outlining 
procedures for improving collaboration and for 
strengthening cooperation against drug trafficking. 
 
  National legislation, policy and action 
 
521. The National Drug Control Strategy of 
Afghanistan (S/2006/106, annex) was adopted in 
January 2006. The strategy is comprehensive, 
addressing supply and demand reduction, alternative 
livelihoods and the strengthening of government 
institutions. The Afghan Ministry of Counter Narcotics 
is the lead agency for implementing the strategy, and 
action plans for its implementation have been finalized. 
The Board urges the Government and the international 
community to ensure that the strategy is implemented 
properly. 
522. In Afghanistan, the total area of opium poppy 
eradicated in 2005 (5,000 hectares) increased threefold 
in 2006, to 15,300 hectares, most of which was 
eradicated by provincial governors (13,050 hectares). 
The remainder was eradicated by the Afghan 
Eradication Force, an agency of the Government of 
Afghanistan. That development indicates that 
significant progress has been made in the cooperation 
of the Government with provincial governments on the 
drug issue, as only 4,000 hectares of opium poppy 
were eradicated by provincial governments in 2005. 
523. On 1 August 2006, the Government of 
Afghanistan established the Drug Regulation 
Committee, in order to regulate the licensing, sale, 
dispensation, import and export of all drugs for licit 
purposes in the country. The Committee includes 
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officials from the Ministry of Counter Narcotics, the 
Ministry of Public Health and the Ministry of Finance 
of Afghanistan. 
524. In May 2006, the Meshrano Jirga (Upper House) 
of the National Assembly of Afghanistan adopted a 
resolution banning the activities of a certain non-
governmental organization based in France. The 
organization had been advocating legalization of the 
cultivation of opium poppy in Afghanistan for the 
manufacture of opiate medications. The Government, 
the Board43 and the Commission on Narcotic Drugs 
have opposed the idea, stating that it would lead to a 
further deterioration in the drug control situation in 
Afghanistan. 
525. Drug demand reduction action teams have been 
established in Afghanistan to deal with the mounting 
problem of drug abuse. The teams have focused their 
activity on community-based treatment and 
rehabilitation of drug addicts. 
526. The Board notes with concern that throughout 
Afghanistan, many of the prerequisites for successful 
legitimate livelihood programmes, such as adequate 
irrigation, agricultural skills and a functioning credit 
system, are lacking. The Board also notes with concern 
that the drug control efforts of the Government of 
Afghanistan continue to be hampered by limited 
coordination between drug control authorities at the 
national and provincial levels. The Government has 
attempted to address the issue by initiating the revival 
of alternative livelihood working groups at the 
provincial level. The Board urges the Government to 
continue those efforts. The Board stresses that this will 
necessarily be a long-term project, one that will require 
a concerted and sustained approach by both the 
Government and international donors. 
527. In early 2006, the Government of the Islamic 
Republic of Iran announced an emergency plan to 
provide 3,000 people abusing drugs by injection in 
Tehran with a three-month treatment course. The 
Government also implemented a nationwide plan for 
the rehabilitation of drug addicts from November 2005 
to March 2006. The Government is also taking various 
measures to deal with serious problems involving drug 
abuse in prisons. 
__________________ 
 43  Report of the International Narcotics Control Board for 
2005 …, para. 208. 
528. In November 2005, the President of Kazakhstan 
signed a new strategy for combating drug trafficking 
and for the prevention of drug abuse for the period 
2006-2014. In February 2006, the Parliament of 
Kazakhstan adopted a law amending the national drug 
control legislation, introducing stricter sentences for 
drug dealers and requiring government approval of 
equipment used in the production of drugs. 
529. In April 2006, the Government of Turkmenistan 
approved a new national programme on the fight 
against drug trafficking for the period 2006-2010. The 
programme includes measures to strengthen the 
legislative bases for implementing the national drug 
control law, developing and adopting legislation 
against money-laundering, and improving regional and 
international cooperation in combating trafficking, as 
well as measures to prevent the further spread of drug 
abuse and HIV. 
530. In May 2006, a financial intelligence unit was 
established under the Prosecutor-General’s Office of 
Uzbekistan. The unit will monitor all financial 
transactions and maintain a centralized computerized 
system for collecting and analysing information on 
methods used in the laundering of criminal proceeds. 
531. In June 2006, the Parliament of Kyrgyzstan 
adopted a law to combat the financing of terrorism and 
money-laundering. The law, which is based on the 
recommendations of the Financial Action Task Force 
on Money Laundering and includes mandatory 
reporting of all suspicious transactions by all financial 
institutions in Kyrgyzstan, empowers the independent 
financial intelligence unit, established in September 
2005, to undertake effective action to combat money-
laundering. 
 
  Drug trafficking and abuse situation 
 
  Narcotic drugs 
 
532. In 2006, the total area under illicit opium poppy 
cultivation in Afghanistan increased to a record 
165,000 hectares, an increase of 59 per cent over the 
figure recorded in 2005, and more than twice the figure 
for 2003. The harvest in 2006 was approximately 
6,100 tons of opium. In the southern province of 
Helmand, where attacks by Taliban forces against 
government and international troops have increased, 
illicit cultivation soared to 69,300 hectares, 
demonstrating once again the linkage between ensuring 
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adequate security and combating illicit crop 
cultivation. Only six of the 34 provinces in 
Afghanistan are free of the scourge of illicit opium 
poppy cultivation. 
533. Although it has not reached the high level of the 
early 1990s (over 10,000 hectares), illicit cultivation of 
opium poppy in Pakistan has, in recent years, again 
been on the increase. The Government continued its 
efforts to reverse the trend and succeeded in 
eradicating illicit opium poppy cultivation in the 
province of Balochistan. The Board encourages the 
Government to continue its efforts at both the national 
and the provincial levels to eradicate illicit opium 
poppy cultivation. In several countries in Central Asia, 
opium poppy is cultivated on a small scale; however, 
eradication campaigns have virtually eliminated the 
risk of a significant increase in opium poppy 
cultivation in those countries. 
534. Besides opium poppy, cannabis plant is illicitly 
cultivated in Afghanistan; it also grows wild in the 
country. Illicit cultivation of cannabis plant also 
continues in Lebanon, as well as in countries in Central 
Asia, in particular Kyrgyzstan. 
535. In West Asia, routes used for cannabis trafficking 
have changed since the early 1990s, with Lebanon 
supplying less illicit cannabis to other countries in the 
region and cannabis from Afghanistan being smuggled 
through Jordan. There was a sharp decrease in the 
amount of seized cannabis in the United Arab 
Emirates. Cannabis accounts for 72 per cent of all 
drugs seized in Central Asia. In 2005, about 25.5 tons 
of cannabis were seized in Central Asia, 85 per cent of 
which were seized in Kazakhstan. 
536. Large amounts of opiates continue to be seized in 
West Asia and Central Asia, giving a clear indication of 
the significant amounts of Afghan opiates being 
smuggled through that area. Seizures of Afghan opiates 
in the Islamic Republic of Iran increased considerably 
in 2005, reaching 350 tons. Seizures of opium in 
Pakistan have remained at a relatively low level 
compared with the seizure levels in its neighbouring 
countries. Pakistan deployed 10,000 additional troops 
to its border with Afghanistan in June 2006, in part to 
strengthen efforts to prevent drug trafficking. 
537. In Turkey, seizures of heroin continued to 
increase. That increase is partly attributable to 
strengthened law enforcement efforts. However, at the 
same time, there has been a decrease in seizures of 
opium in Turkey, indicating that heroin is being 
manufactured from opium in clandestine laboratories 
outside of the country before it is smuggled through 
Turkey. There was also a significant increase in the 
amount of heroin seized in 2006 in Israel, the Syrian 
Arab Republic and the United Arab Emirates. 
538. Although the total amount of opiates seized in 
Central Asia declined by 37 per cent in 2005, in the 
first half of 2006 that figure increased sharply by 
32 per cent, reaching a total of 4.3 tons. During the 
first half of 2006, seizures of heroin showed an 
increase in all Central Asian States except Kazakhstan. 
The amount of heroin seized in Tajikistan during the 
first half of 2006 increased by 45 per cent compared 
with the same period of the previous year. 
539. One new trend is the smuggling of heroin from 
Pakistan into China, both by air and by land. There is 
information indicating that, in addition to being used 
for the increasing domestic market, heroin entering 
China is smuggled further to markets in Europe 
through the Hong Kong SAR of China. In 2005, 
23 seizures were made from departing passengers at 
international airports in Pakistan, compared with only 
3 seizures in 2004. The traffickers were bound for 
several different airports in China. 
540. The amount of cocaine seized in Israel increased 
in 2005 because of several large-scale seizures at 
border points. During the period under review, a record 
120 kg of cocaine were seized in a container arriving 
from Europe. It appears that the drugs were bound for 
Europe and were not intended for the illicit market in 
Israel. 
541. The smuggling of large quantities of opium 
poppy from Afghanistan continues to lead to severe 
problems in the abuse of opiates in neighbouring 
countries, in particular Iran (Islamic Republic of) and 
Pakistan. The Islamic Republic of Iran is the country 
with the world’s highest rate for the abuse of opiates: 
the most recent information available indicates an 
abuse rate of 2.8 per cent. The Islamic Republic of Iran 
is also facing an increasing problem of heroin abuse by 
injection and the attendant risk of HIV infection. In 
Pakistan, the rate of abuse of opiates is also high 
(0.8 per cent), according to the most recent data 
available. 
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542. In Central Asia, drug abusers are estimated to 
account for almost 1 per cent of the total population. In 
all countries in the subregion, drug abuse is increasing 
and heroin has replaced cannabis and opium as the 
main drug of abuse. The incidence of heroin 
dependence in Central Asia ranges from 50 to 
80 per cent of all registered drug abusers, the highest 
rates being recorded in Tajikistan and Uzbekistan. The 
number of registered drug abusers in Central Asia 
reached 89,000 in 2005, 55,000 of whom are in 
Kazakhstan. According to official estimates, the actual 
number of drug abusers in Central Asian countries is at 
least five times higher. 
543. Drug abuse is a growing problem in Afghanistan. 
The first nationwide survey of drug abuse in the 
country, published in late 2005, indicated that 0.6 
per cent of the adult population abused opium and 
0.2 per cent abused heroin. A survey of opium poppy 
growers showed that personal consumption was the 
second main reason (20.6 per cent) for the increasing 
illicit opium poppy cultivation in 2005. However, 
“hashish” (cannabis resin) is by far the most commonly 
abused drug in Afghanistan, with an abuse rate of 
2.2 per cent. 
544. The Board notes with concern the problem of 
drug abuse among Afghan refugees in neighbouring 
countries, including Iran (Islamic Republic of) and 
Pakistan. Approximately 35 per cent of male and 
25 per cent of female drug abusers in Afghanistan first 
abused opium as refugees outside of Afghanistan, 
particularly in the Islamic Republic of Iran and in 
refugee camps in the North West Frontier Province of 
Pakistan. The Board also notes that evidence suggests a 
high risk of transmission of HIV among persons who 
abuse drugs by injection in Afghanistan, particularly 
among refugees returning from the Islamic Republic of 
Iran who abuse drugs by injection. 
545. There are indications that drug abuse in Iraq is 
increasing. The Board urges the Government to take 
immediate measures to assess the scope of the problem 
and ensure adequate steps are taken to combat drug 
trafficking and abuse. 
546. Drug abuse by injection remains one of the main 
driving forces behind the spread of the virus in Central 
Asia. The fastest spread of HIV has been recorded in 
Kazakhstan and Uzbekistan, and up to 93 per cent of 
new cases of HIV infection in Tajikistan are accounted 
for by persons who abuse drugs by injection. Estimates 
suggest that 40,000 persons are infected with HIV in 
Central Asia. 
547. Drug abuse by injection is increasingly becoming 
the main mode of transmission of HIV in the southern 
Caucasus, accounting for 57 per cent of new cases in 
Azerbaijan, 53 per cent in Armenia and 67 per cent in 
Georgia. 
 
  Psychotropic substances 
 
548. There has been a significant increase in 
trafficking in MDMA in Turkey in recent years. The 
MDMA smuggled in Turkey is largely intended for the 
domestic market. There are indications that the abuse 
of MDMA in Turkey has spread from the main 
metropolitan and tourist areas to other areas, in 
particular among the youth population. 
549. The abuse of synthetic drugs, in particular 
MDMA, in the Islamic Republic of Iran is increasing at 
a fast pace. The number of persons aged 25-30 who 
abuse MDMA is also increasing sharply. 
550. The trafficking in and abuse of fenetylline 
remains a problem in the countries on the Arabian 
peninsula. Jordan is used mainly as a transit point for 
fenetylline tablets destined for Saudi Arabia. In 2005, 
Jordanian authorities seized almost 11.2 million 
fenetylline tablets, a considerable increase over 
previous years. That increase in seizures has been 
attributed mainly to strengthened law enforcement 
efforts. 
551. Turkey is also used for the trans-shipment of 
fenetylline destined for countries on the Arabian 
peninsula. While traditionally fenetylline in tablet form 
has been smuggled through Turkey, recent evidence 
shows that substances used in the manufacture of 
fenetylline are also being trafficked through Turkey. 
552. Trafficking in and abuse of synthetic drugs and 
psychotropic substances have also been reported in 
Central Asia. In particular, MDMA and amphetamines 
are increasingly becoming available on the illicit 
market in Kazakhstan, as evidenced by the fact that 
36,000 MDMA tablets were seized by law enforcement 
authorities in 2005. 
553. The abuse of pharmaceutical medications remains 
a serious problem in Afghanistan. The slow pace of 
reconstruction of the administrative structure for the 
licit control of drugs means that a wide range of 
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pharmaceutical preparations containing controlled 
substances continue to be available without 
prescription in the country, in pharmacies, other retail 
outlets and roadside stalls. 
 
  Missions 
 
554. In January 2006, a mission of the Board visited 
Yemen. Yemen has been taking important steps to 
strengthen its efforts to combat drug trafficking, 
including by the establishment of the Anti-Narcotics 
General Directorate, which coordinates all drug control 
activities in the country. The Board notes with concern, 
however, that the lack of a proper legal framework and 
adequate financial resources is hampering drug control 
activities. The Board therefore urges the Government 
of Yemen to ensure that the Anti-Narcotics General 
Directorate is able to carry out its mandate effectively. 
555. The smuggling of illicit drugs in and out of 
Yemen through various ports of entry and the coastline 
is occurring, but the extent of drug abuse in the country 
is not known. The Board recommends the authorities to 
carry out, with the support of WHO, an assessment of 
the situation in order to be able to plan adequate 
control and preventive measures. 
556. The Board remains concerned about the elevated 
cultivation of khat and its widespread abuse in Yemen. 
The Board calls upon the authorities to consider taking 
appropriate measures to control its cultivation, trade 
and use and recommends that campaigns be initiated to 
raise community awareness regarding the addictive 
nature of khat and its negative impact on society. 
 
 
 D. Europe  
 
 
  Major developments 
 
557. Cannabis continues to be the most commonly 
abused drug in Europe. The European countries with 
the highest prevalence for cannabis abuse include the 
Czech Republic, Denmark, France and the United 
Kingdom. According to estimates of the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), about 20 million people (or 6 per cent of 
the adult population) in the member States of the 
European Union and in Iceland, Liechtenstein, Norway 
and Switzerland have tried cannabis once in their 
lifetime. Among young adults (persons 15-34 years of 
age) in Europe the prevalence rate for cannabis abuse 
has been consistently high.  
558. National policies in Europe vary, reflecting the 
drug abuse situation and political context in individual 
countries. Many European countries have recently 
adopted preventive measures to counter widespread 
abuse of cannabis among youth. Such measures include 
the provision of information on cannabis abuse through 
media campaigns, brochures or websites targeting 
potential drug abusers. 
559. Europe has become the second largest illicit 
market for cocaine in the world. Statistics show that 
the total amount of cocaine seized in Europe and the 
number of persons who abuse that drug have increased 
compared with the previous year. According to the 
World Drug Report 200644 of UNODC, Western and 
Central Europe account for about one quarter of all 
cocaine abused worldwide. After opiates and cannabis, 
cocaine is the drug of abuse most commonly reported 
by those entering programmes for the treatment of drug 
abuse in member States of the European Union, as well 
as in Iceland, Liechtenstein, Norway and Switzerland. 
Cocaine abusers account for about 10 per cent of drug 
abusers admitted for treatment in the European Union. 
In most European countries, the percentage of drug 
abusers entering public treatment programmes for 
cocaine abuse is quite low, the exceptions being the 
Netherlands and Spain (38 per cent and 26 per cent, 
respectively, in 2005). The countries in Europe with 
the highest prevalence rate for cocaine abuse are Spain 
and the United Kingdom. 
560. Europe continues to be one of the main illicit 
markets in the world for stimulants. Only cannabis is 
more commonly abused than MDMA (“ecstasy”). The 
main source of illicitly manufactured ATS in Europe 
continues to be the Netherlands, followed by Poland, 
Belgium, Lithuania and Estonia. The illicit 
manufacture of amphetamines continues to expand 
throughout Europe. According to EMCDDA, however, 
the use of ATS in the United Kingdom has continued to 
fall.  
561. The abuse of methamphetamine continues to be 
reported by the authorities in the Czech Republic, 
Estonia, Latvia and Slovakia. The illicit manufacture of 
methamphetamine appears to be taking place on a 
small scale but is growing, the main source countries 
__________________ 
 44  United Nations publication, Sales No. E.06.XI.10. 
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being the Czech Republic, Lithuania, Moldova and 
Slovakia.  
562. Heroin abuse has remained largely stable or even 
declined in Western and Central Europe, while the 
level of abuse of opiates has increased in Eastern 
Europe, particularly in members of the Commonwealth 
of Independent States (CIS) and countries in South-
Eastern Europe situated along the Balkan route. 
According to UNODC, of the 4 million abusers of 
opiates in Europe, an estimated 3.3 million are heroin 
abusers. Of the 2.46 million abusers of opiates in 
Eastern Europe, an estimated 1.7 million, or 1.2 per 
cent of the population aged 15-64, are heroin abusers. 
 
  Regional cooperation 
 
563. In June 2005, the Council of the European Union 
endorsed the European Union Drugs Action Plan 
(2005-2008).45 The Action Plan covers four priority 
areas (demand reduction, supply reduction, 
international cooperation and research and information 
and evaluation) and lists specific measures to be 
implemented by the European Union and its member 
States by the end of 2008. Assessment tools and 
indicators, as well as responsibility for implementation 
and deadlines, are clearly indicated for each action. 
According to the Action Plan, the European Union is to 
contribute fully to the evaluation of the implementation 
of the commitments set out by the General Assembly at 
its twentieth special session, held in 1998. 
564. In July 2005, the second German-French working 
conference hosted by the French and German drug 
commissioners was held in Strasbourg, France, to 
discuss the treatment of cannabis abusers and cross-
border cooperation to prevent the abuse of cannabis.  
565. Germany and Switzerland are currently 
conducting a bilateral assistance project called 
“Realize it” to help juvenile cannabis abusers stop 
using the drug. Germany, together with four other 
European countries, is also participating in a research 
project on the treatment of young cannabis abusers.  
566. In anticipation of the parliamentary ratification of 
the bilateral law enforcement cooperation treaties 
between Belgium and Germany, practical measures, 
including more stringent cross-border surveillance, 
__________________ 
 45  Official Journal of the European Union, C 168, 8 July 
2005. 
have recently been taken to reduce drug trafficking in 
border areas. 
567. The Second Ministerial Conference on Drug 
Trafficking Routes from Afghanistan (“Paris 2 – 
Moscow 1”) was hosted by the Russian Federation, 
with the support of UNODC, in Moscow from 26 to 
28 June 2006. Ministers and heads of delegations 
attending the conference adopted the Moscow 
Declaration, which was then circulated in the General 
Assembly and in the Security Council. The Declaration 
calls for, inter alia, further support to be provided to 
the Government of Afghanistan in implementing its 
National Drug Control Strategy, for improvement of 
regional measures against trafficking in precursor 
chemicals, for a more systematic exchange of 
information and for an extension of the Paris Pact 
Initiative. 
568. Building on the success of the operation Channel 
2004, the federal drug control service of the Russian 
Federation, in cooperation with the competent drug 
control authorities of member States of the Collective 
Security Treaty Organization (CSTO) (Armenia, 
Belarus, Kazakhstan, Kyrgyzstan, Russian Federation 
and Tajikistan), carried out in October and December 
2005 a two-phase operation, Channel 2005, with the 
participation of the law enforcement authorities of 
CSTO observer States (Azerbaijan, China, Iran 
(Islamic Republic of), Ukraine and Uzbekistan). The 
first phase of the operation Channel 2006 was carried 
out from 22 to 29 May 2006 with the participation of 
the law enforcement authorities of observer States, as 
well as Mongolia and the United States. The second 
phase, carried out in October 2006, was aimed at the 
detection and suppression of national and international 
trafficking in synthetic drugs along routes leading from 
Europe, the dismantling of clandestine laboratories 
manufacturing synthetic drugs and the disruption of 
drug trafficking routes leading from Afghanistan 
through the territories of the participating countries. 
Besides the competent drug control authorities of 
CSTO member States, law enforcement authorities 
from Estonia, Finland, Latvia, Lithuania, Poland and 
the United States participated in the second phase as 
observers. The two-phase operation resulted in the 
seizure of more than 23 tons of narcotic drugs, 
including approximately 250,000 tablets of synthetic 
drugs, and more than 165 tons of precursor chemicals. 
During the operation, several new drug trafficking 
routes were detected. 
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569. In December 2005, the NATO-Russia Council 
agreed on a pilot project for the training of personnel 
from the drug control agencies of Afghanistan and 
countries in Central Asia. The project is aimed at 
improving the capacity of the anti-narcotics agencies 
of those countries to fight the drug trafficking threat 
from Afghanistan. 
570. GUAM member States Azerbaijan, Georgia, 
Moldova and Ukraine participated in the fortieth 
session of the Subcommission on Illicit Drug Traffic 
and Related Matters in the Near and Middle East, held 
in Baku from 12 to 16 September 2005. The resulting 
Baku Accord on Regional Cooperation against Illicit 
Drugs and Related Matters: a Vision for the Twenty-
first Century (Economic and Social Council 
resolution 2006/30, annex) will further strengthen 
cooperation in the region to combat drug trafficking 
and other forms of crime. The GUAM action plan for 
2006 contains a number of actions to be taken by the 
GUAM member States, in cooperation with the South-
East European Cooperative Initiative, to counter 
terrorism, trafficking in human beings, illegal 
migration, corruption and drug trafficking. In line with 
the protocol on cooperation between UNODC and the 
CIS Executive Committee, signed on 1 July 2005, an 
international law enforcement cooperation seminar was 
jointly organized in Minsk from 28 to 30 June 2006. 
571. The ninth European Conference on Drugs and 
Infections Prevention in Prison, held in Ljubljana from 
5 to 7 October 2006, was organized by the European 
Network on Drugs and Infections Prevention in Prison. 
The theme of the Conference was “From the principle 
of equivalence to the practice of care: bridging the 
gap”. The Conference provided an opportunity for 
dialogue on the development and implementation of 
effective drug prevention and health promotion 
policies and services aimed at preventing drug abuse 
and promoting health among persons who come in 
contact with the criminal justice system. 
 
  National legislation, policy and action 
 
572. In November 2005, the parliament of Bosnia and 
Herzegovina adopted a law on the prevention and 
suppression of the abuse of narcotic drugs. The law, 
which entered into force in February 2006, establishes 
a national inter-ministerial committee and a national 
agency to oversee and coordinate drug control efforts 
at the national level. The Board regrets that the new 
legislation did not take into account several aspects of 
the control of psychotropic substances.  
573. The Government of Denmark has recently taken 
initiatives aimed at reducing the demand for drugs, 
especially cannabis, among young people. Under the 
project “Drugs out of town”, the Government has 
initiated the development of new measures to 
encourage partners in the community to join forces and 
reduce the illicit distribution of drugs at the local level. 
The Government also supports projects aimed at 
establishing services for treatment for young people 
who are drug abusers. The Government has decided to 
impose a minimum fine for possession of small 
quantities of drugs (including cannabis) for personal 
use. 
574. In France, a national information campaign to 
boost medical treatment for cannabis and heroin 
abusers was launched in 2005 within the framework of 
the action plan “Programme drogue et toxicomanie” 
(drug and addiction programme). The action plan 
provides funding for European Union and 
United Nations agencies dealing with drug control 
programmes in four priority regions: Africa; Central 
Asia; Central and Eastern Europe; and Latin America 
and the Caribbean. Additional initiatives taken by the 
Government of France in 2005 included measures to 
counter drug trafficking through increased cooperation 
with neighbouring countries and Morocco and 
measures to facilitate the confiscation of drug 
traffickers’ assets. 
575. Germany has continued to implement its Action 
Plan on Drugs and Addiction, launched in 2003. The 
Action Plan established a comprehensive multi-year 
strategy to combat narcotic drugs. The key pillars 
include: prevention; therapy and counselling; survival 
aid as an immediate remedy for drug addicts; and 
interdiction and supply reduction. “Addiction therapy” 
programmes focus on drug-free treatment, 
psychological counselling and substitution therapy. The 
findings of a pilot project on heroin-based treatment 
for long-term opiate addicts are expected to be made 
available before the end of 2006.  
576. The number of drug injection rooms in Germany 
continued to increase during 2006. There are currently 
25 drug injection rooms in Germany. The Board has 
repeatedly expressed its concern that such rooms 
(called “drug consumption rooms” in Germany) are in 
violation of the international drug control treaties. The 
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Board encourages the Government to continue its 
efforts to ensure that adequate services are made 
available to those in need of treatment, rehabilitation 
and social integration in conformity with the 
international drug control treaties, rather than continue 
operating drug injection rooms (see paras. 175-179 
above). 
577. The Federal Criminal Police Office (BKA) of 
Germany established a telephone hotline in March 
2005 for anonymous tips regarding the smuggling of 
goods, including narcotic drugs. According to BKA, 
since the establishment of the hotline, callers have 
provided tips that have proved useful in a number of 
investigations. 
578. In Italy, new legislation adopted in March 2006 
has eliminated the legal distinction between the abuse 
of “hard” and “soft” drugs and has decreased the 
threshold for possession of a “moderate quantity” of 
drugs, making possession of drugs for personal use 
virtually illegal. In November 2006, the Government 
reversed the existing policy on cannabis by increasing, 
through an administrative act, the current maximum 
quantity of cannabis permitted for personal use from 
500 mg to 1,000 mg without incurring penal sanctions. 
In 2005, the Dipartimento nazionale per le politiche 
antidroga (national department of anti-drug policies) 
signed several programme agreements with the 
Ministry of Justice, the Ministry of Health and the 
Ministry of Education, University and Research. It 
should be noted that, among those programmes, one is 
designed to tackle the country’s “cocaine emergency” 
and another is aimed at family-based prevention of 
drug abuse. 
579. In Latvia, in August 2005 the Government 
approved the State programme for the control of 
narcotic drugs and psychotropic substances for the 
period 2005-2008. The national strategy is aimed at 
reducing the spread of drug abuse, especially among 
young people, and promoting the rehabilitation of drug 
abusers. 
580. In November 2005, the Government of the 
Netherlands made an assessment of its policy on 
cannabis and concluded that the policy allowing the 
sale of medicinal cannabis in pharmacies had largely 
failed and could only be effective if cannabis-based 
medicine were registered. The Minister of Health 
indicated that he intended to end the experiment if the 
pharmaceutical industry failed to develop such a 
medicine within one year. The Minister of Justice 
proposed amending the Opium Act to make it easier for 
local governments to close down establishments where 
drugs were sold illegally. A regulation introduced in 
July 2005 facilitated the prosecution of cocaine 
couriers arrested at Schiphol airport, near Amsterdam; 
as a result, seizures of cocaine at Schiphol airport have 
increased. In June 2005, the Government decided to 
expand projects providing free heroin to hard-core drug 
abusers to include an additional 15 municipalities.  
581. In July 2005, the Government of Norway 
published a progress report on its Action Plan to 
combat drug- and alcohol-related problems. In January 
2005, the Ministry of Social Affairs opened the first 
drug injection room for addicts in Oslo. The Board 
encourages the Government of Norway to continue its 
efforts to ensure that adequate services are made 
available to those in need of treatment, rehabilitation 
and social integration in conformity with the 
international drug control treaties, rather than continue 
operating drug injection rooms (see paras. 175-179 
above). 
582. In November 2005, the Government of Romania 
adopted the National Anti-Drug Strategy for the period 
2005-2012. In addition, a new law on the judicial 
regime of narcotic drugs and psychotropic substances 
and plants and pharmaceutical products containing 
such substances, which had been adopted by the 
parliament in 2005, entered into effect in July 2006. 
The new legislation provides for enhanced security in 
the dispensing of prescriptions for controlled 
pharmaceuticals. The new legislation is the result of 
three years of collaboration between the Government 
and WHO aimed at identifying and removing 
regulatory barriers to pain relief. The Board welcomes 
such collaborative activities aimed at improving the 
medical use of morphine and other opioids for pain 
relief.  
583. In September 2006, UNODC released the study 
Sweden’s Successful Drug Policy: a Review of the 
Evidence, which includes an analysis of Sweden’s drug 
policies since the 1960s. After having experienced 
problems in the 1960s (linked to experiments with 
liberal drug control policies), Sweden, in the 1970s and 
1980s, successfully reduced the level of drug abuse, 
tightened drug control laws and sent a clear political 
message that illicit drugs would not be tolerated in 
Swedish society. Sweden’s success was linked to 
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decisive measures on both the supply side and the 
demand side, including extensive programmes for the 
treatment and rehabilitation of drug abusers, based on 
strong political consensus. Improved coordination and 
funding following the implementation of the national 
action plan and the introduction of the National Drug 
Policy Coordinator also helped to lower the levels of 
drug abuse.  
584. The Government of Switzerland has proposed the 
revision of the Swiss drug control law, which, if 
adopted, would have in effect created a legal market 
for cannabis. In February 2006, the Government 
indicated that a revision of the drug control law was 
being debated in the parliament and that the bill did not 
include any of the provisions regarding the 
decriminalization of cannabis. The Board welcomes 
that development and urges the Government to ensure 
that any modifications to the legislation should be in 
line with the international drug control treaties. 
585. The Swiss authorities have extended to 2009 the 
heroin maintenance prescription programmes that were 
originally intended to end in December 2004. 
Switzerland is one of the countries in Europe where 
drug injection rooms are part of the national drug 
control policy. According to the Government, in 
November 2005, there were 12 drug injection rooms in 
the country. The Board encourages the Government to 
continue its efforts to ensure that adequate services are 
made available to those in need of treatment, 
rehabilitation and social integration in conformity with 
the international drug control treaties, rather than 
continue operating drug injection rooms (see 
paras. 175-179 above). 
586. The Board calls on the Government of the 
United Kingdom not to open drug injection rooms, 
which would be a violation of the international drug 
control treaties. In early 2005, the Home Secretary of 
the United Kingdom requested a review of the cannabis 
reclassification decision, in the light of recent studies 
that had established a correlation between the regular 
abuse of cannabis and mental illness. The Advisory 
Council on the Misuse of Drugs issued its report in 
December 2005 but did not make recommendations 
with regard to cannabis. 
 
  Drug trafficking and abuse  
 
  Narcotic drugs 
 
587. Spain and Portugal continue to be used as the 
main trans-shipment points for cannabis consignments 
from Morocco destined for Europe. According to 
Spanish police officials, drug traffickers transport 
cannabis and other narcotic drugs along the 
Mediterranean coast (see para. 244 above). 
588. Albania continues to be a major exporter of 
cannabis herb. Albanian cannabis is smuggled by land 
through the former Yugoslav Republic of Macedonia 
and Bulgaria into Turkey, as well as into Croatia, 
Bosnia and Herzegovina, Montenegro, Serbia and 
Slovenia and then into Western Europe. Illicit cannabis 
plant cultivation has also been reported in Bulgaria. 
About half of the cannabis illicitly cultivated in 
Bulgaria is destined for the illicit market in that 
country. Polish authorities have reported the illicit 
cultivation of cannabis plants in central, south-eastern 
and western Poland, hidden in grain fields, in gardens 
and in greenhouses; about 45 per cent of the cannabis 
produced locally is exported, mainly to Western 
Europe. While in Europe cannabis abuse is usually 
associated with cannabis resin, the market for cannabis 
herb is also significant. For example, in the Czech 
Republic and Estonia, the market for cannabis herb is 
larger than the market for cannabis resin. 
589. Cocaine trafficking increased sharply in Europe 
in 2005. Traffickers have been increasingly using 
routes leading through Portugal and Spain to smuggle 
cocaine into other countries in Europe. The authorities 
in Spain have identified three main routes used by 
traffickers to smuggle cocaine into Europe: the north 
route, leading from the Caribbean to the Azores, 
Galicia (in Spain), Portugal and the coast of the 
Cantábrico (in Spain); the central route, leading from 
South America to the European coast, from Cape Verde 
or Madeira and the Canary Islands, the most frequently 
used route by sea; and the African route, leading from 
South America mainly to the countries in Western 
Africa and the Gulf of Guinea then to Galicia or 
northern Portugal, either by air or by sea. Cocaine 
seizures in Portugal increased by 125 per cent in 2005 
compared with 2004. According to the Government of 
Portugal, 19 tons of cocaine were seized in that country 
in 2005, 20 per cent of the total amount of cocaine 
seized in all the member States of the European Union. 
Authorities in Portugal are particularly concerned 
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about the growing importance of Western Africa in 
international drug trafficking (see paras. 245-247 
above). 
590. During the Sixth Meeting of Heads of National 
Drug Law Enforcement Agencies, Europe, held in 
Vienna from 7 to 11 February 2005, concerns were 
expressed about the potential development of new 
trafficking routes through Eastern Europe and the 
potential risk that cocaine could be smuggled by 
traditional heroin trafficking groups operating along 
the Balkan route. 
591. In 2005 and 2006, the Italian police led several 
operations involving law enforcement agencies from 
other countries that resulted in major seizures of 
cocaine. One of the operations, carried out in late 
2005, involved five countries (Argentina, France, Italy, 
the Netherlands and Spain) and resulted in the seizure 
of approximately 1.5 tons of cocaine and over 
120,000 tablets of MDMA and the arrest of more than 
60 people. In October 2005, Italian Carabinieri 
dismantled an international drug trafficking network 
based in southern Italy; over 40 individuals were 
arrested and about 100 others were investigated. 
592. In August 2005, police in the Netherlands seized 
4.5 tons of cocaine in Rotterdam, the largest cocaine 
seizure ever made in that country. The investigation 
involved close cooperation with the drug enforcement 
agencies of Belgium, the Netherlands, Spain and the 
United States. In October 2005, Spanish police seized 
3.5 tons of cocaine on a fishing boat bound for Spain. 
In September 2006, French and Spanish police, in a 
joint operation, seized 3.3 tons of cocaine hidden on a 
boat off the coast of Spain. Cooperation among the 
police in Germany, the Netherlands and Spain led to 
the seizure of 1.6 tons of cocaine at the port of 
Rotterdam in November 2005. The Government of 
Greece has confirmed that the amount of cocaine 
seized in 2004 increased by 474 per cent compared 
with 2003.  
593. Most of the heroin found in Europe comes from 
Afghanistan. According to the World Drug Report 
2006, in Europe seizures of opiates rose by 49 
per cent46 in 2004 to 29 tons, the highest figure ever 
recorded. The increase in seizures of opiates in Europe 
was mainly attributable to the fact that such seizures 
doubled in South-Eastern Europe, especially in 
__________________ 
 46  World Drug Report 2006 …, pp. 14 and 65. 
Albania, Croatia, Montenegro, Serbia, the former 
Yugoslav Republic of Macedonia and Turkey. Record 
seizures of opiates were also made in the Russian 
Federation. Most of the heroin continues to be 
smuggled in trucks. The heroin on the illicit market in 
Europe is mainly smuggled from Turkey along the 
Balkan route, via Bulgaria, Romania and Hungary. In 
addition, a southern branch of the Balkan route has 
developed: heroin and other opiates from Turkey are 
smuggled via Bulgaria and the former Yugoslav 
Republic of Macedonia into Albania, Italy, Austria and 
Germany. There have been reports of shipments of 
opiates from Afghanistan to the Islamic Republic of 
Iran being smuggled through the Caucasus into 
Ukraine and then into Romania before reaching their 
final destinations in Western Europe. The northern 
route through Central Asia is increasingly being used 
to transport heroin to other major illicit markets for 
heroin, such as the Russian Federation and countries in 
Eastern Europe. A new route for smuggling heroin 
from East Asia into the United Kingdom was recently 
uncovered, resulting in the interception of heroin 
consignments at ports in the United Kingdom. 
594. Large heroin seizures have been recorded in the 
following European countries (listed in decreasing 
order): United Kingdom, Italy, Netherlands, Germany, 
France and Russian Federation. Increased seizures of 
opiates were also reported in Austria, the Czech 
Republic, Denmark, Finland, Iceland, Luxembourg, 
Norway, Poland, Spain and Sweden. Clandestine 
heroin laboratories were detected and destroyed in 
Moldova and the Russian Federation.  
595. According to government reports, in 2006 the 
market for illicit drugs in Belarus experienced a major 
shift, from heroin to synthetic drugs. The availability 
of methadone and ATS on the local markets has 
gradually increased. Methadone has gradually replaced 
heroin as the most commonly abused substance. 
During the past two years, it was discovered that 
methadone was being illicitly manufactured on the 
premises of research institutes in Minsk, the capital. 
596. In Georgia, the Government has launched a 
prevention campaign called “Anything but Subutex®” 
to raise awareness of the negative health effects of the 
abuse of buprenorphine. Since 2003, the number of 
registered drug abusers in Georgia has increased by 
80 per cent, to 275,000. 
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597. In the United Kingdom, according to the 
sixteenth surveillance report on drug-related deaths, 
published in January 2006 by the National Programme 
on Substance Abuse Deaths, based at the International 
Centre for Drug Policy, St. George’s, University of 
London, there was an increase in drug-related deaths 
involving the abuse of heroin/morphine and cocaine in 
the first half of 2005, compared with the same period 
in 2004. In particular, deaths due to polydrug use, 
particularly involving combinations of 
heroin/morphine and cocaine, have increased in the 
United Kingdom. 
598. Estonia has one of the highest growth rates for 
HIV infection in Europe: an estimated 10,000 persons 
infected with HIV. Of the estimated 30,000 persons in 
Estonia who abuse drugs by injection, about 
13 per cent are infected with HIV. In Latvia, there are 
an estimated 10,000 persons infected with HIV and 
17 per cent of the estimated 12,000 persons who abuse 
drugs by injection are HIV-positive. In Lithuania, there 
are an estimated 3,300 persons infected with HIV. Of 
the estimated 11,000 persons who abuse drugs by 
injection in Lithuania, 3 per cent are infected with HIV.  
599. According to government statistics, in the 
Russian Federation the number of HIV/AIDS cases 
among hospitalized drug abusers stabilized at about 
6.8 per cent in the period 2003-2005. In 2005, persons 
who abused drugs by injection accounted for 
approximately 74 per cent of the total number of 
registered drug abusers, 9 per cent of whom were 
infected with HIV. HIV outbreaks have been observed 
in over 30 cities and in 82 out of 89 oblasts (regions) 
of the Russian Federation.  
600. In Sweden, lifetime prevalence of drug abuse 
among youth declined by 35 per cent between 2001 
and 2006. The drug abuse level in Sweden is currently 
about one third of the level in Europe as a whole, and 
HIV related drug abuse by injection is about one tenth 
of the European average. 
601. According to estimates of the Ministry of Health 
of Albania, in January 2006 there were 30,000 drug 
abusers in the country, compared with 5,000 in 1995 
and 20,000 in 1998, and 4,000 of the drug abusers 
currently in the country are in need of special treatment 
that cannot be sufficiently provided in the country.  
 
  Psychotropic substances 
 
602. On 29 November 2005, as a result of a joint 
investigation of the national crime squad of Belgium 
and the tax investigation service of the Netherlands, a 
clandestine MDMA laboratory in Nederweert (southern 
Limburg Province), the largest ever found in the 
Netherlands, was dismantled. It is estimated that the 
laboratory had a manufacturing capacity of 20 million 
MDMA tablets. Six people were arrested, all of them 
from the Limburg Province. The investigation, which 
had begun in May 2005, was carried out in close 
cooperation with Belgian and German authorities. It 
was the first MDMA laboratory discovered in 2005; 
until then, only clandestine amphetamine laboratories 
had been dismantled during 2005.  
603. The illicit manufacture of methamphetamine in 
Europe takes place mainly in the Czech Republic, 
Lithuania, Moldova and Slovakia.  
604. Bosnia and Herzegovina and Bulgaria, as well as 
Montenegro and Serbia, have been identified as 
countries used as sources for the illicit manufacture of 
amphetamine. There have been reports of the illicit 
manufacture of P-2-P, a chemical used for the 
manufacture of amphetamine, in the Russian 
Federation and Ukraine; there are also indications that 
amphetamine is being illicitly manufactured in Estonia 
and Lithuania. 
605. Population surveys carried out by EMCDDA 
show an increase in the abuse of amphetamine and 
MDMA among young adults in most countries in 
Europe. The exceptions are Germany and Greece, 
where the level of MDMA abuse has not increased, and 
the United Kingdom, where the abuse of that drug has 
recently stabilized at a high level.  
 
  Substances not under international control 
 
606. EMCDDA has published Hallucinogenic 
Mushrooms: an Emerging Trend Case Study. According 
to the study, many young Europeans are currently 
experimenting with hallucinogenic (“magic”) 
mushrooms. Since 2001, six member States of the 
European Union have tightened controls on 
hallucinogenic mushrooms in response to recent 
increases in their use: Denmark in 2001; the 
Netherlands in 2002; Estonia, Germany and the United 
Kingdom in 2005; and Ireland in 2006. In some 
countries, the stricter legislation is helping to prevent 
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diffusion of the trend. Reports in the United Kingdom, 
for example, suggest stricter legislation has had an 
impact on the availability of hallucinogenic 
mushrooms and the volume of such mushrooms sold 
through the Internet. The publication on hallucinogenic 
mushrooms is the first in a series of reports to be 
published under a new EMCDDA pilot project to help 
detect, track and understand emerging drug trends in 
Europe. 
 
  Missions 
 
607. The Board sent a mission to Belarus in May 2006 
to review the drug control situation and the progress 
made by the Government following its mission to that 
country in 1994. The Board notes with satisfaction that 
the Government continues to be committed to fighting 
drug trafficking and abuse and gives high priority to 
improving in a timely manner the legislative bases and 
updating its drug control policy, as reflected in the 
adoption of a new national drug control programme in 
2006, and the initiatives of Belarus to improve regional 
cooperation.  
608. The Board notes with appreciation that Belarus 
has built up a strong law enforcement system and 
attaches great importance to efforts to resolve the 
problem of increasing trafficking in synthetic drugs 
and precursors. A number of well-coordinated law 
enforcement activities have taken place in Belarus, 
resulting in the detection of some illicit laboratories 
with substantial capacity for manufacturing methadone 
and ATS. The Board encourages the Government to 
continue its efforts in that area, with a view to 
addressing the increasing activities of organized 
criminal groups, especially those activities related to 
drug trafficking. The Government should further 
strengthen customs and border guard services in order 
to increase their capabilities to prevent the smuggling 
of illicit drugs into Belarus, in particular through the 
Russian Federation, with which Belarus shares an 
unguarded border, and through other neighbouring 
countries. 
609. The Board shares the concern of the Government 
of Belarus over the worsening drug abuse situation in 
the country, particularly with regard to the significant 
increase in drug abuse by injection and heroin 
addiction. Noting that access to treatment is often 
difficult for drug abusers in Belarus, the Board 
strongly encourages the Government to accord higher 
priority to the treatment and rehabilitation of drug 
abusers and to increase the resources, as well as the 
efficiency, of such treatment services. 
610. In May 2006, a mission of the Board visited 
Estonia. The National Strategy on the Prevention of 
Drug Dependence 2004-2012 and its action plans 
covering long-term and mid-term objectives are 
ambitious programmes calling for numerous activities 
at different levels and within different time frames. 
However, the implementation and monitoring of those 
programmes require additional efforts, including more 
frequent meetings of the coordinating committee.  
611. Estonia is currently experiencing a shift among 
drug abusers, from the abuse of natural products (such 
as cannabis) to synthetic drugs (such as amphetamines 
and MDMA. Fentanyl and 3-methylfentanyl have, to a 
large extent, replaced heroin on the illicit drug market 
in Estonia; the higher potency of those substances has 
led to a rise in the number of drug-related deaths. One 
matter of particular concern is the increasing 
prevalence of the abuse by injection of heroin, 
amphetamines and illicitly manufactured fentanyl and 
3-methylfentanyl, which has contributed to an increase 
in HIV infections. Estonia, like the other Baltic 
countries, is confronted with a specific phenomenon 
involving drug tourism: Finnish drug addicts travel to 
Estonia to purchase pharmaceutical preparations 
containing buprenorphine and oxycodone. In response, 
Estonia has strengthened drug control requirements 
and the conditions under which such preparations can 
be prescribed. 
612. In May 2006, a mission of the Board visited 
Latvia. The Board notes that the Government of Latvia 
has shown the political commitment and the will to 
deal with drug abuse, drug trafficking and organized 
crime. Drug control policies, national drug control 
legislation and the institutional framework to carry out 
those policies and implement that legislation are well 
developed. Under the chairmanship of the Prime 
Minister of Latvia, a council for the coordination of 
drug control and the prevention of drug addiction has 
been established to ensure the effective implementation 
of the national programme for combating drug abuse. 
However, the implementation of the ambitious 
programmes of the Coordinating Council has been 
delayed because of insufficient funds. Additional funds 
are also required to enhance training programmes for 
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all law enforcement units and to improve technical 
equipment. 
613. In Latvia, there has been an increase in the abuse 
of amphetamine and methamphetamine. Other major 
concerns of the Latvian authorities are the increasing 
polydrug abuse and the high drug abuse rates among 
adolescents. Former diversions and misuse of 
pharmaceuticals used in substitution therapy, 
particularly by tourists from Finland, have been 
countered by additional control measures. With regard 
to availability of narcotic drugs for treatment of pain, 
the Latvian authorities have considerably improved the 
situation by including morphine medications in the list 
of pharmaceuticals of their national health insurance 
system. 
614. The Board sent a mission to Luxembourg in 
October 2006 to review the implementation of the 
international drug control treaties and maintain its 
ongoing dialogue with the Government on issues 
related to drug control. The Board notes with grave 
concern that a drug injection room has been in 
operation in Luxembourg since 2005, in violation of 
the provisions of the international drug control treaties. 
The Board urges the Government to close the facility 
immediately and to implement measures against the 
abuse of drugs that are in compliance with its 
international treaty obligations.  
615. The Board recommends to the Government of 
Luxembourg that it improve coordination among the 
various ministries and agencies involved in drug 
control matters. Such coordination has not always been 
adequate; as a result, various reports required under the 
international drug control treaties have not always been 
submitted to the Board. The Board also recommends to 
the Government that it strengthen its efforts in 
collecting information on the drug abuse situation 
within the country, in view of the fact that there is no 
national survey on the subject. Finally, the Board notes 
the measures being taken by the Government to deal 
with the problem of diversion of methadone from 
substitution treatment and encourages the Government 
to continue strengthening its efforts in that area. 
 
 
 E. Oceania 
 
 
  Major developments 
 
616. The majority of the cannabis abused in Australia 
continues to have been produced in that country. 
617. The illicit manufacture of methamphetamine 
continues to be a problem in Australia. Most of the 
pseudoephedrine used in illicit methamphetamine 
manufacture has been extracted from commercially 
available pharmaceutical preparations. The abuse 
(including by smoking) of methamphetamine among 
young drug abusers is increasing in Australia. There 
are indications that Oceania may be developing into a 
significant transit area and a potential consumption 
area for methamphetamine. 
618. There was evidence of large-scale illicit 
manufacture of MDMA in Australia, particularly 
during the last quarter of 2005. 
619. Oceania continues to be used as a major trans-
shipment area for illicit drugs. 
 
  Regional cooperation 
 
620. HIV/AIDS, organized crime, border management 
and money-laundering were among the important 
issues discussed at the annual meeting of the Regional 
Security Committee of the Pacific Islands Forum, held 
in Nadi, Fiji, in June 2006. 
621. In March 2006, the eighth annual conference of 
customs heads of the Oceania Customs Organisation 
was held in Sigakota, Fiji. Strengthening trade security, 
combating transnational crime and strengthening 
regional cooperation were the key themes of the 
conference. The participants agreed on a workplan for 
the period 2006-2007, including activities related to 
law enforcement and security. 
622. The seventeenth administrative meeting of 
contact points of the Regional Intelligence Liaison 
Office for Asia and the Pacific was held in 
Christchurch, New Zealand, in November 2005. The 
Minister of Customs of New Zealand highlighted the 
pre-eminent role of the Regional Intelligence Liaison 
Office in countering the smuggling of precursor 
chemicals. 
623. Australia and New Zealand continued to provide 
capacity-building assistance to other countries in 
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Oceania. The Australian and New Zealand customs 
services have appointed, for a 12-month period, two 
senior officers as head and deputy head of the Tonga 
Customs Service, which is part of the joint New 
Zealand and Australian Finance and Economic 
Management Programme for Tonga. The objective is to 
promote secure trade and borders, including the 
prevention of drug trafficking. The New Zealand 
Customs Service is also strengthening customs support 
in Oceania by sponsoring the establishment of the 
Oceania Customs Organizations in Fiji. The Australian 
Federal Police continued to provide capacity-building 
assistance to Nauru, Papua New Guinea and Solomon 
Islands. 
624. Drug control legislation in Fiji and Tonga has 
been based on the Illicit Drug Control Bill, which calls 
for drug control legislation in Oceania to be consistent 
with respect to offences, penalties, classes of illicit 
drugs, investigations and law enforcement. The bill 
was drafted by a joint working group established to 
devise a common approach to illicit drug control in the 
region. 
625. The collaboration among the New Zealand 
customs and police, the National Drug Intelligence 
Bureau of New Zealand and the Narcotics Bureau of 
the police of the Hong Kong SAR of China led to the 
seizure in May 2006 of approximately 95 kg of 
methamphetamine and 150 kg of pseudoephedrine 
(used in the illicit manufacture of methamphetamine), 
the largest haul of those types of drugs ever made in 
New Zealand. New Zealand customs and police 
authorities seized shipments of methamphetamine and 
pseudoephedrine originating in China. Seven suspects 
have been arrested in connection with the seizures. 
 
  National legislation, policy and action 
 
626. The Board welcomes the accession of Vanuatu to 
the 1988 Convention and encourages it to accede to the 
1961 Convention and the 1971 Convention without 
delay. However, the Board continues to be concerned 
by the low rate of accession to the international drug 
control treaties by countries in Oceania. As traffickers 
have been known to take advantage of loopholes in 
national legislation, the Board calls on those States in 
the region that have not yet done so to ratify the 
treaties without further delay. 
627. In December 2005, the New Zealand Customs 
Service updated the focus of its drug law enforcement 
strategy for the next five years. The recently published 
national drug law enforcement strategy will support the 
efforts of the New Zealand Customs Service aimed at 
protecting communities and reducing the supply of 
illicit drugs, within the framework of the national drug 
control policy. The five-year strategy updates the 
1988 customs drug strategy, building on study findings 
from 2002. The main objectives of the new strategy 
include maintaining an overview of up-to-date national 
and international intelligence about the illicit drug 
scene, combating the smuggling of drugs and 
precursors into and out of New Zealand by using new 
and existing interdiction and investigative techniques, 
identifying and targeting emerging drug threats and 
actively contributing to international efforts to combat 
the illicit drug trade. 
628. Police in New Zealand continued to give high 
priority to substance-related offences, targeting illicit 
drug manufacturers, importers and dealers in 2005. 
High-quality intelligence was also a factor in several 
successful operations, leading to the disruption of 
illicit drug supply chains, particularly those with a 
transnational dimension, where strong links with 
overseas law enforcement agencies proved to be highly 
effective. 
629. Australia has been promoting a campaign to 
prevent illegal sales of pseudoephedrine. In January 
2006, national legislation to tighten controls on 
pseudoephedrine went into effect. 
630. In September 2006, the Pacific Islands Forum 
secretariat established a Pacific Anti-Money 
Laundering Programme to assist Governments in 
preventing money-laundering and the financing of 
terrorism, pursuant to the relevant United Nations 
conventions and Security Council resolutions. The 
Government of Australia will be providing additional 
funding over the next five years to fight serious tax 
fraud and money-laundering. In particular, the funds 
will be used to detect and dismantle organized criminal 
enterprises involved in serious tax fraud and money-
laundering. 
 
  Situation with regard to drug trafficking and 
abuse 
 
  Narcotic drugs 
 
631. The majority of the cannabis abused in Australia 
is produced locally; cannabis plants are illicitly 
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cultivated in all states and territories in that country. In 
New Zealand the large-scale cultivation of cannabis 
plants is taking place in a number of rural areas, 
including Northland and the Bay of Plenty. In addition, 
outdoor cultivation of cannabis plants in New Zealand 
has recently been supplemented by operations that use 
sophisticated indoor hydroponics to produce cannabis. 
Cannabis plants are also illicitly cultivated in Fiji, 
Papua New Guinea, Samoa and Tonga. 
632. There have been reports of barter trade involving 
the exchange of illicit drugs for arms in the coastal 
cities of Lae, Madang, Wewak and Port Moresby in 
Papua New Guinea. 
633. The largest seizures of opium, heroin and cocaine 
in Oceania were reported in Australia. In May 2006, as 
a result of cooperation between the Australian Crime 
Commission and the federal and regional police and 
customs, four suspects were arrested and over 3 kg of 
heroin were seized, together with cash and other 
evidence, in raids in Sydney and Melbourne targeting 
an international syndicate trafficking in heroin. Large 
seizures of heroin have recently been made in Fiji and 
Vanuatu. 
634. The total amount of cocaine seized in Australia in 
2005 was the lowest since 1999. While the number of 
cocaine consignments detected at the Australian border 
decreased during the period 2004-2005, most of the 
cocaine entered the country through the postal system. 
635. Cannabis continued to be abused in many 
countries in Oceania. Cannabis remained the drug of 
choice among drug abusers in Australia, Micronesia 
(Federated States of), New Zealand, Papua 
New Guinea, Samoa, Solomon Islands, Tonga and 
Vanuatu. However, a survey conducted by the 
Department of Health and Ageing of Australia found 
that fewer children in secondary schools are abusing 
cannabis. In 2005, 18 per cent of such children had 
abused cannabis, compared with 35 per cent in 1996. 
Micronesia (Federated States of) and Papua 
New Guinea have the highest prevalence of cannabis 
abuse in the region. 
 
  Psychotropic substances 
 
636. In Australia, ATS are supplied predominantly by 
clandestine laboratories operating within the country 
itself, which primarily manufacture methamphetamine. 
The illicit manufacture of methamphetamine seems to 
be increasing in New Zealand, where 204 laboratories 
involved in the illicit manufacture of meth-
amphetamine were dismantled in 2005, compared with 
182 in 2004. Organized criminal groups use Oceania as 
a trans-shipment area for ATS, including 
methamphetamine and MDMA. 
637. In Australia, there was a sharp decrease in the 
total amount of ATS seized in 2005 compared with 
previous years. Police in New Zealand have been 
seizing larger amounts of methamphetamine. In 
New Zealand, authorities seized 8.1 kg of 
methamphetamine concealed in water filters from 
China in January 2006 and 95 kg of the substance in 
May 2006. In April 2006, following a joint operation 
involving the Australian Crime Commission and 
police, three suspects were arrested and 2 kg of 
methamphetamine were seized. In November 2005, as 
a result of joint law enforcement partnerships among 
the Australian Crime Commission, the Australian Tax 
Office, the Queensland police and the Crime and 
Misconduct Commission, a person was convicted and 
sentenced to 15 years of prison for trafficking in and 
possession of methamphetamine and the convicted 
person’s considerable assets were confiscated. 
638. South East Asian methamphetamine is smuggled 
through Oceania to Canada and, to a lesser extent, the 
United States. 
639. The total amount of MDMA seized in Australia in 
2005 was 1,365 kg, the highest amount reported in the 
past six years. Almost two thirds of that total (820 kg) 
was discovered inside an oven in an air cargo 
consignment from Germany. During the last quarter of 
2005, six MDMA manufacturing sites were uncovered 
(compared with only three sites during the entire year 
in 2004). Large amounts of 3,4-methylenedioxyphenyl-
2-propanone were discovered at two of the sites, 
signalling a possible shifting towards local 
manufacturing of MDMA. The uncovering of tablet 
presses may also be an indication that some of the 
MDMA available in Australia has been illicitly 
manufactured in that country. 
640. Australian customs authorities seized 12.5 kg of 
pseudoephedrine concealed in children’s books. The 
books had been imported in seven separate postal items 
from Malaysia, which were intercepted at the 
Melbourne international mail centre between August 
and September 2005. Investigations resulted in the 
arrest of 16 people and the dismantling of nine 
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clandestine laboratories in South Australia that had 
been illicitly manufacturing methamphetamine. Two 
clandestine laboratories used for the illicit manufacture 
of methamphetamine were dismantled in 2005 in the 
Australian Capital Territory. There is evidence that 
most of the pseudoephedrine used in the illicit 
manufacture of methamphetamine had been extracted 
from commercially available pharmaceutical 
preparations. 
641. The police in New Zealand continued to detect 
attempted diversions of consignments of medicines 
from China containing pseudoephedrine. The illicit 
market continued to be supplied with such medicines 
through the diversion of over-the-counter medicines 
and theft. During 2005, over 146 kg of 
pseudoephedrine and 20 kg of ephedrine were seized in 
New Zealand. 
642. In Australia, the abuse (including by smoking) of 
methamphetamine among young drug abusers is 
increasing. Methamphetamine is the drug most 
commonly abused by injection in Australia. 
New Zealand published its findings on recent trends in 
the abuse of methamphetamine and other illicit drugs 
from the 2005 Illicit Drug Monitoring System, which 
were based on interviews with frequent 
methamphetamine abusers. The study found that, in 
addition to methamphetamine, the interviewed persons 
abused cannabis, MDMA, LSD, opiates, GHB and 
cocaine. The drugs most commonly abused by 
injection were opiates and methamphetamine. The high 
level of drug abuse by injection among frequent 
methamphetamine abusers might indicate that persons 
who traditionally abused opiates were turning to 
methamphetamine. Several of the interviewed persons 
reported increased abuse of methamphetamine that had 
been smuggled into New Zealand. An increasing 
number of people receiving treatment for drug abuse in 
New Zealand are identifying amphetamine as their 
primary drug of abuse; according to centres for the 
treatment of drug abuse, amphetamine is the third most 
commonly abused drug in the country, after alcohol 
and cannabis. 
 
  Substances not under international control 
 
643. In New Zealand, 10 kg of gamma-butyrolactone 
(GBL) were seized in 2005. GBL is becoming 
increasingly popular among drug abusers in 
New Zealand. In addition, there are indications that the 
abuse of “party pills” containing benzylpiperazine has 
become a growing problem in New Zealand; the pills 
are rapidly gaining popularity as an alternative to 
MDMA and methamphetamine. In Australia, seizures 
of khat have increased. 
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 IV. Recommendations to Governments, the United Nations and other 
relevant international and regional organizations 
 
 
644. The Board examines, on an ongoing basis, the 
functioning of the international drug control regime, 
identifies shortcomings in the implementation by 
Governments of the three main international drug 
control treaties and formulates recommendations for 
further action addressed to national drug control 
agencies and relevant international and regional 
organizations. Those recommendations, which are 
aimed at assisting Governments in fully complying 
with their treaty obligations and at further developing 
the international drug control regime, are included in 
each annual report of the Board, which is disseminated 
to all Governments. 
645. In its report for 2005, the Board included a new 
chapter highlighting some selected key 
recommendations and proposals for further action, in 
order to assist Governments, relevant United Nations 
organizations and other international and regional 
organizations responsible for drug control issues in 
focusing their attention on the main recommendations. 
The Board is pleased to note that a number of those 
recommendations have already been implemented. The 
recommendations made in the report for 2005 continue 
to be valid, and the Board invites all those concerned 
to examine them again and to implement them, as 
applicable. Pertinent recommendations are included 
again in this chapter, along with new recommendations 
made by the Board after its examination of the world 
drug control situation in 2006.  
 
 
 A. Recommendations to Governments 
 
 
646. The recommendations to Governments are 
grouped according to the following subject areas: 
treaty adherence; treaty implementation and control 
measures; prevention of illicit drug trafficking and 
abuse; availability and rational use of narcotic drugs 
and psychotropic substances for medical purposes; and 
the Internet and smuggling by mail. 
 
  Treaty adherence 
 
647. The 1961 Convention, the 1961 Convention as 
amended by the 1972 Protocol, the 1971 Convention 
and the 1988 Convention form the basis of the 
international drug control system. The accession of all 
States to those treaties is a fundamental prerequisite for 
effective drug control worldwide. 
  Recommendation 1: The Board reiterates its 
request to States that are not yet parties to one or 
more of the international drug control treaties to 
take immediate action to accede to those 
treaties.47 
 
  Treaty implementation and control measures 
 
648. Universal treaty adherence will, however, not be 
sufficient without effective and universal 
implementation of all the provisions of the three main 
international drug control treaties and the application 
of the necessary control measures by all Governments. 
  Recommendation 2: Provision of mandatory 
information to the Board is one of the key 
elements of the international drug control 
mechanism. The Board reiterates its request to all 
Governments to furnish in a timely manner all 
statistical reports required under the three 
international drug control treaties.  
  Recommendation 3: The system of control 
measures laid down in the 1961 Convention 
__________________ 
 47  The following States are not parties to the international 
drug control treaties and/or the 1972 Protocol amending 
the 1961 Convention: 
   (a) Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol: Andorra, Democratic 
People’s Republic of Korea, Equatorial Guinea, Kiribati, 
Nauru, Samoa, Timor-Leste, Tuvalu and Vanuatu; 
   (b) Protocol Amending the Single Convention on 
Narcotic Drugs, 1961: Afghanistan, Chad and Lao 
People’s Democratic Republic; 
   (c) Convention on Psychotropic Substances of 1971: 
Andorra, Cook Islands, Democratic People’s Republic of 
Korea, Equatorial Guinea, Haiti, Kiribati, Liberia, 
Nauru, Nepal, Samoa, Solomon Islands, Timor-Leste, 
Tuvalu and Vanuatu; 
   (d) United Nations Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances of 1988: 
Democratic People’s Republic of Korea, Equatorial 
Guinea, Holy See, Kiribati, Liechtenstein, Marshall 
Islands, Namibia, Nauru, Palau, Papua New Guinea, 
Solomon Islands, Somalia, Timor-Leste and Tuvalu. 
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provides effective protection against attempts at 
the diversion of narcotic drugs from international 
trade into illicit channels. The Board urges all 
Governments to implement fully the system of 
estimates and export authorizations and to ensure 
that no exports of narcotic drugs are authorized 
from their countries in excess of the 
corresponding total of the estimates of the 
respective importing country.  
  Recommendation 4: A number of 
Governments have for several years not updated 
the assessments of their requirements for 
psychotropic substances. The earlier assessments 
may no longer reflect their actual medical and 
scientific requirements for psychotropic 
substances. The Board wishes to remind all 
Governments of their obligation to regularly 
update their assessments and to keep the Board 
informed of any modifications. 
  Recommendation 5: Several importing 
countries issued import authorizations for 
quantities of psychotropic substances in 
Schedules II, III and IV of the 1971 Convention 
in absence or in excess of the corresponding 
assessments. The Board reiterates its request to 
all Governments to establish a mechanism to 
ensure that no imports exceeding the assessments 
are authorized. 
  Recommendation 6: The Board invites all 
States that have not yet done so to introduce 
mandatory import authorizations for all 
psychotropic substances in Schedules III and IV 
of the 1971 Convention, in accordance with 
Economic and Social Council resolutions 
1985/15, 1987/30, 1991/44, 1993/38 and 
1996/30, as that measure has proved particularly 
effective in the identification of diversion 
attempts. The Board invites all exporting 
countries to use the assessments of requirements 
of psychotropic substances, which are 
published48 by the Board on a regular basis, to 
verify the legitimacy of orders that have been 
placed.  
__________________ 
 48  Assessments are published each year in the technical 
report of the Board on psychotropic substances in 
accordance with relevant provisions of Economic and 
Social Council resolutions. Monthly updates can be 
found on the website of the Board (www.incb.org). 
  Recommendation 7: In accordance with 
Economic and Social Council resolutions 
1985/15 and 1987/30, Governments should, in 
their annual statistical reports on psychotropic 
substances, provide the Board with details of 
trade in substances in Schedules III and IV of the 
1971 Convention. Such details should include the 
identification of countries of origin for imports 
and countries of destination for exports. The 
Board encourages the Governments concerned to 
improve their data collection systems to ensure 
the submission of details of trade in their annual 
statistical reports. 
  Recommendation 8: The Board notes that 
while the majority of Governments have 
responded adequately to its requests to provide 
information regarding progress made in drug 
control following the Board’s missions to their 
countries, a number of Governments have failed 
to provide such information. The Board 
underlines the importance of reviewing such 
progress and requests the cooperation of 
Governments in this exercise.  
  Recommendation 9: Drug injection rooms 
(sometimes called “drug consumption rooms”) 
continue to operate in a small number of 
countries, mainly in Europe. The Board reiterates 
its position that, insofar as they are facilities 
where persons can abuse with impunity drugs 
acquired on the illicit market, such rooms 
contravene the most fundamental principle of the 
international drug control treaties: drugs should 
be used only for medical or scientific purposes. 
The Board urges the Governments of all countries 
where drug injection rooms are in operation to 
take prompt action to close those facilities and to 
provide appropriate services and facilities for the 
treatment of drug abusers, in accordance with the 
provisions of the international drug control 
treaties. 
  Recommendation 10: The PEN Online 
system, an electronic system for the exchange of 
pre-export notifications for precursor chemicals, 
was officially launched by the Board in 
March 2006 to ensure the quick and more 
efficient exchange of data. The Board encourages 
all Governments to register for and use the new 
online system. 
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  Recommendation 11: Following its 
recommendation to Governments to estimate 
their licit requirements for precursor chemicals 
and to submit those estimates to it, the Board has 
published information on countries’ annual 
legitimate needs for those chemicals in its 
2006 report on the implementation of article 12 
of the 1988 Convention.49 The Board encourages 
competent authorities to inform it of any 
methodology that they have found useful in 
estimating their country’s needs. Governments 
are invited to review the published requirements, 
amend them if necessary and inform the Board of 
any required changes. The Board calls upon 
Governments that have not yet done so to furnish 
their estimated requirements for precursors.  
  Recommendation 12: Free trade zones are 
being created in various regions. Traffickers may 
attempt to use free trade zones and free ports to 
divert narcotic drugs, psychotropic substances 
and precursor chemicals into illicit channels. The 
Board requests all Governments concerned to 
apply control measures in free trade zones and in 
free ports that are no less stringent than in other 
parts of their territories, in accordance with their 
treaty obligations.  
  Recommendation 13: The Board prepared, 
in cooperation with the Laboratory and Scientific 
Section of UNODC, guidelines for the import and 
export of drug and precursor reference standards, 
for use by national drug testing or forensic 
laboratories and national competent authorities 
responsible for issuing import and export 
authorizations for drug and precursor reference 
standards. The guidelines shall help to optimize 
regulatory procedures and to facilitate imports 
and exports of reference standards. The Board 
calls upon national drug testing and forensic 
laboratories, as well as the competent national 
authorities responsible for issuing import and 
export authorizations for drug and precursor 
reference standards, to implement those 
guidelines, as appropriate. 
 
__________________ 
 49  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2006 …, annex IV. 
  Prevention of illicit drug trafficking and abuse  
 
649. One of the fundamental objectives of the 
international drug control treaties is to limit to 
legitimate purposes the production, manufacture, 
export, import and distribution of, trade in and use of 
controlled substances and to prevent their diversion 
and abuse.  
  Recommendation 14: Countries in various 
regions are affected by the illicit cultivation of 
cannabis plants. The Board recommends that the 
Governments concerned carry out, together with 
eradication activities, legitimate alternative 
development programmes. Governments may 
wish to seek information on the best practices in 
that regard from UNODC and Governments of 
countries with considerable experience in 
implementing such programmes.  
  Recommendation 15: In view of the 
increasing smuggling of drugs and precursor 
chemicals, particularly through Africa, the Board 
encourages all Governments concerned to support 
initiatives such as the provision of training in 
preventing drug trafficking and diversion of 
precursor chemicals in that region. 
  Recommendation 16: The Board is 
concerned about the increasing cocaine abuse in 
Europe. The Board is also concerned about the 
growing trafficking in and abuse of cocaine in 
Africa and Asia, where, traditionally, cocaine has 
not been a major problem. The Board urges the 
Governments concerned to take appropriate 
measures as necessary to reduce trafficking in 
and abuse of cocaine. 
  Recommendation 17: In many countries, the 
monitoring of drug abuse trends and patterns 
remains inadequate and, as a result, data on drug 
abuse in such countries are limited. The Board 
encourages Governments that have not yet done 
so to ensure that the extent of drug abuse in their 
countries is measured at regular intervals. 
  Recommendation 18: The diversion from 
domestic distribution channels and abuse of 
pharmaceutical preparations containing narcotic 
drugs and psychotropic substances pose problems 
in many countries. The Board urges the 
Governments concerned to develop programmes 
specifically aimed at preventing the abuse of such 
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preparations. The Board invites each Government 
to establish a mechanism for the systematic 
collection of data on the diversion and abuse of 
such preparations and to use the mechanism as a 
basis for taking appropriate countermeasures. The 
mechanism should ensure that, inter alia, 
feedback on seized pharmaceutical products is 
provided on a regular basis to the regulatory 
authorities. The mechanism should include 
surveys aimed at establishing the extent and types 
of drug abuse. 
  Recommendation 19: Increasing trafficking 
in and abuse of fentanyl and its analogues have 
been reported in North America and some 
countries in Europe. The Board calls upon all 
Governments to implement effective measures to 
prevent the diversion and abuse of 
pharmaceutical preparations containing fentanyl 
and the illicit manufacture of fentanyl and its 
analogues. The Board encourages Governments 
to ensure that forensic laboratories include 
analyses of fentanyl and its analogues in their 
programmes. Governments are obliged under the 
international drug control treaties to report the 
abuse and illicit manufacture of fentanyl and its 
analogues, as well as seizures of those substances 
to the Board and relevant international 
organizations. 
  Recommendation 20: The Board urges the 
Governments of countries where opioids such as 
buprenorphine and methadone are used for 
substitution treatment to take all necessary 
measures to prevent their diversion into illicit 
channels. Those measures include supervised 
consumption, application of appropriate 
conditions for drugs to be taken home, treatment 
according to clinical standards, prescription 
monitoring systems and mandatory training of 
health-care professionals. The Board reiterates its 
request to the Governments concerned to 
establish a mechanism for the systematic 
collection of information on the diversion and 
abuse of drugs prescribed for substitution 
treatment, using, inter alia, statistics on 
emergencies related to drug abuse and statistics 
on drug-related deaths. 
  Recommendation 21: The Board welcomes 
the adoption of Commission on Narcotic Drugs 
resolution 49/6 entitled “Listing of ketamine as a 
controlled substance”, and calls upon all 
Governments to implement that resolution 
without delay. In particular, the Board encourages 
all Governments concerned to take steps to 
determine the extent of the abuse of ketamine 
and, where warranted, to introduce national 
legislation on the control of ketamine. 
Furthermore, the Board urges all Governments to 
provide to it, as well as to WHO, all available 
information on the abuse of ketamine in their 
countries, in order to assist the WHO Expert 
Committee on Drug Dependence, at its next 
meeting, in its assessment of whether to 
recommend placing ketamine under international 
control. 
  Recommendation 22: As controls over 
international trade in precursor chemicals 
improve, traffickers are increasingly developing 
new methods and routes of diversion, especially 
utilizing domestic distribution channels. The 
Board therefore urges all parties to the 
1988 Convention, in addition to international 
controls, in accordance with article 12, 
paragraph 8 (a), of the 1988 Convention, to take 
all the necessary measures to monitor, within 
their territories, the manufacture and distribution 
of precursor chemicals under international 
control. 
  Recommendation 23: West Asia is 
increasingly being used by criminal networks as a 
trans-shipment area for consignments of 
ephedrine and pseudoephedrine destined for the 
illicit manufacture of methamphetamine. The 
Board urges the Governments of importing 
countries in the region, including within the 
framework of the Subcommission on Illicit Drug 
Traffic and Related Matters in the Near and 
Middle East, to take appropriate measures to 
monitor the manufacture, distribution and export 
of preparations of ephedrine and pseudo-
ephedrine, in order to ensure that the end-users 
are legitimate and to prevent the accumulation of 
those substances in quantities exceeding their 
licit requirements. The Board recommends that 
all Governments adopt specific measures, in 
particular the use of pre-export notifications for 
pharmaceutical preparations, as well as the 
assessment of their licit requirements for 
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ephedrine, pseudoephedrine and preparations 
containing the two substances. 
  Recommendation 24: Within the framework 
of Project Prism, the Board has assisted national 
authorities in monitoring thousands of shipments 
in international trade and, in numerous cases, in 
preventing the diversion of precursor chemicals 
into illicit channels. The Board encourages 
Governments that are currently not participating 
in Project Prism to join that initiative and begin 
cooperating with the participating Government 
without further delay. 
  Recommendation 25: With regard to Project 
Cohesion, the Board calls on participating 
Governments to expand their activities under the 
project by considering the launch of activities 
targeting drug trafficking in the relevant regions, 
such as Operation Trans-shipment. The Board 
wishes to encourage the authorities of countries 
in the Americas to devise similar activities to 
address trafficking in potassium permanganate. In 
particular, the authorities of Colombia and its 
neighbouring countries should urgently launch 
investigations to identify the sources and routes 
from, or along which, the substance is being 
smuggled into areas where the illicit manufacture 
of cocaine takes place. 
  Recommendation 26: The Board notes with 
appreciation the establishment by WHO of the 
International Medical Products Anti-
Counterfeiting Taskforce (IMPACT). The Board 
calls upon all Governments to cooperate closely 
with, and provide all the necessary support to, 
IMPACT and WHO, in the fight against the 
counterfeiting of medicines, including medicines 
containing narcotic drugs and psychotropic 
substances. The Board also encourages competent 
national authorities to make full use of the 
“Guidelines for the development of measures to 
combat counterfeit drugs”50 prepared by WHO in 
1999 in order to assist Governments in their 
efforts to prevent their national drug distribution 
channels from being infiltrated by counterfeit 
drugs (see para. 38 (h) above).  
 
__________________ 
 50  WHO/EDM/QSM/99.1. 
  Availability and rational use of narcotic drugs 
and psychotropic substances for medical 
purposes 
 
650. Another core objective of the international drug 
control treaties is to ensure the availability of narcotic 
drugs and psychotropic substances for medical 
purposes and to promote the rational use of controlled 
drugs. 
  Recommendation 27: To ensure the 
appropriate medical use and availability of 
controlled substances, the Board again requests 
all Governments to promote the rational use of 
narcotic drugs and psychotropic substances for 
medical purposes, including the use of opioids for 
the treatment of pain, in accordance with the 
pertinent recommendations of WHO. 
  Recommendation 28: The education and 
training of health-care professionals and, as 
appropriate, professionals in legal and regulatory 
disciplines, as well as social and behavioural 
sciences, play an important role in promoting the 
rational use of narcotic drugs and psychotropic 
substances. The Board encourages all 
Governments to ensure that the rational use of 
narcotic drugs and psychotropic substances for 
medical purposes and the risks associated with 
drug abuse are included as subjects in university 
curricula for health-care professionals and other 
professionals. 
  Recommendation 29: In accordance with 
Commission on Narcotics Drugs resolutions 45/5 
and 46/6, the Board calls on all Governments that 
have not yet done so to inform it without delay of 
restrictions on travellers under medical treatment 
carrying preparations containing internationally 
controlled substances. The Board will ensure that 
the information is widely disseminated so that 
Governments will be able to advise travellers on 
the relevant restrictions. 
 
  The Internet and smuggling by mail 
 
651. In view of the global nature of the problems of 
illegal sales of controlled substances through the 
Internet and the smuggling of controlled substances by 
mail, concerted action by the international community 
is required. In particular, there is a need to establish a 
mechanism that will ensure the sharing of experiences 
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and the rapid exchange of information on specific 
cases, as well as the standardization of data. 
  Recommendation 30: The Board requests all 
Governments that have not yet done so to identify 
focal points for activities related to illegally 
operating Internet pharmacies and to furnish to 
the Board information on those activities. 
Furthermore, the Board calls upon all 
Governments to provide it with details of 
legislation and regulations on Internet services 
and sites and on the use of the mail for individual 
shipments of controlled drugs. 
 
 
 B. Recommendations to the United 
Nations Office on Drugs and Crime 
 
 
652. In the implementation of their treaty-based 
obligations, States may require operational support 
from the United Nations and other relevant 
organizations. Therefore, as UNODC is the primary 
United Nations entity responsible for the provision of 
technical assistance in drug control issues, as well as 
the coordination of such assistance provided by 
Governments and other organizations, the 
recommendations below are addressed to UNODC for 
appropriate action. 
  Recommendation 31: The Board notes that 
the control of licit activities related to narcotic 
drugs, psychotropic substances and precursors in 
a number of countries remains weak. The Board 
encourages UNODC to develop programmes 
aimed at increasing the capacity of the countries 
concerned to implement the relevant provisions 
of the treaties. 
  Recommendation 32: Noting the increase in 
the abuse of and trafficking in fentanyl and its 
analogues and concerned that many Governments 
are not in a position to counteract that problem in 
a timely manner, owing to, inter alia, inadequate 
laboratory analysis, the Board wishes to 
encourage UNODC to support Governments in 
their efforts to include the analyses of fentanyl 
and fentanyl analogues in the programmes of 
their forensic laboratories. (See also the 
corresponding request addressed to Governments 
in recommendation 19 above.) 
  Recommendation 33: Concerned about the 
continuing diversion of pharmaceutical 
preparations containing internationally controlled 
substances, the Board reiterates its request to 
UNODC to assist the Governments concerned in 
monitoring trends and preventing the diversion 
and abuse of such preparations. (See also the 
corresponding request addressed to Governments 
in recommendation 18 above.) 
  Recommendation 34: In view of information 
on the increasing trafficking in and abuse of 
GHB, a sedative-hypnotic added to Schedule IV 
of the 1971 Convention in 2001, the Board again 
requests UNODC to include the prevention of 
GHB abuse in its drug abuse prevention 
programmes. 
  Recommendation 35: Concerned that misuse 
of the mail or illegal use of the Internet have 
become important methods of obtaining drugs to 
supply illicit markets, the Board reiterates its 
request to UNODC to develop programmes to 
address the problem of illegally operating 
Internet pharmacies and the smuggling of 
controlled drugs by mail and to share its 
experiences with the Board. 
 
 
 C. Recommendations to the World Health 
Organization 
 
 
653. The treaty-based function of WHO in the 
international drug control system is to provide 
recommendations, based on scientific assessments, 
regarding changes in the scope of control of narcotic 
drugs under the 1961 Convention and the scope of 
control of psychotropic substances under the 
1971 Convention. Furthermore, WHO plays a key role 
in supporting the rational use of narcotic drugs and 
psychotropic substances worldwide and in giving 
guidance on the provision of adequate treatment for 
drug addicts. 
  Recommendation 36: The Board notes that 
in response to the invitation contained in the 
Economic and Social Council resolution 2004/40, 
WHO, in collaboration with UNODC, is 
developing guidelines for psychosocially assisted 
pharmacotherapy for the management of opioid 
dependence. The Board trusts that the guidelines 
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will remind all those involved in the provision of 
substitution treatment of their obligation to 
implement the provisions of the international 
drug control treaties and national legislation 
regarding opioids and that the guidelines will 
provide specific guidance on preventing the 
diversion of opioids used in pharmacotherapy.  
  Recommendation 37: The Board welcomes 
the establishment of the West African Drug 
Regulatory Agencies Network, the newly created 
subregional body of drug regulators, which is 
aimed at combating counterfeit and fake drugs. 
The Board calls upon IMPACT, the newly 
established task force of WHO, to extend 
cooperation to that body, as appropriate. 
  Recommendation 38: Noting the adoption 
by the Commission of Narcotic Drugs of 
resolution 49/6, entitled “Listing of ketamine as a 
controlled substance”, and the continuing 
widespread abuse of ketamine reported in many 
countries, the Board invites WHO to take the 
measures necessary to assess ketamine in order to 
determine whether to recommend that it be 
placed under international control. The Board is 
ready to assist the WHO Expert Committee on 
Drug Dependence at its next meeting in the 
assessment of ketamine. (See the corresponding 
request addressed to Governments in 
recommendation 21 above.) 
 
 
 D. Recommendations to other relevant 
international organizations 
 
 
654. In cases where States require additional 
operational support in specific areas, such as drug law 
enforcement, the Board addresses relevant 
recommendations pertaining to the specific spheres of 
competence of the relevant international organizations, 
including Interpol, the Universal Postal Union (UPU) 
and the World Customs Organization. 
  Recommendation 39: The Board welcomes 
the participation of Interpol and the World 
Customs Organization as members of the task 
forces of Project Prism and Project Cohesion. The 
Board recommends that those organizations 
continue to support activities under Project Prism 
to address the problem of trafficking in 
precursors of ATS and that they provide 
backstopping for and actively participate in law 
enforcement operations under Project Cohesion 
to address the continuing problem of the 
smuggling of acetic anhydride into Afghanistan.  
  Recommendation 40: Noting the increase in 
the clandestine manufacture of and trafficking in 
synthetic opioids, such as fentanyl, in some 
regions, the Board invites Interpol and the World 
Customs Organization to share with it any 
information they may have on such new 
developments. 
  Recommendation 41: The Board reiterates 
the need to address the problems of illegally 
operating Internet pharmacies and the smuggling 
of controlled drugs by mail and invites 
international organizations, in particular UPU, 
Interpol and the World Customs Organization, to 
share with it relevant experiences gained from 
any programmes they are implementing in this 
regard. (A similar request is addressed to 
UNODC in recommendation 35 above.) 
 
 
 (Signed) (Signed) 
 Philip O. Emafo Tatyana Borisovna Dmitrieva 
 President  Rapporteur 
 
(Signed) 
Koli Kouame 
Secretary 
 
 Vienna, 16 November 2006 
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Annex I 
 
 
  Regional groupings used in the report of the International 
Narcotics Control Board for 2006 
 
 
 The regional groupings used in the report of the International Narcotics 
Control Board for 2006, together with the States in each of those groupings, are 
listed below. 
Africa 
Algeria 
Angola 
Benin 
Botswana 
Burkina Faso 
Burundi 
Cameroon 
Cape Verde 
Central African Republic 
Chad 
Comoros 
Congo 
Côte d’Ivoire 
Democratic Republic of the Congo 
Djibouti 
Egypt 
Equatorial Guinea 
Eritrea 
Ethiopia 
Gabon 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya 
Lesotho 
Liberia  
Libyan Arab Jamahiriya 
Madagascar 
Malawi 
Mali 
Mauritania 
Mauritius 
Morocco 
Mozambique 
Namibia 
Niger 
Nigeria 
Rwanda 
Sao Tome and Principe 
Senegal 
Seychelles 
Sierra Leone 
Somalia 
South Africa 
Sudan 
Swaziland 
Togo 
Tunisia 
Uganda 
United Republic of Tanzania 
Zambia 
Zimbabwe 
Central America and the Caribbean 
Antigua and Barbuda 
Bahamas 
Barbados 
Belize 
Costa Rica 
Cuba 
Dominica 
Dominican Republic 
El Salvador 
Grenada 
Guatemala 
Haiti 
Honduras 
Jamaica 
Nicaragua 
Panama 
Saint Kitts and Nevis 
Saint Lucia 
Saint Vincent and the Grenadines 
Trinidad and Tobago 
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North America 
Canada 
Mexico 
 
United States of America 
South America 
Argentina 
Bolivia 
Brazil 
Chile 
Colombia 
Ecuador 
 
Guyana 
Paraguay 
Peru 
Suriname 
Uruguay 
Venezuela (Bolivarian Republic of) 
 
East and South-East Asia 
Brunei Darussalam 
Cambodia 
China 
Democratic People’s Republic of Korea 
Indonesia 
Japan 
Lao People’s Democratic Republic 
Malaysia 
 
Mongolia 
Myanmar 
Philippines 
Republic of Korea 
Singapore 
Thailand 
Timor-Leste 
Viet Nam 
 
South Asia 
Bangladesh 
Bhutan 
India 
 
Maldives 
Nepal 
Sri Lanka 
 
West Asia 
Afghanistan 
Armenia 
Azerbaijan 
Bahrain 
Georgia 
Iran (Islamic Republic of) 
Iraq 
Israel 
Jordan 
Kazakhstan 
Kuwait 
Kyrgyzstan 
 
Lebanon 
Oman 
Pakistan 
Qatar 
Saudi Arabia 
Syrian Arab Republic 
Tajikistan 
Turkey 
Turkmenistan 
United Arab Emirates 
Uzbekistan 
Yemen 
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Europe 
Albania 
Andorra 
Austria 
Belarus 
Belgium 
Bosnia and Herzegovina 
Bulgaria 
Croatia 
Cyprus 
Czech Republic 
Denmark 
Estonia 
Finland 
France 
Germany 
Greece 
Holy See 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Liechtenstein 
 
Lithuania 
Luxembourg 
Malta 
Moldova 
Monaco 
Montenegro 
Netherlands 
Norway 
Poland 
Portugal 
Romania 
Russian Federation 
San Marino 
Serbia 
Slovakia 
Slovenia 
Spain 
Sweden 
Switzerland 
The former Yugoslav Republic of 
  Macedonia 
Ukraine 
United Kingdom of Great Britain 
  and Northern Ireland 
 
Oceania 
Australia 
Cook Islands 
Fiji 
Kiribati 
Marshall Islands 
Micronesia (Federated States of) 
Nauru 
New Zealand 
 
Niue 
Palau 
Papua New Guinea 
Samoa 
Solomon Islands 
Tonga 
Tuvalu 
Vanuatu 
 
 
E/INCB/2006/1  
 
96 
Annex II 
 
 
  Current membership of the International Narcotics Control 
Board 
 
 
 
  Joseph Bediako Asare 
 
 
 Born in 1942. National of Ghana. Private 
Consultant and Psychiatrist. 
 Medical Academy of Krakow, Poland (1965-
1971); postgraduate training at Graylands and 
Swanbourne Psychiatric Hospitals, Perth, Australia 
(1976-1977); Leicestershire Area Health Authority 
(1977-1980). Senior Registrar in Psychiatry, West 
Berkshire and South Oxford Area Health Authority 
(1981-1982); Chief Psychiatrist, Ghana Health Service; 
and specialist in charge at Accra Psychiatric Hospital; 
Chairman, Ghana Chapter, West African College of 
Physicians; Vice-President, West African College of 
Physicians (2000-2004); Advisor to the Ministry of 
Health of Ghana (since 1984); Member of the 
Narcotics Control Board of Ghana (since 1990); 
Chairman, Subcommittee on Demand Reduction, 
Narcotics Control Board of Ghana (since 1991). Part-
time lecturer in psychiatry, University of Ghana 
medical school (since 1984). Faculty Fellow of the 
International Council on Alcohol and Addictions 
training programme on alcohol and drug abuse in 
Benin City, Nigeria (1986 and 1987); President, 
Psychiatric Association of Ghana (1999-2002). 
Member, Royal College of Psychiatrists (1980); 
Fellow, West African College of Psychiatrists; Fellow, 
Ghana College of Physicians and Surgeons. Author of 
numerous works, including: Substance Abuse in 
Ghana; The Problem of Drug Abuse in Ghana: a Guide 
to Parents and Youth (1989); Alcohol Use, Sale and 
Production in Ghana: a Health Perspective (1999); 
Alcohol and Tobacco Abuse in Deheer (1997); 
“Psychiatric co-morbidity of drug abuse”, Assessing 
Standards of Drug Abuse (1993); “Baseline survey of 
the relationship between HIV and substance abuse in 
Ghana” (2004). Recipient of the Grand Medal (Civil 
Division) of Ghana (1997). Participant in numerous 
meetings, including: consultative group that developed 
the manual on assessment standards of care in drug 
abuse treatment (1990-1992); NGO World Forum on 
Drug Demand Reduction, Bangkok (1994); drug 
programme expert meeting, Cleveland, United States 
of America (1995); Drug Expert Forum for Western 
and Central Africa, Cameroon (1995); local expert 
meeting for Western Africa, Dakar (2003). 
 Member of the International Narcotics Control 
Board (since 2005). Member of the Standing 
Committee on Estimates (2006). 
 
 
  Sevil Atasoy 
 
 
 Born in 1949. National of Turkey. Professor of 
Biochemistry and Forensic Science, Istanbul 
University (since 1988). 
 Bachelor of Science in Chemistry (1972), Master 
of Science in Biochemistry (1976) and Doctor of 
Philosophy (Ph.D.) in Biochemistry (1979), Istanbul 
University. Hubert H. Humphrey Fellow, United States 
Information Agency (1995-1996); German Academic 
Exchange Service (DAAD) Fellow (1976, 1978 and 
1994); European Molecular Biology Organization 
Fellow (1985); North Atlantic Treaty Organization 
Fellow (1978). Expert witness in civil and criminal 
courts (since 1980). Director, Institute of Forensic 
Science, Istanbul University (1988-2005). Director, 
Department of Narcotics and Toxicology, Ministry of 
Justice of Turkey (1980-1993). Chairperson, 
Department of Forensic Basic Sciences, Istanbul 
University (1983-1987); Professor of Biochemistry, 
Cerrahpasa School of Medicine, Istanbul University 
(1988-2005); Educational Counsellor, Turkish 
International Academy against Drugs and Organized 
Crime (2000-2005). Guest scientist, School of Public 
Health, University of California, Berkeley, and Drug 
Abuse Research Center, University of California, 
Los Angeles; Department of Genetics, Stanford 
University; Department of Genetics, Emory University; 
California Criminalistics Institute; Federal Bureau of 
Investigation, Virginia; Crime Laboratories, 
Los Angeles Sheriff’s Department; Federal Criminal 
Police (BKA), Wiesbaden, Germany; United Nations 
Drug Laboratory, Vienna; Ludwig-Maximilian 
University; Munich Institute for Physical Biochemistry 
and Institute of Legal Medicine; Center of Human 
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Genetics, Bremen University; Institute of Legal 
Medicine, Muenster University. Recipient of numerous 
awards, including: Rotary International (1993 and 
2001), for the improvement of investigative techniques 
in Turkey. Chairperson, first Regional Symposium on 
Criminalistics (2000); and Chairperson, third European 
Academy of Forensic Science Meeting (2003). 
Member of the Istanbul University Senate (1987-2005) 
and Research Foundation (1987-2002); Member of the 
Experts Group on Technical Challenges to the Drug 
Community, United Nations Office on Drugs and 
Crime (UNODC) and Office of National Drug Control 
Policy of the United States (2003 and 2004); Member 
of the expert group on risk reduction linked to 
substance use other than by injection, Pompidou Group 
of the Council of Europe (2002); Member of the 
Mediterranean Network of the Pompidou Group (since 
2001). Member of the Turkish delegation to the 
Commission of Narcotic Drugs (2001 and 2002); the 
special commissions on the improvement of judiciary 
and security affairs, Prime Ministry, VIII. 
Development Plan for the Years 2001-2005, the 
Republic of Turkey Higher Commission on Human 
Rights (1997-1998). Adviser on improving 
investigations and protecting child victims, General 
Command of Gendarmerie Internal Security Units 
(2001-2003); adviser on prevention of violence, suicide 
and drug abuse, Land Forces Command (2000-2004); 
adviser on driving under influence of controlled 
substances, Traffic Accidents Prevention Commission, 
Turkish Grand National Assembly (2000); adviser on 
preventing drug abuse and violence in schools, 
Ministry of National Education (since 1999); adviser 
on drug testing and the improvement of treatment of 
offenders, General Directorate of Correctional 
Facilities, Ministry of Justice (since 1999). Founding 
editor, Turkish Journal of Legal Medicine (1982-1993). 
Member of the scientific board of national and 
international journals, including the International 
Criminal Justice Review, the Turkish Journal on 
Addiction, the Turkish Journal of Forensic Sciences 
and the Croatian Journal of Legal Medicine. Founding 
President, Turkish Society of Forensic Sciences (since 
1998); Honorary Member of the Mediterranean 
Academy of Forensic Sciences (since 2003); Member 
of the Standing Committee, European Academy of 
Forensic Sciences (1999-2003). Member of the 
International Society of Forensic Toxicology; the Indo-
Pacific Association of Law, Medicine and Science; the 
European Network of Forensic Science Institutes; the 
International Association of Forensic Toxicologists; the 
American Academy of Forensic Sciences; the 
American Society of Crime Laboratory Directors; the 
Forensic Science Society, United Kingdom of Great 
Britain and Northern Ireland; the American Society of 
Criminology; the Interagency Council on Child Abuse 
and Neglect; and the United Nations Academic 
Council. Participant in projects on illicit drug issues, 
including: Crime Mapping of Drug Offences for the 
Ministry of Home Affairs (1998-2000); Global Study 
of Illicit Drug Markets: Istanbul, Turkey, for the United 
Nations Interregional Crime and Justice Research 
Institute (2000-2001); National Assessment of Nature 
and Extent of Drug Problems in Turkey, for UNODC 
(2002-2003); European School Survey on Alcohol and 
Other Drugs (2002-2003); Modeling the World Heroin 
Market, for the RAND Drug Policy Research Center 
and the Max Planck Institute (2003). Author of over 
130 scientific papers, including papers on drug testing, 
drug chemistry, drug markets, drug-related and drug-
induced crime, drug abuse prevention, clinical and 
forensic toxicology, neuropharmacology, crime scene 
investigation and deoxyribonucleic acid (DNA) 
analysis, including “Excavating Y-chromosome 
haplotype strata in Anatolia”, Human Genetics (2004); 
“DNA fingerprinting of cannabis sativa, accessions 
using RAPD and AFLP markers”, Forensic Science 
International (2003); “H. gamma-vinyl-GABA 
potentiates the severity of naloxone-precipitated 
abstinence signs in morphine-dependent rats”, 
Pharmacological Research (1998). 
 Member of the International Narcotics Control 
Board (since 2005). Member of the Committee on 
Finance and Administration (2006). Second Vice-
President of the Board (2006). Chairman of the 
Standing Committee on Estimates (2006). 
 
 
  Madan Mohan Bhatnagar 
 
 
 Born in 1934. National of India. Various senior 
positions in narcotics control and administration in the 
Government of India (since 1972). Member of the 
Delhi High Court Bar Association (since 1993). 
 Bachelor of Law (1956) and Master of Arts in 
Political Science (1955), Patna University, India. 
Deputy Narcotics Commissioner (1972-1974). Officer 
on Special Duty (Narcotics) (1976-1979). Narcotics 
Commissioner of India (1979-1985). Director-General, 
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Narcotics Control Bureau, Government of India (1988-
1990). Member (Anti-Smuggling and Narcotics) of the 
Central Board of Excise and Customs and Additional 
Secretary to the Government of India (1990-1992). 
Author of numerous publications, including: “Current 
national laws and policies on narcotics control in 
India”, Current Research on Drug Abuse in India, All 
India Institute of Medical Sciences Research Book; 
“Drug trafficking: Indian perspective”, Narcontrol, 
Journal of Narcotics Control Bureau of India. Drafter 
of the provisions of the Narcotic Drugs and 
Psychotropic Substances Act of India (1985). Drafter 
of the licit opium production and export policy for 
India and the national strategy for combating the illicit 
traffic in drugs for India. Member of the expert group 
to study the modification of the Single Convention on 
Narcotic Drugs of 1961, Vienna (1982). Chairman of 
several international conferences on drug control, inter 
alia, the Tenth Meeting of Heads of National Drug Law 
Enforcement Agencies (HONLEA), Asia and the 
Pacific (1983), the Indo-Pakistan Committee meeting 
against drug trafficking (1989) and the South Asian 
Association for Regional Cooperation meeting on 
harmonization of drug laws (1989). First Vice-
Chairman, Second Interregional Meeting of Heads of 
National Drug Law Enforcement Agencies, Vienna 
(1989). Participant in the Indo-United States bilateral 
talks on narcotics, Washington, D.C. (1989). 
Participant in the seventeenth special session of the 
General Assembly (1990). Member of the 
intergovernmental expert group on the economic and 
social consequences of drug abuse and illicit 
trafficking, Vienna (1990). Expert and Vice-Chairman, 
Economic and Social Commission for Asia and the 
Pacific (ESCAP) regional seminar on drug abuse, 
Manila (1990). Head of the Indian delegation to the 
Commission on Narcotic Drugs (1990 and 1992), 
several meetings of HONLEA and the Subcommission 
on Illicit Drug Traffic and Related Matters in the Near 
and Middle East. Vice-Chairman, Commission on 
Narcotic Drugs (1992).  
 Member of the International Narcotics Control 
Board (since 2002). Member of the Standing 
Committee on Estimates (since 2002). Rapporteur of 
the Board (2003). First Vice-President of the Board 
(2004). Member of the Committee on Finance and 
Administration (since 2004). Vice-Chairman of the 
Standing Committee on Estimates (2005). Chairman of 
the Committee on Finance and Administration (2002 
and 2006). 
 
 
  Elisaldo Luiz de Araújo Carlini 
 
 
 Born in 1930. National of Brazil. Full Professor 
of Psychopharmacology, Federal University of 
São Paolo (since 1978); Director, Brazilian Centre for 
Information on Psychotropic Drugs (since 1988). 
 Master of Science, Yale University, United States 
(1962). Founder and President of the Latin American 
Society of Psychobiology (1971-1973). Member and 
Founder of the Academy of Sciences of the State of 
São Paulo (1976). President, Brazilian Society of 
Medication Vigilance (1991-1993). National Secretary, 
Sanitary Surveillance, Ministry of Health of Brazil 
(1995-1997). Member of the World Health 
Organization (WHO) Expert Advisory Panel on Drug 
Dependence and Alcohol Problems, Geneva (1997-
1998 and since 2002). Member of the Brazilian 
Academy of Sciences (2003). Recipient of numerous 
honours and awards, including: Councillor Emeritus, 
Federal Council of Narcotics of Brazil (1987); 
Honorary President, XI Symposium on Brazilian 
Medicinal Plants, João Pessoa, Brazil (1990); Member 
Emeritus, Department of Biological Psychiatry, 
Brazilian Association of Psychiatry (1993). “Doctor of 
the Year”, Brazilian Chapter of the Medical Society of 
Israel (1993). “Personality of the Year”, Brazilian 
Association of Pharmachemical Industries (1996); 
Medal of “Grand Officer” of the Order of Rio Branco, 
Presidency of the Republic of Brazil (1996); Grand 
Cross Class of the Order of Scientific Merit, 
Presidency of the Republic of Brazil (2000); Doctor 
honoris causa, Federal University of Rio Grande do 
Norte, Brazil (2002). Author of more than 
310 publications, including: “Use of anorectic 
amphetamine-like drugs by Brazilian women”, Eating 
Behaviors (2002); “Plants and the central nervous 
system” (2003); “National Survey on Drug 
Consumption by Brazilian Students” (2004). 
 Member of the International Narcotics Control 
Board (since 2002).  
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  Tatyana Borisovna Dmitrieva 
 
 
 Born in 1951. National of the Russian Federation. 
Director, V. P. Serbsky State Research Centre for 
Social and Forensic Psychiatry (since 1998). Chief 
Expert Psychiatrist, Ministry of Health and Social 
Development of the Russian Federation (2005). 
 Graduate of the Ivanovskii State Medical Institute 
(1975). Master of Science (1981) and Doctor of 
Medical Sciences (M.D.) (1990). Professor of 
Medicine (since 1993). Head of the Department of 
Psychiatry (1986-1989), Deputy Director of Research 
(1989-1990) and Director (1990-1996), V. P. Serbsky 
State Research Centre for Social and Forensic 
Psychiatry. Minister of Health of the Russian 
Federation (1996-1998). Chairman, Russian Security 
Council Commission on Health Protection (1996-
2000).  
 Member of the Presidium of the Russian 
Academy of Medical Sciences (since 2001); Vice-
Chairman, Russian Society of Psychiatrists (since 
1995); Vice-President, World Association for Social 
Psychiatry Academician; Corresponding Member of 
the Russian Academy of Medical Sciences (since 
1997); Member of the Russian Academy of Medical 
Sciences (since 1999). Author of over 350 scientific 
works, recipient of five authors’ certificates for 
inventions and author of three books on drug abuse 
therapy, including Abuse of Psychoactive Substances 
(General and Forensic Psychiatric Practice) (2000) 
and Abuse of Psychoactive Substances: Clinical and 
Legal Aspects (2003). Editor-in-Chief, Russian 
Psychiatric Journal. Editor-in-Chief, Clinical Research 
on Medication in Russia. Member of the editorial 
boards of several Russian and foreign medical journals, 
including the journal Narcology. Member of the 
editorial council, International Medical Journal; and 
member of the editorial council, Siberian Journal of 
Psychiatry and Narcology. Recipient of the Order for 
Services to the Country, fourth class (2001) and third 
class (2006); the Order of Honour (1995). Participant 
and speaker on psychiatry and drug abuse therapy at 
national and international congresses and conferences, 
including those organized by the World Health 
Organization (WHO), the European Union, the Council 
of Europe, the World Psychiatric Congress and the 
World Psychiatric Association. 
 Member of the International Narcotics Control 
Board (since 2005). Rapporteur of the Board (2006). 
Member of the Standing Committee on Estimates 
(2006). 
 
 
  Philip Onagwele Emafo 
 
 
 Born in 1936. National of Nigeria. 
 Lecturer, Biochemistry, University of Ibadan 
(1969-1971). Lecturer and Senior Lecturer, 
Pharmaceutical Microbiology and Biochemistry, 
University of Benin, Nigeria (1971-1977). Chief 
Pharmacist and Director, Pharmaceutical Services, 
Federal Ministry of Health of Nigeria (1977-1988). 
Chairman, Pharmacists Board of Nigeria (1977-1988). 
Member of the WHO Expert Advisory Panel on the 
International Pharmacopoeia and Pharmaceutical 
Preparations (1979-2003). Rapporteur-General, 
International Conference on Drug Abuse and Illicit 
Trafficking, Vienna (1987). Chairman, Commission on 
Narcotic Drugs at its tenth special session (1988). 
Member of the Secretary-General’s Group of Experts 
on the United Nations Structure for Drug Abuse 
Control (1990). Member of the WHO Expert 
Committee on Drug Dependence (1992, 1994 and 
1998). Consultant to the United Nations International 
Drug Control Programme (1993-1995). Member of the 
ad hoc intergovernmental advisory group established 
by the Commission on Narcotic Drugs to assess 
strengths and weaknesses of global drug control efforts 
(1994). Member of the expert group convened by the 
Secretary-General pursuant to Economic and Social 
Council resolution 1997/37 to review the 
United Nations machinery for drug control (1997-
1998). Member of the Advisory Group of the 
International Narcotics Control Board to review 
substances for control under article 12 of the United 
Nations Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988 (1998-
1999). Consultant to the Organization of African Unity, 
Addis Ababa (1998-1999). 
 Member of the International Narcotics Control 
Board (since 2000). Member of the Standing 
Committee on Estimates (2000-2004). Rapporteur of 
the Board (2001). First Vice-President of the Board 
(2005). President of the Board (2002, 2003 and 2006). 
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  Gilberto Gerra 
 
 
 Born in 1956. National of Italy. Coordinator of 
the Centre for Studies on Drug Addiction, Drug 
Addiction Service, Health Department of Parma, Italy. 
University lecturer (master’s degree in neurology) on 
psychopharmacology, University of Parma. Recipient 
of a university degree in medicine (1981), a master’s 
degree in internal medicine (1986) and a master’s 
degree in endocrinology (1989). 
 Medical doctor at outpatient Drug Addiction 
Service, Health Department, Parma (1987-1994); head 
of Drug Addiction Service, Health Department, Parma 
(1995-2001). University lecturer (master’s degree in 
internal medicine and physical therapy), University of 
Parma (1990-1996). Researcher of drug-related issues 
at the University of Parma and other universities in 
Italy and the United States (New York State Psychiatric 
Institute, Columbia University) (1994, 1996 and 2001); 
participant in a research project supported by the 
National Institute on Drug Abuse Invest Programme 
(1996); coordinator of the Regional Committee for 
Addiction Research of the Emilia Romagna region 
(1995-2001); research collaboration with the Istituto 
Superiore de Sanità, Rome (1998-2000); consultant to 
the Ministry of the Interior for research on substance 
abuse (1996-1997); consultant to the United Nations 
International Drug Control Programme on 
amphetamine derivatives (1996-1999); consultant to 
the Department of Social Affairs on pharmacological 
and clinical aspects of substance abuse (1998-2000); 
expert for the National Plan of Information for Drug 
Prevention (Presidency of Ministries Consilium) 
(1999); lecturer at several universities in Italy on 
neurobiology of substance abuse (1998-2005). 
Consultant to the National Department on Drug Policy 
in the field of neurobiology of addiction, 
pharmacology and prevention (2003-2005). Member of 
the National Scientific Committee for Health 
Education and Prevention of Substance Abuse of the 
Ministry of Education of Italy (1997-2001); member of 
the expert group of the Ministry of the Interior 
(European Information on Drugs and Drug Addiction 
(Reitox) focal point) to prepare the national report on 
substance abuse for the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) (1998); 
member of the International Society of 
Psychoneuroendocrinology; member of the College on 
Problems of Drug Dependence (2002-2006); member 
of the Board of the Italian Society on Drug Addiction 
(2005-2006); member of the Scientific Board of the 
international journal Heroin Addiction and Related 
Clinical Problems; member of the Scientific Board of 
the Bollettino per le Farmacodipendenze e 
l’Alcoolismo (Italian Journal on drug addiction and 
alcoholism), published by the Ministry of Health of 
Italy, in collaboration with the United Nations 
Interregional Crime and Justice Research Institute. 
Consultant (seconded) at the National department on 
drug policy, in addiction neurobiology, clinical 
pharmacology and prevention, Rome (2003-2006) 
published by the Ministry of Health of Italy, in 
collaboration with the United Nations Interregional 
Crime and Justice Research Institute. Co-author of the 
Italian Ministry of Interior of the national report on 
drug abuse for EMCDDA; referee of nine international 
journals on substance abuse and psychiatry; 
contributed to over 50 publications in scientific 
medical journals (1994-2006), including “Aggressive 
responding in abstinent heroin addicts: neuroendocrine 
and personality correlates”, Progress in Psycho-
Neuropharmacology and Biology (2004); “Substance 
use among high-school students: relationship with 
temperament, personality traits and parental care 
perception”, Substance Use and Misuse (2004); “Long-
term methadone maintenance effectiveness: 
psychosocial and pharmacological variables”, Journal 
of Substance Abuse Treatment (2003); “Effects of 
ecstacy on dopamine system function in humans”, 
Behavioural Brain Research (2002); “Intravenous 
flumazemil versus oxazepam tapering in the treatment 
of benzodiazepine withdrawal: a randomized placebo-
controlled study”, Addiction Biology (2002). Speaker 
at the United Nations International Drug Control 
Programme expert meeting on amphetamine-type 
stimulants, Vienna (1996); speaker at the North 
Atlantic Treaty Organization Advanced Study Institute 
conference on the biosocial bases of violence, Rhodes, 
Greece (1996); participant at the National Institute on 
Drug Abuse consensus conference concerning 
detoxification with alpha-2-agonists, clonidine and 
lofexidine, Bethesda, Maryland, United States (1998); 
participant at the annual meeting of the International 
Society of Psychoneuroendocrinology, Pisa, Italy 
(2003); speaker at the United Nations Office on Drugs 
and Crime meeting on young people and drug abuse: 
prevention and treatment, Stockholm (2003); expert at 
the EMCDDA meeting on targeted prevention, family 
prevention and community prevention, Lisbon (2003); 
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speaker at an Andean Parliament meeting on anti-drug 
policies, Guayaquil, Ecuador (2003); speaker at a 
meeting organized by EMCDDA and the European 
Parliament on drug use among young people, Malaga, 
Spain (2003). Speaker at the meeting of the European 
Association of Addiction Therapy, London (2006). 
Speaker at the congress of the European Opiate 
Addiction Treatment Association, Bratislava (2006). 
 Member of the International Narcotics Control 
Board (since 2004). Member of the Standing 
Committee on Estimates (2004). Member of the 
Committee on Finance and Administration (2004). 
Chairman of the Committee on Finance and 
Administration (2005). 
 
 
  Hamid Ghodse 
 
 
 Born in 1938. National of the Islamic Republic of 
Iran. Professor of Psychiatry and of International Drug 
Policy, University of London (since 1987). Director, 
International Centre for Drug Policy, St. George’s 
University of London (since 2003); Medical Director, 
National Clinical Excellence Awards (2006); President, 
European Collaborating Centres for Addiction Studies 
(since 1992); Member of the Executive Committee of 
the Federation of Clinical Professors, United Kingdom 
(since 1994); Member of the Scientific Committee on 
Tobacco and Health, United Kingdom (since 2000); 
Director of the Board of International Affairs and 
Member of the Council, Royal College of Psychiatrists 
(since 2000); Non-Executive Director, National 
Clinical Assessment Authority of England and 
subsequently patients safety agency (since 2001); 
Chairman, Higher Degrees in Psychiatry, University of 
London (since 2003); Member of the Medical Studies 
Committee, University of London (since 2003). 
 Recipient of the following degrees: Doctor of 
Medicine (M.D.), Islamic Republic of Iran (1965); 
Diploma Psychological Medicine, United Kingdom 
(1974); Doctor of Philosophy (Ph.D.), University of 
London (1976); and Doctor of Science (D.S.G.), 
University of London (2002). Fellow of the Royal 
College of Psychiatrists (F.R.C.Psych.), United 
Kingdom (1985); Fellow of the Royal College of 
Physicians (F.R.C.P), London (1992); Fellow of the 
Royal College of Physicians of Edinburgh (F.R.C.P.E.), 
Edinburgh (1997); Fellow of the Faculty of Public 
Health Medicine (F.F.P.H.), United Kingdom (1997). 
Member of the WHO Expert Advisory Panel on 
Alcohol and Drug Dependence (since 1979); Adviser, 
Joint Formulary Committee, British National 
Formulary (since 1984); Honorary Consultant 
Psychiatrist, St. George’s and Springfield University 
Hospitals, London (since 1978); Honorary Consultant 
Public Health, Wandsworth Primary Care Trust (since 
1997); Director, Regional Drug Dependence Treatment 
Training and Research Unit, London (1987-1993); 
Director of the Education and Training Unit and of the 
Research, Evaluation and Monitoring Unit and 
Chairman of the Department of Addictive Behaviour 
and Psychological Medicine, St. George’s Hospital 
Medical School, University of London, and Joint 
Faculty of Health Sciences, Kingston University 
(1987-2003). Consultant Psychiatrist, St. Thomas’s 
Teaching Hospital and Medical School, London (1978-
1987); member, rapporteur, chairman and convener of 
various WHO and European Community expert 
committees, review groups and other working groups 
on drug and alcohol dependence; M. S. McLeod 
Visiting Professor, Southern Australia (1990); 
Honorary Professor, Peking University (since 1997). 
Visiting Professor, Keele University, United Kingdom 
(since 2002). Author or editor of over 300 scientific 
books and papers on drug-related issues and 
addictions, including the following books: The Misuse 
of Psychotropic Drugs, London (1981); Psychoactive 
Drugs and Health Problems, Helsinki (1987); 
Psychoactive Drugs: Improving Prescribing Practices, 
Geneva (1988); Substance Abuse and Dependence, 
Guildford (1990); Drug Misuse and Dependence: the 
British and Dutch Response, Lancashire, United 
Kingdom (1990); Misuse of Drugs (3rd ed.), London 
(1997); Drugs and Addictive Behaviour: a Guide to 
Treatment (3rd ed.), Cambridge (2002); Young People 
and Substance Misuse, London (2004). Addiction at 
Workplace, Aldershot (2005). Editor-in-Chief, 
International Psychiatry (since 2002); Editor, 
Substance Misuse Bulletin; Member of the Editorial 
Board, International Journal of Social Psychiatry. 
Convener of WHO expert groups on medical education 
(1986), pharmacy education (1987), nurse education 
(1989) and rational prescribing of psychoactive drugs. 
Member of the British Medical Association (since 
1995); Member of the Executive Board, Medical 
Council on Alcoholism (since 1997); Honorary 
Secretary/Chairman, Association of Professors of 
Psychiatry of the British Isles (since 1991); Chairman, 
Association of European Professors of Psychiatry; 
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Director, National Programme on Substance Abuse 
Deaths (since 1997); Member of the International 
Association of Epidemiology (since 1998); Member of 
the Institute for Learning and Training in Higher 
Education (since 2001). 
 Member of the International Narcotics Control 
Board (since 1992). Member of the Standing 
Committee on Estimates (1992). President of the Board 
(1993, 1994, 1997, 1998, 2000, 2001, 2004 and 2005). 
 
 
  Melvyn Levitsky 
 
 
 Born in 1938. National of the United States. 
Retired Ambassador in the United States Foreign 
Service. Lecturer in Public Policy and International 
Relations and Senior Fellow, International Policy 
Center, Gerald R. Ford School of Public Policy, 
University of Michigan.  
 United States diplomat for 35 years, serving as, 
inter alia, Deputy Assistant Secretary of State for 
Human Rights and Humanitarian Affairs, United States 
Department of State (1982-1983); Deputy Director, 
Voice of America (1983-1984); Ambassador of the 
United States to Bulgaria (1984-1987); Executive 
Secretary and Special Assistant to the Secretary of the 
United States Department of State (1987-1989); 
Assistant Secretary of State for International Narcotics 
Matters (1989-1993); and Ambassador of the United 
States to Brazil (1994-1998). Consul, United States 
consulates in Frankfurt, Germany (1963-1965) and 
Belem, Brazil (1965-1967). Political officer, United 
States Embassy in Moscow (1973-1975). Officer-in-
charge for bilateral relations, Office of Soviet Union 
Affairs (1975-1978), and Director, Office of United 
Nations Political Affairs (1980-1982), United States 
Department of State. Professor of International 
Relations and Public Administration, Maxwell School 
of Citizenship and Public Affairs, Syracuse University 
(1998-2006). Recipient of several United States 
Department of State Meritorious and Superior Honor 
Awards, Presidential Meritorious Service Awards and 
the United States Secretary of State’s Distinguished 
Service Award. Member of the Washington Institute of 
Foreign Affairs, the American Academy of Diplomacy, 
the American Foreign Service Association. Member of 
the Advisory Board, Drug Free America Foundation. 
Member of the Institute on Global Drug Policy. 
Member of the Board, Global Panel of the Prague 
Society. Member, Public-Private Working Group on 
Sale of Controlled Substances via the Internet (Harvard 
University Law School). Distinguished Fellow, Daniel 
Patrick Moynihan Institute of Global Affairs, Maxwell 
School of Citizenship and Public Affairs, Syracuse 
University. Member of the University of Michigan 
Substance Abuse Research Center. 
 Member of the International Narcotics Control 
Board (since 2003). Chairman of the Committee on 
Finance and Administration (2004); Chairman of the 
Working Group on Strategy and Priorities (2005). 
 
 
  Robert Jean Joseph Chrétien Lousberg 
 
 
 Born in 1941. National of the Netherlands. 
Former Head of the Netherlands regulatory office for 
narcotic drugs and psychotropic substances. Former 
associate and senior scientist, National Institute of 
Health, Bethesda, Maryland, United States. Senior 
scientist and lecturer, University of Utrecht, 
Netherlands. 
 Recipient of a doctoral degree, University of 
Utrecht (1969). Author of numerous articles published 
in international journals on pharmacologically active 
principles of opiate and cannabinoid origin. Co-
coordinator for the regulation of methadone 
programmes for the treatment of heroin addicts. 
National coordinator of the investigation of leuco-
encephalopathy among heroin addicts. Member of the 
delegation of the Netherlands at numerous sessions of 
the Commission on Narcotic Drugs. Member of 
International Narcotics Control Board expert groups on 
the preparation of article 12 of the 1988 Convention. 
Member of the delegation of the Netherlands at the 
United Nations Conference for the Adoption of a 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances (1988). Representative for 
European Union directives and regulations on 
article 12 of the 1988 Convention. Appointments by 
the Minister of Health of the Netherlands: member of 
the supervisory board of the national drug information 
and monitoring system and the board investigating the 
medical prescription of heroin for the treatment of 
heroin addicts; member of the supervisory board for 
the assessment and monitoring of drugs in the 
Netherlands; and member of the supervisory board of 
the national agency for national hemp production for 
scientific and medicinal purposes. Expert, assessment 
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of Macedonia carried out within the scope of the 
European Union-Phare licit drug control project. 
Representative at meetings for the assessment of new 
synthetic drugs by the Extended Scientific Committee 
of the European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon. Chairman, Pompidou 
Group/International Narcotics Control Board 
Conference on the Control of Psychotropic Substances 
in Europe. Chairman, WHO Working Group on 
Revised Guidelines for the WHO Review of 
Dependence-Producing Psychoactive Substances for 
International Control.  
 Member of the International Narcotics Control 
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on Finance and Administration (2003). Second Vice-
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neurochemistry and neuropharmacology, Laboratory of 
Preclinical Pharmacology, National Institute of Mental 
Health, Washington, D.C. (1978-1980). Recipient of a 
Master’s degree in Toxicology, University of Vienna 
(1998). Author of 85 articles published in the fields of 
drug addiction, neuropharmacology, clinical 
pharmacology and analytical chemistry. Co-Chairman, 
4th International Congress of Therapeutic Drug 
Monitoring and Clinical Toxicology, Vienna (1995). 
Member of the expert panel on designer drugs of the 
Ministry of Health of Austria and of the Drug Expert 
Forum of the City of Vienna (since 1997). Project 
leader of several scientific projects of the city of 
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committee of international scientific congresses on 
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analysis. Member of numerous national and 
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of the Committee on Finance and Administration 
(2004). Chairman of the Standing Committee on 
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 Born in 1963. National of Colombia. Medical 
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Clinic Fray Bartolomé de las Casas; consultant, 
National Drug Council. Numerous university teaching 
posts in forensics and clinical toxicology. 
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of Our Lady of the Rosary (1989); specialization in 
toxicology, School of Medicine, University of 
Buenos Aires (1990); specialization in occupational 
toxicology (1997), University Teacher’s Certificate 
(1998), diplomas in hospital management (1998) and 
social security administration (1999), University of 
Our Lady of the Rosary; diploma in toxicological 
emergencies, FUNDASALUD (1998); master in social 
services management, Alcala de Enares University 
(2002). Former forensic medical doctor, toxicologist, 
technical coordinator and manager in several hospitals 
and institutions. Scientific Director, Toxicology Clinic, 
Uribe Cualla; Toxicological Assessment Centre; 
Director, Clinical Toxicology, Fray Bartolomé de Las 
Casas Clinic (until 1991); Vice-President, Tropical 
Medicine Institute Corporation “Luis Patiño Camargo” 
(until 1992); Medical Coordinator and Director, 
Emergency National Plan (1993); Director, Health 
Services Management Programme, School of Public 
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Colombian Internal Medicine Association (1992); 
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International Congress of Toxicology, University of 
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professional conferences and seminars, including 
several meetings of the Latin American Congress of 
Toxicology; National Congress of Toxicology and 
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committees, including: the expert advisory group on 
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International Substance Abuse and Addiction 
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Narcotic Drugs (2003). Speaker of the National 
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(2005). 
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Board (since 2005). Member of the Standing 
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The role of the International Narcotics Control Board 
 
 
 The International Narcotics Control Board (INCB) is an independent and quasi-judicial control organ, 
established by treaty, for monitoring the implementation of the international drug control treaties. It had 
predecessors under the former drug control treaties as far back as the time of the League of Nations. 
 
Composition 
 
 INCB consists of 13 members who are elected by the Economic and Social Council and who serve in their 
personal capacity, not as government representatives (see annex II of the present publication for the current 
membership). Three members with medical, pharmacological or pharmaceutical experience are elected from a list 
of persons nominated by the World Health Organization (WHO) and 10 members are elected from a list of 
persons nominated by Governments. Members of the Board are persons who, by their competence, impartiality 
and disinterestedness, command general confidence. The Council, in consultation with INCB, makes all 
arrangements necessary to ensure the full technical independence of the Board in carrying out its functions. INCB 
has a secretariat that assists it in the exercise of its treaty-related functions. The INCB secretariat is an 
administrative entity of the United Nations Office on Drugs and Crime, but it reports solely to the Board on 
matters of substance. INCB closely collaborates with the Office in the framework of arrangements approved by 
the Council in its resolution 1991/48. INCB also cooperates with other international bodies concerned with drug 
control, including not only the Council and its Commission on Narcotic Drugs, but also the relevant specialized 
agencies of the United Nations, particularly WHO. It also cooperates with bodies outside the United Nations 
system, especially Interpol and the Customs Co-operation Council (also called the World Customs Organization). 
 
Functions 
 
 The functions of INCB are laid down in the following treaties: the Single Convention on Narcotic Drugs of 
1961 as amended by the 1972 Protocol; the Convention on Psychotropic Substances of 1971; and the United 
Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Broadly 
speaking, INCB deals with the following: 
 (a) As regards the licit manufacture of, trade in and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels does not occur. INCB also monitors Governments’ control 
over chemicals used in the illicit manufacture of drugs and assists them in preventing the diversion of those 
chemicals into the illicit traffic; 
 (b) As regards the illicit manufacture of, trafficking in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contributes to correcting such situations. INCB is also responsible 
for assessing chemicals used in the illicit manufacture of drugs, in order to determine whether they should be 
placed under international control. 
 In the discharge of its responsibilities, INCB: 
 (a) Administers a system of estimates for narcotic drugs and a voluntary assessment system for 
psychotropic substances and monitors licit activities involving drugs through a statistical returns system, with a 
view to assisting Governments in achieving, inter alia, a balance between supply and demand; 
 (b) Monitors and promotes measures taken by Governments to prevent the diversion of substances 
frequently used in the illicit manufacture of narcotic drugs and psychotropic substances and assesses such 
substances to determine whether there is a need for changes in the scope of control of Tables I and II of the 
1988 Convention; 
 (c) Analyses information provided by Governments, United Nations bodies, specialized agencies or other 
competent international organizations, with a view to ensuring that the provisions of the international drug 
control treaties are adequately carried out by Governments, and recommends remedial measures; 
 (d) Maintains a permanent dialogue with Governments to assist them in complying with their obligations 
under the international drug control treaties and, to that end, recommends, where appropriate, technical or 
financial assistance to be provided. 
 INCB is called upon to ask for explanations in the event of apparent violations of the treaties, to propose 
appropriate remedial measures to Governments that are not fully applying the provisions of the treaties or are 
encountering difficulties in applying them and, where necessary, to assist Governments in overcoming such 
difficulties. If, however, INCB notes that the measures necessary to remedy a serious situation have not been 
taken, it may call the matter to the attention of the parties concerned, the Commission on Narcotic Drugs and the 
Economic and Social Council. As a last resort, the treaties empower INCB to recommend to parties that they stop 
   
 
importing drugs from a defaulting country, exporting drugs to it or both. In all cases, INCB acts in close 
cooperation with Governments. 
 INCB assists national administrations in meeting their obligations under the conventions. To that end, it 
proposes and participates in regional training seminars and programmes for drug control administrators. 
 
Reports 
 
 The international drug control treaties require INCB to prepare an annual report on its work. The annual 
report contains an analysis of the drug control situation worldwide so that Governments are kept aware of 
existing and potential situations that may endanger the objectives of the international drug control treaties. INCB 
draws the attention of Governments to gaps and weaknesses in national control and in treaty compliance; it also 
makes suggestions and recommendations for improvements at both the national and international levels. The 
annual report is based on information provided by Governments to INCB, United Nations entities and other 
organizations. It also uses information provided through other international organizations, such as Interpol and 
the World Customs Organization, as well as regional organizations. 
 The annual report of INCB is supplemented by detailed technical reports. They contain data on the licit 
movement of narcotic drugs and psychotropic substances required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are required for the proper functioning of the system of 
control over the licit movement of narcotic drugs and psychotropic substances, including preventing their 
diversion to illicit channels. Moreover, under the provisions of article 12 of the 1988 Convention, INCB reports 
annually to the Commission on Narcotic Drugs on the implementation of that article. That report, which gives an 
account of the results of the monitoring of precursors and of the chemicals frequently used in the illicit 
manufacture of narcotic drugs and psychotropic substances, is also published as a supplement to the annual 
report. 
 Since 1992, the first chapter of the annual report has been devoted to a specific drug control issue on which 
INCB presents its conclusions and recommendations in order to contribute to policy-related discussions and 
decisions in national, regional and international drug control. The following topics were covered in past annual 
reports: 
 1992:  Legalization of the non-medical use of drugs 
 1993:  The importance of demand reduction 
 1994:  Evaluation of the effectiveness of the international drug control treaties 
 1995:  Giving more priority to combating money-laundering 
 1996:  Drug abuse and the criminal justice system 
 1997:  Preventing drug abuse in an environment of illicit drug promotion 
 1998:  International control of drugs: past, present and future 
 1999:  Freedom from pain and suffering 
 2000:  Overconsumption of internationally controlled drugs 
 2001: Globalization and new technologies: challenges to drug law enforcement in the twenty-first 
 century 
 2002:  Illicit drugs and economic development 
 2003:  Drugs, crime and violence: the microlevel impact 
 2004:  Integration of supply and demand reduction strategies: moving beyond a balanced approach 
 2005: Alternative development and legitimate livelihoods 
 Chapter I of the report of the International Narcotics Control Board for 2006 is entitled “Internationally 
controlled drugs and the unregulated market”. 
 Chapter II presents an analysis of the operation of the international drug control system based primarily on 
information that Governments are required to submit directly to INCB in accordance with the international drug 
control treaties. Its focus is on the worldwide control of all licit activities related to narcotic drugs and 
psychotropic substances, as well as chemicals used in the illicit manufacture of such drugs. 
 Chapter III presents some of the major developments in drug abuse and trafficking and measures by 
Governments to implement the international drug control treaties by addressing those problems. Specific 
comments are made on the drug control situation in each of the countries in which an INCB mission or technical 
visit took place. 
 Chapter IV presents the main recommendations addressed by INCB to Governments, the United Nations 
Office on Drugs and Crime, WHO and other relevant international and regional organizations. 
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